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Just as artificial limbs replace the physical function of a missing arm or leg, small molecule 
surrogates acting as prosthetics on the molecular scale could replace protein functions that are 
either dysfunctional or absent in humans. These ‘molecular prosthetics’ could build upon and 
interface with the existing architecture and residual function of the organism to restore normal 
physiology. Importantly, small molecules with the capacity to move ions across lipid membranes 
and act as surrogates for channels or transporters have already been shown to restore physiology 
in protein-deficient cells and animals. This approach could now potentially address diseases 
caused by a deficiency of protein function, even in cases of severely reduced or absent protein 
production, such as cystic fibrosis (CF).  
Amphotericin B (AmB) is a natural product known to self-assemble into nonspecific ion 
channels in sterol-containing lipid membranes. It was long believed that AmB killed yeast 
through its inherent ion channel activity, existing primarily in the form of small aggregates that 
could insert into the lipid bilayer and cause toxic permeabilization. We demonstrate here that 
AmB actually predominantly forms large, extramembranous aggregates that kill yeast by 
extracting ergosterol (Erg), a required sterol in yeast membranes. Additionally, AmB is toxic to 
cells only when the ratio of AmB present exceeds that of membrane sterols. These mechanistic 
findings led to the development of two strategies to separate the ion channel forming capacity of 
AmB from its toxicity to eukaryotic cells. The first strategy utilizes low doses of AmB so as not 
to exceed the total membrane sterol content. The second strategy is to pre-complex AmB with 
the native sterol (ergosterol or cholesterol) to mitigate toxicity while retaining the channel 
forming activity. These two strategies proved to be successful in restoring growth to a strain of 
yeast missing essential potassium transporter proteins. 
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Cystic fibrosis (CF) is caused by loss-of-function mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) anion channel, some of which result in little to no 
protein produced, rendering protein substrate-dependent current therapies ineffective in these 
cases. Loss-of-function mutations in the CFTR anion channel result in reduced apical 
bicarbonate transport and decreased airway surface liquid (ASL) pH, which impairs respiratory 
host defenses and leads to chronic lung infections. Because basolateral pumps and channels 
remain active in the absence of functional CFTR, we hypothesized that an outward-facing 
bicarbonate gradient would develop across the apical membrane, which could be harnessed by a 
bicarbonate-permeable small molecule channel. 
Our current mechanistic understanding of the AmB ion channel allowed us to use it as a 
probe to test that hypothesis that an imperfect but anion-permeable small molecule ion channel 
surrogate for CFTR could restore ASL physiology. Here we report that AmB facilitates apical 
bicarbonate transport thereby increasing ASL pH. This effect is sustained for at least 48 hours 
and restores ASL viscosity and antimicrobial activity in CF patient-derived human lung epithelia 
across a range of genotypes, including those with little to no production of CFTR. AmB similarly 
increases ASL pH in CFTR-/- piglets. Dependence of the AmB-mediated rescue on Na+/K+ 
ATPase indicates that this unselective CFTR surrogate is functionally interfaced with the 
endogenous ion transport network driving transepithelial bicarbonate movement. Additionally, 
non-channel-based activities of CFTR, including regulation of other apical ion transporters, are 
not required for maintaining these key parameters of ASL physiology. These results suggest a 
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CYSTIC FIBROSIS AND THE PROSPECT OF MOLECULAR PROSTHETICS 
1.1 DISEASE INTRODUCTION TO CYSTIC FIBROSIS 
Diseases caused by an excess of protein function can often be treated with small molecule 
inhibitors, which interact with overactive proteins to shut off the excess activity. A classic 
example is the small molecule inhibitor imatinib (Gleevec®). Chromosomal translocation in the 
gene BCR-ABL produces a constitutively active form of the enzyme tyrosine kinase, which then 
stimulates uncontrolled cell growth in white blood cells and leads to chronic myelogenous 
leukemia (CML). Imatinib is a specific inhibitor of the BCR-ABL tyrosine kinase and has had 
remarkable clinical impact on CML patients since its discovery (1). However, diseases instead 
caused by a deficiency of protein function, either from a dysfunctional or even completely 
missing protein, can be difficult to treat. Examples of these diseases include lysosomal storage 
disorders such as Tay-Sachs (2) and Fabry disease (3), hemoglobinopathies like β-thalassemia 
(4), and channelopathies like Bartter syndrome, Dravet syndrome, and Dent’s disease (5). Our 
particular research interest was in this latter category, channelopathies: diseases characterized by 
a dysfunctional or missing protein ion channel.  
One of the most recognizable of the channelopathies is cystic fibrosis (CF), a disease caused 
by loss-of-function mutations in the CF transmembrane conductance regulator (CFTR) protein, a 
1480-amino acid cAMP-regulated anion channel (6). Patients with CFTR mutations exhibit 
abnormal epithelial anion (chloride and bicarbonate) transport, which leads to pancreatic 
insufficiency, gastrointestinal disease, hepatobiliary failure, male infertility, and elevated sweat 
chloride concentrations, which serves as a diagnostic marker. Importantly, it is the disease 
manifestations in the lung that contribute most to the morbidity and mortality in CF patients, an 
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accumulation of thick mucus, neutrophilic inflammation, progressive bronchiectasis, and chronic 
bacterial infection typically by Pseudomonas aeruginosa, Staphylococcus aureus and Burkhol-
deria cepacia (6-8). While the CFTR gene was first characterized almost 30 years ago in 1989, it 
is considered an orphan disease affecting one in 3,000 live births and treatment of the underlying 
pathophysiology of CF is still challenging (8). This is likely due to the fact that the exact 
mechanism by which the loss of CFTR-mediated anion transport, both chloride and bicarbonate, 
leads to chronic airway infection is still unknown (7). The discovery of genetic mutations in the 
CFTR gene allows for relative ease of diagnosis but unfortunately, options for treatment remain 
limited (6).  










One of the major reasons why CF is so difficult to treat is because there are almost 2,000 
known CFTR mutations, including missense, frameshift, nonsense and splice site defects, 
Figure 1.1. Classification of CFTR mutations. Hundreds of CF mutations cause disease through at least five 
major mechanisms of functional loss. Incidence is indicated within parenthesis and a specific example of each 
mutation class is given. 
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truncations, and in-frame deletions/insertions (6). Hundreds of these mutations cause disease in 
CF patients through at least five major mechanisms of functional loss (Fig. 1.1) (8). Comprising 
10% of CFTR defects, Class I includes nonsense mutations (specifically single point alterations 
that cause premature termination codons or PTCs) and splice site defects that interrupt CFTR 
biosynthesis and result in reduced or absent protein production (8). Because these mutations 
make little to no protein substrate, they are difficult to target with current small molecule-based 
therapies (6). 
Class II mutations include the most common deletion of phenylalanine 508 (ΔF508), which 
appears in 85% of all CF patients, 50% of these bearing two copies of this allele (ΔF508/ΔF508). 
This class of mutations produces misfolded CFTR, which results in premature degradation 
before the protein reaches the cell membrane. Interestingly, when ΔF508/ΔF508 CFTR 
misfolding is corrected with small molecule-based therapies, it has gating and regulation defects 
similar to class III mutations as well as defective recycling and decreased stability in the plasma 
membrane as seen in class IV mutants. This phenomenon can make single classification difficult 
and therefore, may require therapies with broader application across mutations classes (6, 8). 
Gating and regulation defects characterize class III mutations, which include the G551D 
allele. This is the third most common CFTR mutation and occurs in 2-4% of all CF patients. The 
protein is inserted into the membrane but has reduced open probability due to its defect, which 
interferes with ATP binding and phosphorylation. Class IV mutations are fairly rare and results 
in reduced single-channel anion conductance due to perturbations in ion-ion interactions inside 
the CFTR pore (6). In class V mutations, which are seen in less than 1% of all patients with CF, 
normal plasma membrane protein is produced but in drastically reduced quantities due to 
transcriptional dysregulation. This is largely due to splice defects, which make the level of 
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functional CFTR in each patient with these mutations highly variable even between different 
organs within the same patient (8). Sixth and seventh classes of mutations have also been 
proposed but not universal in CF literature, where CFTR is destabilized within the plasma 
membrane and disposed early by endocytosis or large deletions lead to untreatable mutations, 
respectively (6). 
1.3 PROPOSED MECHANISMS OF CF PATHOPHYSIOLOGY  
While the specific underlying mechanism of CF pathophysiology in the lung remains highly 
debated, both current major hypotheses revolve around maintenance of airway surface liquid 
(ASL) physiology. CFTR-mediated anion (chloride and bicarbonate) secretion as well as 
epithelial sodium channel (ENaC)-mediated sodium absorption comprise the majority of 
electrophysiological activity at the apical membrane of lung epithelia. It is universally accepted 
that cyclic AMP-stimulated chloride secretion is decreased in all CF animals. However, the 
competing hypotheses contend two different essential aspects of ASL physiology that must be 
corrected: 1) the hydration model proposes a detrimental decrease in lung fluid, while 2) the salt 
model, which later evolved into the pH model, suggests a salt imbalance in the airway that 
negatively affects the activity of antimicrobial proteins in the ASL (9, 10). 
The ASL consists of a mucus layer, which traps debris and pathogens from further entering 
the body, and a periciliary liquid layer (PCL), which maintains clearance between the mucus 
layer and the underlying epithelia. In normal lungs, the PCL is approximately the same height as 
the length of the cilia when it is fully outstretched (7 µm) and allows for normal beating 
movement unimpeded by the mucus layer above (11-14). In the first major hypothesis for CF 
pathophysiology, largely championed by the Boucher group at the University of North Carolina, 
the lack of chloride secretion by CFTR results in reduced fluid movement to the airway surface 
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(10). As CFTR is hypothesized to inhibit ENaC, either through chloride ion movement or 
directly via protein-protein interaction, the loss of this inhibition then leads to sodium 
hyperabsorption (15-18). These two consequences compound to dehydrate and reduce the height 
of the ASL in CF cultured human lung epithelia to 3 µm, causing the mucus layer to physically 
obstruct the cilia and results in inhibited ciliary movement that normally clears mucus and debris 
from airway passages and protects against lung infections (11-14). This dehydration can be 
prevented by chemically inhibiting ENaC with the specific blocker amiloride (9). CF mice as 
well as mice with overexpression of ENaC also exhibit this same phenotype of reduced ASL 
height (9, 11). In this model, normal and CF ASL salt concentrations are similar (10). 
A second hypothesis emerged when the Welsh group at the University of Iowa looked to 
determine the underlying cause of chronic CF airway infection. In CF cultured human lung 
epithelia, they found that ASL sodium and chloride concentrations were significantly higher than 
that of non-CF, but ASL height and sodium absorption were similar, contrary to the findings in 
support of the hydration model (10, 19, 20). One possible explanation for this is that the chloride 
conductance by CFTR and the ENaC conductance are parallel processes in the apical membrane, 
and elimination of chloride conductance magnifies sodium-dependent electrophysiological 
properties without actually increasing sodium absorption (21). More importantly, they also found 
that some bactericidal factor in non-CF ASL is active against Pseudomonas aeruginosa, 
Staphylococcus aureus, and Escherichia coli and therefore prevented infection, but it is 
inactivated in CF ASL due to this observed high ASL salt concentration. As the concentration of 
NaCl in the ASL increased, antibacterial activity against these strains decreased, but when salt 
concentration was decreased, bacterial killing was restored (22). 
The production of a CF porcine model by the Welsh group in 2008 provided a tool with 
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which to further develop this hypothesis (23). Pigs were chosen because their anatomy, 
physiology, biochemistry, genetics, size, and lifespan better resemble those of humans than mice, 
the previous leading model for CF (23). Importantly, in these CF piglets, the Welsh group 
observed that ASL height and sodium hyperabsorption did not differ by genotype (21). Instead, 
the ASL isolated from newborn CF pigs had reduced antibacterial activity compared to non-CF 
pigs against Staphylococcus aureus, the most common organism isolated from young children 
with CF (7, 24). Since they had previously determined that increasing salt concentration 
decreased antibacterial activity in human lung epithelial cultures, they tested if the same was true 
in the CF pig. Interestingly, when sodium and potassium concentrations in ASL collected from 
newborn pigs were measured, they did not differ by genotype and therefore could not explain 
defective bacterial killing in CF (24). 
ASL pH had been previously proposed to differ between CF and non-CF epithelia, due to the 
loss of bicarbonate transport through CFTR (21, 25, 26). As decreased pH has also been 
hypothesized to affect antimicrobial activity, the Welsh group then measured ASL pH in vivo 
(directly on the trachea), ex vivo (collected ASL), and in primary cultured airway epithelia and 
found that in all preparations, CF pig ASL had a lower pH than non-CF (24). In support of this 
model, it was found that neonates with CF had a lower nasal airway-surface liquid than infants 
without CF (27). It is important to note, however, that genotype-dependent differences in the pH 
of nasal airway-surface liquid in older children and adults may be more variable (9, 27). They 
also found that decreasing pH in ex vivo ASL from non-CF pigs with HCl decreased antibacterial 
activity; increasing pH increased bacterial killing, indicating a pH-dependence (24, 28). 
Increasing airway CO2 in non-CF pigs decreased ASL pH and inhibited antibacterial activity, 
while aerosolizing NaHCO3 into the trachea of CF pigs to increase ASL pH enhanced bacterial 
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killing (24). Aerosolization of bicarbonate or other basic buffer into the airways of CF patients 
also increased ASL pH and improved antimicrobial activity (29). These experiments directly 
linked loss of bicarbonate secretion through CFTR to decreased ASL pH, which in turn impairs 
killing of bacteria that enter the lung (24). Additionally, it was found that decreased ASL pH 
leads to increased ASL viscosity, possibly through influencing mucin electrostatic interactions, 
consistent with previous reports of mucociliary abnormalities in CF epithelia (20). 
The pH hypothesis was further supported by studies that determined why CF mice do not 
manifest lung disease while humans and pigs do. All three species rely on CFTR to secrete 
bicarbonate into the ASL to maintain pH, but in humans and pigs, unchecked H+ secretion by the 
nongastric H+/K+ adenosine triphosphatase (ATP12A) decreased ASL pH and led to downstream 
pathophysiology including increased ASL viscosity and decreased antimicrobial activity. CF 
mice do not manifest lung disease because they do not express ATP12A and therefore did not 
have genotype-dependent differences in ASL pH. When ATP12A was inhibited chemically with 
ouabain in human and pig airways, defects in ASL physiology were corrected; conversely, 
expressing ATP12A in CF mouse airways decreased ASL pH and impaired host defenses as 
observed in pigs and humans (30). These findings are the most compelling evidence for the pH 
model as the basis for CF pathophysiology. While it is possible that the hydration model may 
play some role in the manifestation of CF, the pH model has thus far presented more clinically 
relevant evidence and therefore we justified our decision to test our hypothesis largely within 
that framework. 
1.4 CURRENT AND DEVELOPING THERAPIES FOR CF 
As seen with ΔF508/ΔF508, combination therapies may be required due to multiple 
molecular defects attributed to a single mutation, making classification and therefore specific 
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drug discovery difficult (6). Even patients with the same genotype can present variably in the 
clinic. Because of this, symptomatic therapies of CF are still the first line of treatment and have 
been shown to extend the median life expectancy of patients past 40 years. These include 
mucolytics like dornase-alpha, myriad oral, intravenous or inhaled antibiotics, hydrators of the 
airway surface such as hypertonic saline and mannitol, anti-inflammatory drugs, replacement 
pancreatic enzymes, and mechanical clearance of the airway mucus. To address ASL 
abnormalities, aerosolized mucolytics and osmotics agents are used (6). Another option currently 
being explored is aerosolizing bicarbonate and other basic buffers like tromethamine to increase 
ASL pH and improve bacterial killing in CF airways (29). 
Inhibitors of other protein ion channels have been targeted to mitigate ASL physiology 
hypothesized to be downstream of the CFTR defect by the two models of pathophysiology. P-
1037, a compound that inhibits ENaC and corrects abnormal ASL hydration is currently in phase 
II clinical trials. Other channels targeted for this same restoration of water and electrolyte 
balance in CF airways are calcium-activated chloride channels (CaCCs) such as anoctamin 1 
(ANO-1, TMEM16A) (6). It was also discovered that using ouabain to block ATP12A in the 
nasal epithelia of both non-CF and CF subjects compared to control increased ASL pH (31). This 
could be a viable future strategy to address downstream effects in the pH model. However, along 
with symptomatic treatments, these approaches do not address the fundamental underlying defect 
of the disease, the mutated CFTR protein, and therefore result in an overwhelming and 
impractical number of medications and procedures for the average CF patient (6). 
Gene therapy has long been pursued to correct the underlying defect of CF, as it is a 
monogenic disease and hypothetically, an ideal target. However, more than 200 gene therapy 
trials have been undertaken since the 1990s and none of these trials have resulted in US Food 
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and Drug Administration (FDA) approval or even shown effective clinical outcomes (6, 8). 
Delivery of the functional CFTR gene is perhaps the greatest challenge of gene therapy, as the 
entry of viral or non-viral vectors are largely blocked by the inherent barriers that lung epithelia 
have, which are exacerbated in CF patients with excess mucus and inflammation. More recently, 
the use of plasmid-DNA liposomes resulted in modest improvement of lung function with 
monthly administration in patients (32). The same group is also developing F/HN-pseudotyped 
lentiviral vectors that are preparing to begin clinical trial this year (33). Genome editing is 
another direction gene therapy is recently going in, correcting the CFTR gene defect by 
removing mutated segments of the gene using engineered nucleases and then inducing 
homologous recombination with the wild type gene. This approach would specifically edit 
mutant CFTR and not WT CFTR using techniques such as CRISP/Cas9 and specific RNA 
guides. Another approach is RNA editing, where single-strained antisense RNA-based 
oligonucleotides replace deleted mRNA segments. Repaired RNA can then be translated into 
wild type CFTR. There is an ongoing phase I study with QR-010, an oligonucleotide designed to 
repair CFTR-encoded mRNA, administered intranasally and targeting patients who are either 
homozygous or compound heterozygous for ΔF508. An oligonucleotide that would selectively 
inhibit ENaC is also in development to target other potential effectors of ASL physiology (6). 
Small molecule-based approaches to CF have been vastly more successful than gene therapy 
thus far, although these treatments are mutation-specific. Because it has been demonstrated that 
restoring CFTR function to approximately 20–30% of the normal value is sufficient to have 
clinical impact, drugs targeting CF have been developed to restore just enough CFTR function to 
mitigate the CF phenotype (34). The most clinically impactful of these drugs have been 
potentiators and correctors of the CFTR protein.   
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Potentiators largely target class III and IV mutations, which are CFTR mutants with gating 
and conductance defects (ex: G551D) to increase anion movement (8). While Vertex 
Pharmaceutical developed a number of molecules for this purpose using high-throughput 
screening, VX-770 (ivacaftor/Kalydeco®) was the first CFTR potentiator to get FDA approval 
for use in CF patients with the G551D allele mutation (35). Recently, Kalydeco® was FDA 
approved to treat another 23 similar gating mutations (36-38).  The mechanism by which 
ivacaftor increases channel open probability is not understood, but it is known that it can 
promote the open configuration of CFTR and restore chloride transport to G551D CFTR up to 
50% of that of WT (35). It is also known that ivacaftor can increase phosphorylation-dependent 
channel gating independent of ATP and uncouples gating from ATP hydrolysis (39-41). 
Potentiators can also increase anion transport of ΔF508 CFTR if it has been trafficked to the 
plasma membrane (8). However, ivacaftor destabilizes G551D-CFTR to improve its function 
because it is too rigid for channel gating, and this same effect can be deleterious for other 
mutations that are not stable enough, such as ΔF508 CFTR. This may be why the combination of 
ivacaftor and CFTR correctors such as lumacaftor/Orkambi® have had modest impact in the 
clinic at best (42-45). Potentiators that do not have this destabilizing effect or may have synergy 
with ivacaftor are currently in development or are in clinical trial (6). Kalydeco® alone has 
demonstrated impressive clinical impact, showing statistically significant increases in forced 
expiratory volume in one second (FEV1), an important marker of lung function; improved body 
weight and quality of life, and decreased incidence of pulmonary exacerbation in patients with a 
G551D allele (46, 47). 
Correctors act directly upon the CFTR protein to correct folding defects and thereby increase 
productive trafficking and plasma membrane expression, primarily targeting class II or 
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misfolding mutations (ex: ΔF508). The primary defect in ΔF508 CFTR is a misfolded, unstable 
protein that is degraded within the cell before it can reach the plasma membrane. Interestingly, 
culturing these cells at a low temperature (26–30 °C) or using glycerol as a chemical chaperone 
can encourage insertion into the membrane, but these are not practical approaches in patients (6, 
8). As with potentiators, high-throughput screening led to the discovery of several small 
molecules that can act upon ΔF508 CFTR and correct misfolding, most notably VX-809 
(lumacaftor) and VX-661 (tezacaftor) by Vertex Pharmaceuticals	 (48-50). These correctors 
directly bind CFTR to increase processing efficiency and stabilize the immature protein. High-
throughput screens are now being used to identify second-generation correctors that may bind 
different sites on CFTR and have a synergistic effect with lumacaftor or tezacaftor (6). As 
mentioned previously, combination treatments involving potentiators (such as ivacaftor) and 
correctors (lumacaftor and tezacaftor) are difficult to develop because of potential drug 
interactions. Because of this, molecules with dual activity to both correct and potentiate are 
currently being explored, such as aminoarylthiazoles (AATs) (51), 4,6,4'-trimethylangelicin (52) 
and phosphodiesterase-5 inhibitors like sildenafil and vardenafil (53). 
Another approach is the development of proteostasis modulators that regulate the cellular 
environment to indirectly improve CFTR trafficking to the cell membrane and autophagy.  One 
such compound is suberolyanilide hydroxamic acid (SAHA), which inhibits histone deacetylase 
and regulates the Hsp90 chaperone protein. SAHA has been shown to restore surface channel 
activity of ΔF508 CFTR in primary human airway epithelia to levels that are 28% of those of 
WT CFTR (54).  ΔF508 CFTR exit from the endoplasmic reticulum (ER) and trafficking to the 
cell membrane are improved by silencing the expression of the Hsp90 c-chaperon Aha1 (55). 
Mature CFTR degradation can be prevented by inhibiting S-nitrosoglutathione reductase and 
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modulating Hsp70/Hsp90 organizing protein (HOP) nitrosylation (56). Other proteostasis 
modulators being developed increase autophagic flux and modulate the phosphoproteome (6). In 
epithelia with ΔF508 CFTR, protein aggregation is increased and autophagy, a key pathway of 
adaptation to cell-autonomous or environmental stresses, is suppressed. This results in the 
accumulation of autophagic substrates, which then bind to ubiquitinated ΔF508 CFTR and lead 
to its degradation. These deleterious changes in proteostasis are largely due to SUMOylation of 
the enzyme transglutaminase-2 (TG2), which leads to its constitutive activity. Interestingly, 
CFTR inhibition activates TG2 and inhibits autophagy, and TG2 inhibition and autophagy 
induction increase the abundance of functional ΔF508 CFTR. This makes TG2 and autophagy 
important targets for the restoration of ΔF508 CFTR processing, trafficking and stability at the 
membrane (6). In fact, restoring autophagic flux by inhibiting TG2 with proteostasis regulator 
cysteamine rescues ΔF508 CFTR cell surface expression for at least 24 hours after washout and 
restores functions in human bronchial epithelial cell lines, primary nasal cells from CF patients 
with ΔF508 CFTR, and in ΔF508 CF mice (57). Cysteamine treatment can reduce lung 
inflammation for several days after washout and prevents the intestinal obstruction in ΔF508 CF 
mice that leads to early death, suggesting that targeting autophagy with cysteamine may be a 
viable strategy to rescue and stabilize ΔF508 CFTR in patents (58).  The naturally occurring 
polypeptide thymosin α1 has been shown to have a similar ability to restore autophagy, reduce 
lung inflammation and restore the function of ΔF508 CFTR in human bronchial epithelial cells 
and ΔF508 CF mice (59). More importantly, using rapamycin to stimulate autophagy also 
restores bacterial killing in ΔF508 CFTR epithelia, suggesting that autophagy restoration therapy 
could potentially reduce lung inflammation and improve pathogen clearance in CF airways (60).  
The master protein kinase CK2 phosphorylates CFTR and can stimulate its degradation (59). 
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As such, selective inhibitors of CK2 such as CX-4945 can stabilize ΔF508 CFTR in the 
membrane after rescue with cysteamine (58). Another CK2 inhibitor, the nutraceutical 
epigallocatechin-gallate (EGCG), can similarly stabilize ΔF508 CFTR in the membrane after 
cysteamine washout for up to 48 hours in primary nasal epithelial cells and prolongs the effect of 
cysteamine rescue for several weeks in ΔF508/ΔF508 or ΔF508/null CF mice (58, 61).   In phase 
II clinical trials with ΔF508/ΔF508 and ΔF508 compound heterozygous CF patients, the 
combination of cysteamine and EGCG significantly decreased reduced airway inflammation and 
sweat chloride concentrations (58, 61). Like with the corrector/potentiator approach, 
combination therapy with different proteostasis regulators may be a viable future treatment 
option for CF. 
While proteostasis-based strategies may be less inherently genotype-specific as CFTR 
correctors and potentiators, class I mutations, which lack CFTR protein, are inherently 
untargetable with both of these approaches, as they require a protein substrate to act upon. One 
promising strategy with which to address these defects was the ribosomal read-through of 
premature termination codon (PTC) mutations to enable translation of the whole gene sequence 
and promote synthesis of the mature, full-length CFTR protein. These mutations prevent mRNA 
from being translated into CFTR protein, which is what leads to reduced or absent CFTR 
production. It has been shown that aminoglycoside antibiotics and derivatives like gentamicin or 
NB124 can promote a “read-through” of these PTCs in CFTR mRNA with class I mutations. 
These compounds were promising in cell cultures and CF mouse models but eventually failed to 
improve cell surface expression in human clinical trials (62, 63). Additionally, aminoglycosides 
can be highly toxic, so alternative molecules were sought with high-throughput screening, which 
led to the discovery of the nontoxic PTC124 or Ataluren by PTC Therapeutics, Inc. Ataluren can 
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read through PTCs specifically, not natural stop codons, and promote protein production in both 
a dystrophin-deficient (Duchenne’s) and G542X CF mouse model (64). In a phase II clinical 
trial, 23 adult CF patients with heterozygous nonsense mutations were treated with ataluren for 
two 2-week cycles and nasal potential difference (NPD) was measured. Mean CFTR-dependent 
chloride transport in these patients normalized in more than half of the patients, and the drug was 
safe and well tolerated with minimal side effects (65). Another study in pediatric patients found 
that ataluren reduces electrophysiological abnormalities in children with CFTR nonsense 
mutations (66). Unfortunately in a double blind, placebo-controlled, 48-week phase III clinical 
trial comparing ataluren to placebo in nonsense mutation CF patients, the drug failed to produce 
statistically significant differences between the two study populations in absolute change in 
percent-predicted FEV1 or in rate of pulmonary exacerbations. As such, PTC has discontinued 
current clinical development of ataluren in cystic fibrosis, leaving this class of mutations without 
a viable therapeutic candidate (67). 
1.5 EFFORTS TO DEVELOP ANION-PERMEABLE CHANNELS FOR CF 
There has previously been extensive work developing synthetic ionophores, both small 
molecule and peptide-based, with a main focus on chloride transport and developing cystic 
fibrosis therapeutics. The general strategy was to reduce pathophysiology by opening alternative, 
non-CFTR anion pathways to compensate for the CFTR channel defect. In 1996, El-Etri et al 
first tested if anions can increase the permeability of epithelia to anions using 5,10,15,20-
Tetraphenyl-21H,23H-porphine manganese(III) chloride (TPPMn(III)), a positively charged 
lipophilic anion carrier selective for chloride over other halides. TPPMn(III) did increase anion 
permeability of cultured mouse lung epithelia (MLE) as measured by short-circuit current (Isc) to 
a level similar to that of CFTR activation induced by forskolin analogues (68). However, since 
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this molecule was tested in non-CF epithelia, it is unclear if it actually acts independently of 
CFTR to increase chloride conductance. 
Tomich and coworkers in the late 1990s and early 2000s developed a series of channel-
forming peptides with the core M2GlyR, corresponding to a domain proposed to line the pore of 
the ligand-gated chloride channel. Application of C-K4-M2GlyR to cultured human colonic 
epithelia from the T84 cell line increased Isc and caused fluid secretion, which could be inhibited 
by chloride channel blockers, bumetanide and the removal of external chloride. They concluded 
that membrane insertion of C-K4-M2GlyR and the subsequent anion conductance might 
functionally mimic CFTR (69). A subsequent study determined if restoration of chloride 
transport would also restore glutathione secretion, a major antioxidant in the epithelial lung 
lining fluid, reported to be decreased in the apical fluid of CF airway epithelia. Another peptide 
with the M2GlyR core that also forms chloride channels, N-K4-M2GlyR, and a K+ channel 
activator (chlorzoxazone) increased bumetanide-sensitive Isc, and glutathione efflux, measured 
by high-performance liquid chromatography (HPLC), in CFT1 cultured epithelia. They 
concluded that glutathione efflux occurs in tandem with apical chloride secretion, and that these 
could be restored independently of CFTR (70). Nasal potential difference (PD) studies were also 
performed in ΔF508 homozygous transgenic mice treated with CK4-M2GlyR or NK4-M2GlyR. 
Treated CF nasal epithelia were found to respond to cAMP-agonist isoproterenol to more 
similarly to that of WT animals than to untreated CF epithelia, and sustained chloride 
conductance was observed for up to 6 hours after a single peptide treatment (71). It is unclear if 
these promising studies are still being pursued. 
In 2001, Jiang et al reported increased chloride transport with GL-172, a synthetic analog of 
squalamine in immortalized tracheobronchial epithelial cells derived from a ΔF508 patient 
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(CFT1), as measured by the Cl−-sensitive fluorescent indicator SPQ and patch clamp. Studies of 
normal human lung epithelia (NHBE) in an Ussing chamber showed an increase in Isc with 
addition of GL-172 that was 30% of that observed with cAMP agonist-activated CFTR. The 
magnitude of this change in short-circuit current was ∼30% of that attained when CFTR was 
maximally stimulated with cAMP agonists. Administration of GL-172 to the nasal epithelium of 
gut-corrected CFTR-/- mice (FABP-CFTR-/-) caused hyperpolarization, indicating increased 
anion permeability and restoration of Cl− secretion (72). While promising, the studies relevant 
for translation were only carried out in normal lung epithelia or in CFTR-/- mice, which do not 
manifest typical CF lung disease, making them an non-ideal animal model for testing this 
hypothesis. 
The Davis group has developed several classes of small molecule-based anion transporters, 
including the “cholapods” in 2003. These are shown to increase chloride efflux from liposomes, 
and increase Isc across cultured Madin Darby canine kidney (MDCK) epithelia in an Ussing 
chamber. This response was found to be different from that induced by activating native chloride 
channels in the MDCK epithelia. A recent study from this group evaluated another fifteen 
anionophores in similar fashion, with anion transport from single cells assayed with a novel 
fluorescence technique and electrophysiology once again measured by Ussing chamber (73). 
While the breadth of work from the Davis group is indeed impressive, none have thus far 
translated past electrophysiological changes in vitro and it is unclear if they will have any kind of 
clinical impact.  
In 2012, the Yang group developed a synthetic compound that transports chloride across lipid 
membranes and exhibits single-channel currents by patch clamp that confirm formation of ion 
channels in liposomes. They then studied this compound in CuFi-8 and NuLi cell lines derived 
	 17	
from a ΔF508/ΔF508 and WT patient, respectively, and found that whole-cell currents were 
increased in the first few minutes, and sustained for 15 minutes. The current increase persisted 
even after washing with control buffer for 30 minutes. Most interestingly, compound addition 
resulted in an even larger increase in CuFi-8 cells than activating WT CFTR in the NuLi cells 
with forskolin did, while CuFi-8 cells showed no response to forskolin. This indicates that the 
compound can increase chloride conductance via a non-CFTR pathway (74). Again, it is unclear 
if this promising compound is being pursued in higher organisms, but the Yang group is actively 
developing other small molecule synthetic channels (75). 
The Gale group is also actively developing small molecules that can transport anions. They 
are exploring derivatives of the small molecule natural product prodigiosin, which is known to 
facilitate the co-transport HCl and exchange of chloride across lipid bilayers. They used ion-
selective electrodes to determine that prodigiosin and derivatives can efflux chloride from 
POPC-based liposomes in the presence of external nitrate or bicarbonate anions. This anion 
exchange required the presence of a less hydrophilic anion on the outside of the liposomes. They 
then used a 13C NMR-based assay to determine that these small molecules can facilitate Cl-
/HCO3- exchange similar to that observed with the anion exchanger (AE2) protein. Notably, 
prodigiosin is better at this exchange than its derivatives (76). The Gale group studies anion 
transporters for several different purposes, and this would be a highly interesting molecule to see 
translate to animal studies. 
1.6 THE PROSPECT OF MOLECULAR PROSTHETICS 
Robustness is an inherent property of living systems, meaning that organisms have the ability 
to largely maintain function despite a range of perturbations, such as environmental change or 
and genetic variation (77-80). For example, most humans are missing ~20 proteins yet have no 
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disease phenotype (77), and some people with mutations that typically cause catastrophic 
Mendelian diseases live symptom-free (79). Such resilience is attributed to a variety of 
mechanisms (78, 80), including networks of collaborating proteins (81) that typically provide 
more functional capacity than required for physiology (Fig. 1.2, left). However, in some cases 
these mechanisms are insufficient to maintain physiology, and the capacity for an important 
function drops below the required threshold. This can lead to a dramatic phenotype, such as lack 
of growth in a cell or disease in a patient. In such cases all possible robustness mechanisms are 
likely engaged and a substantial level of functional capacity may still be retained, lessening the 










The concept of robustness and residual function suggests that in cases where an important 
protein is missing, even imperfect replication of its function may be sufficient to restore 
physiology. It became increasingly clear to us that many human diseases caused by the loss of 
protein function remain incurable, and based on our experience and skillset we knew that we 
wanted to come at the problem with a small molecule-based approach. Small molecules have 
Figure 1.2 The prospect of molecular prosthetics. The robustness of 
living systems suggests small molecules that only partially mimic the 
function of missing proteins may be sufficient to restore physiology. 
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many features that can make them exceptionally effective as therapeutics. Relative to proteins 
and oligonucleotides, they are generally more evasive of the immune system, inert to peripheral 
metabolism, cell permeable, orally bioavailable, and cost effective to produce, purify, and store. 
Importantly, just as artificial limbs replace the physical function of a missing arm or leg, we 
hypothesized that small molecule surrogates acting as prosthetics on the molecular scale could 
replace protein functions that are either dysfunctional or absent in humans. Perfectly replicating 
protein function is challenging, especially with a small molecule that may at best mimic one of 
two functions of a multifunctional protein. However, the concept of robustness allows for this 
kind of imperfection, because like an artificial limb, a molecular prosthetic could build upon and 
interface with the existing architecture and residual function of the organism to restore normal 
physiology (Fig. 1.2, right). 
The molecular prosthetics concept within the framework of channelopathies and related ion 
transporter deficiencies relies heavily on the idea of a residual network of pumps and channels 
that remain active despite the missing protein and a subsequent build up of an ion gradient across 
lipid membranes that could be harnessed by a passive small molecule channel or transporter. 
Molecular prosthetics have already been shown to restore whole-animal physiology in disease 
models with a deficiency of iron-transporting protein function that abolishes transmembrane iron 
flux. In these models, iron gradients build up across protein-deficient membranes due to the 
residual action of other iron-transport proteins in the network. My colleagues Tony Grillo and 
Anna SantaMaria found that the small molecule natural product, hinokitiol, can release these 
gradients to restore iron transport into, within, and/or out of cells. Hinokitiol promotes gut iron 
absorption in animal models of divalent metal transporter 1 (DMT1) and ferroportin deficiencies, 
as well as hemoglobinization in DMT1-and mitoferrin-deficient zebrafish (82). Their findings 
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suggest that small molecule prosthetics that partially mimic the function of missing protein ion 
channels or transporters may have potential in treating human diseases. Unfortunately, hinokitiol 
only transports divalent metals (82), so another molecular prosthetic would need to be developed 
for cystic fibrosis. 
     In human lungs, there are several ion channels responsible for maintaining the normal ion 
gradient across the lung epithelium that could potentially functionally interface with a molecular 
prosthetic to rescue CF pathophysiology. Bicarbonate import through the basolateral membrane 
of epithelia is primarily driven by a sodium gradient created by Na+/K+ ATPase. The Na+/H+ 
exchanger (NHE1) provides the cytosolic sodium necessary to fuel the Na+/K+ ATPase and 
works in collaboration with anion exchanger 2 (AE2) to maintain cytoplasmic pH (pHi). NHE1 is 
activated by acidic pHi to extrude excess acid, while AE2 is activated by alkaline pHi to extrude 
excess base. Na+-HCO3- cotransporter 1 (NBC1) is the major basolateral bicarbonate uptake 
transport, which uses the sodium gradient generated by the Na+/K+ ATPase to provide adequate 
bicarbonate accumulation in the cytoplasm. The vacuolar-type H+-ATPase pump and the H+-K+-
ATPase pump in the basolateral membrane can generate steep inward H+ gradients and interface 
with NBC1 to dramatically increase HCO3- loading of the cell (83). These mechanisms would 
help create the gradient that a molecular prosthetic could release to restore bicarbonate secretion. 
Examples of proteins that may help to balance over-permeabilization or relatively unselective ion 
transport by molecular prosthetics by effluxing excess ions could include AE2, K+ leak channels, 
calcium-activated chloride channels (CaCC), and outward-rectifying chloride channels (ORCC) 
(83). These ion channels and pumps collectively represent an endogenous protein network with 
the potential to functionally interface with an imperfect small molecule mimic of the missing 
CFTR anion channel to restore physiology in lung epithelia. 
	 21	
1.7 AMB PRIMARILY KILLS YEAST BY SIMPLY BINDING STEROL 
Fortunately, nature has already provided a small molecule ion channel prototype for us to 
potentially test our molecular prosthetics hypothesis in a CF model. Amphotericin B (AmB) is a 
small molecule natural product used in the clinic as an antifungal for almost 60 years. It is known 
to self-assemble into nonspecific ion channels in sterol-containing lipid membranes that have 
been shown to transport both cations and anions (84, 85). Planar lipid bilayer studies performed 
in our lab revealed that the single ion channel trace of AmB exhibits an opening and closing 
pattern similar to that of a protein ion channel (86). Despite the remarkable ability of AmB to 
form ion channels, it remained a non-ideal candidate for testing our hypothesis, as it has long 
been believed that AmB kills cells via ion channel-mediated membrane permeabilization (87-
93). To use AmB as a probe, our first task was to determine if channel formation and membrane 
permeabilization was indeed its mechanism of toxicity, and if there was some way to separate the 
channel-forming capacity from cell killing.  
The first step was the development of AmB derivatives that test different hypothesis 
regarding sterol binding and channel formation, via site-specific deletions of functional groups 
predicted to play specific roles in the aforementioned activities. Several groups had previously 
determined that the presence of sterols is required for membrane interaction and channel 
formation (84, 87, 88, 91), so it was hypothesized that sterol binding was in fact the killing 
mechanism of AmB. The C41 carboxylate and mycosamine sugar appendages were hypothesized 
to promote the direct binding of membrane-embedded sterols (94-96), and so in the first 
derivative developed, amphoteronolide B (AmdeB), the mycosamine sugar appendage was 
removed (96). 
The second derivative developed was C35deOAmB, where a single oxygen atom was 
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removed from the C35 position (97). This was rationally designed using both leading models for 
the structure of the AmB ion channel. The hydroxyl group at C35 is predicted to be critical for 
channel formation, either by anchoring the channel to one side of the lipid bilayer in the single 
barrel stave model or by connecting two barrel-shaped aggregates together into a membrane-
spanning channel in the double barrel stave model (98). These two molecules served as 
important probes in determining the killing mechanism of AmB and if cell killing and channel 
formation could be separable. 
Isothermal calorimetry was then used to test the binding of these molecules with ergosterol, 
the essential sterol in the yeast membrane, where an increase in isotherm is consistent with 
binding. Liposomes with or without 10% ergosterol were titrated into a chamber containing 
AmB, AmdeB, or C35deOAmB in buffer. As a negative control, no increase in isotherm was 
observed with any of the three molecules with sterol-free liposomes. As expected, an increase in 
isotherm was observed with AmB in the presence of sterol-containing liposomes, consistent with 
literature precedent of AmB’s sterol binding capacity, whereas no increase in isotherm was 
observed with AmdeB. This indicates that loss of the mycosamine sugar results in a complete 
inability to bind ergosterol. In contrast, C35deOAmB fully retains sterol-binding ability, 
exhibiting an increase in isotherm commensurate with that of the original AmB molecule (97). 
To then determine channel-forming capacity of these molecules, potassium efflux was measured 
either in sterol-containing liposomes or Saccharomyces cerevisiae yeast. Importantly, AmB 
caused robust efflux of potassium ions, but both AmdeB and C35deOAmB did not (97). This led 
to the conclusion that AmdeB and C35deOAmB are both unable to form channels.  
With sterol binding and channel-forming activity known, the minimum inhibitory 
concentration (MIC) of these compounds was tested against both Saccharomyces cerevisiae and 
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Candida albicans. It was found that consistent with its inability to bind sterols, AmdeB was 
unable to kill the yeast at any tested concentration. However, despite losing its channel-forming 
ability, C35deOAmB remains potent against both yeast strains like the original AmB molecule. 
Notably, C35deOAmB remains fungicidal like the original molecule, as observed in a killing 
kinetics assay versus AmB and ketoconazole, a fungistatic drug. Another important finding was 
that at the MIC, there are more AmB molecules than ergosterol molecules, suggesting that the 
stoichiometric ratio of the two plays a key role in toxicity (97). Because C35deOAmB cannot 
form channels but still binds sterols and potently kills yeast, our lab concluded that the binding 
of essential sterols is actually the primary mechanism of cell killing by AmB, not channel 
formation. This represented the first hint to us that the channel-forming capacity could indeed be 
separated from cell killing. Because AmB is only toxic when there are more AmB molecules 
present than ergosterol molecules, we could potentially use a low concentration of AmB as a 
nontoxic ion channel surrogate. 
1.8 OUTLOOK 
We now have an extensive understanding of what is currently known about the 
pathophysiology of CF and current therapies, as well as a model framework within which to test 
our hypothesis. This dissertation will determine if even an unregulated and non-selective small 
molecule ion channel could functionally interface with the endogenous protein network to 
increase bicarbonate transport and ASL pH, thereby restoring downstream physiology in CF 
epithelia. Herein, the characterization of a potential molecular prosthetic, AmB, is detailed from 
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CHAPTER 2 
CHARACTERIZATION OF AMPHOTERICIN B AS A POTENTIAL MOLECULAR 
PROSTHETIC 
Robust networks of pumps and channels are generally responsible for the directional 
movement of specific ions in organisms ranging from microbes to humans, and deficiencies of 
these protein ion channels underlie many currently incurable human diseases. This understanding 
led us to question whether minimally selective small molecule mimics of missing protein 
channels might be capable of collaborating with the corresponding protein ion pumps to restore 
physiology. One such ion channel-forming small molecule, amphotericin B (AmB), has 
remained the powerful but highly toxic last line of defense in treating life-threatening fungal 
infections in humans for nearly six decades with minimal development of microbial resistance. 
Understanding how this small molecule kills yeast is critical for determining if its intriguing 
ability to autonomously form ion channels in lipid membranes could potentially be used to 
replace protein ion channels in diseases where they are deficient or missing, while avoiding 
unwanted toxicity.  
In the widely accepted ion channel model for its mechanism of cytocidal action, AmB forms 
aggregates inside lipid bilayers that permeabilize and kill cells. In contrast, we report that AmB 
exists primarily in the form of large, extramembranous aggregates that kill yeast by extracting 
ergosterol from lipid bilayers. These findings reveal that extraction of a polyfunctional lipids like 
sterol underlies the resistance-refractory antimicrobial action of AmB and suggests a roadmap 
for separating its cytocidal and membrane-permeabilizing activities. This new mechanistic 
understanding first guided the usage of the AmB channel as a molecular surrogate for missing 
protein ion channels in a mutant yeast strain missing a potassium transporter. We report vigorous 
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and sustainable restoration of yeast cell growth by replacing the missing protein ion transporters 
with AmB acting as an imperfect small molecule mimic. We further provide evidence that this 
tolerance for imperfect mimicry is attributable to collaboration between the channel-forming 
small molecule and protein ion pumps. These results illuminate a mechanistic framework for 
pursuing small molecule replacements for deficient protein ion channels that underlie a range of 
challenging human diseases. 
Contributions to the work presented in this chapter are as follows: Dr. Thomas Anderson, Dr. 
Alexander Cioffi, and Nashrah Maryum prepared [U-13C]AmB and [13C]Erg. Dr. Thomas 
Anderson, Dr. Alexander Cioffi, Dr. Mary Clay, Dr. Grant Hisao, Dr. Andrew Nieuwkoop, Dr. 
Gemma Comellas, and Dr. Brice Uno prepared samples for SSNMR. Dr. Mary Clay, Dr. Grant 
Hisao, Dr. Andrew Nieuwkoop, Dr. Gemma Comellas, Dr. Marcus Tuttle, and Dr. Chad Rienstra 
acquired SSNMR data. Dr. Alexander Cioffi and Dr. Tamir Gonen performed liposome 
microscopy. Dr. Alexander Cioffi performed yeast rescue assays. Jennifer Hou performed cell 
viability and chemical sensitivity experiments. Dr. Alexander Cioffi and I performed 
AmB:ergosterol complex assays and Erin Wildeman tested permeabilization by AmB:ergosterol 
complex in yeast. Portions of this chapter were adapted from Anderson, T. M.; Clay, M. C.; 
Cioffi, A. G.; Diaz, K. A.; Hisao, G. S.; Tuttle, M. D.; Nieuwkoop, A. J.; Comellas, G.; Wang, 
S.; Uno, B. E.; Wildeman, E. L.; Maryum, N.; Gonen, T.; Rienstra, C. M.; Burke, M. D. 
"Amphotericin Forms an Extramembranous and Fungicidal Sterol Sponge" Nature Chemical 
Biology 2014, 10, 400-406 and Cioffi, A. G.; Hou, J.; Grillo, A. S.; Diaz, K. A.; Burke, M. D. 
"Restored physiology in protein-deficient yeast by a small molecule channel" Journal of the 
American Chemical Society 2015, 137, 10096–10099. 
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2.1 AMPHOTERICIN B AS AN ANTIFUNGAL 
With expanding populations of immunocompromised patients, the incidence of life-
threatening systemic fungal infections continues to rise (1). Substantially exacerbating this 
problem is the concomitant increase in pathogen resistance to almost all clinically approved 
antifungal agents. In contrast, AmB (Fig. 2.1A) has served as the gold standard treatment for 
systemic fungal infections for nearly six decades with minimal development of clinically 
significant microbial resistance (2). This exceptional track record reveals that resistance-
refractory modes of antimicrobial action exist, and the mechanism by which AmB kills yeast is 
one of them. However, because of the often dose-limiting toxicity of this natural product, 
mortality rates for systemic fungal infections persist near 50% (3). As such, there are several 
research objectives that stand to benefit from a clarified molecular description of the biological 
activities and biophysical interactions of AmB within living systems: improving the notoriously 
poor therapeutic index of this drug, developing other resistance-refractory antimicrobial agents, 
and of utmost interest herein, enabling more effective utilization of its remarkable capacity to 
perform ion channel-like functions. 
For decades, the prevailing theory has been that AmB primarily exists in the form of small 
ion channel aggregates that are inserted into lipid bilayers and thereby permeabilize and kill 
yeast cells (Fig. 2.1B) (4-23). An extensive series of structural and biophysical studies, including 
those employing planar lipid bilayers (4-10), liposome permeability (9-13, 17), Corey-Pauling-
Kulton (CPK) modeling (7-9), UV/Vis spectroscopy (9-11, 13, 21), circular dichroism (10, 11, 
13, 21), fluorescence spectroscopy (9, 11), Raman spectroscopy (10), differential scanning 
calorimetry (9, 10, 21), chemical modifications (11-14, 17), atomic force microscopy (21), 
transmission electron microscopy (20), computer modeling (11, 15), electron paramagnetic 
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resonance (10), surface plasmon resonance (22), solution NMR spectroscopy (11), and solid-
state NMR (SSNMR) (16-19) spectroscopy have been interpreted through the lens of this ion 
channel model. Importantly, this model suggests that the path to an improved therapeutic index 
requires selective formation of ion channels in yeast versus human cells (10-20), that the search 
for other resistance-refractory antimicrobials should focus on membrane-permeabilizing 
compounds (24), and that the ion channel-forming and cytotoxic activities of AmB cannot be 
separated.  
Figure 2.1 (A) Structures of AmB, Erg, POPC and paramagnetic probes 5-DOXYL-PC and 16-DOXYL-PC. 5-
DOXYL and 16-DOXYL position a paramagnetic functional group at depths of ∼12 Å and ∼25 Å within the 
lipid bilayer, respectively. (B) The classic ion channel model for the structure and function of AmB. (C) Surface 
adsorption model. (D) A new sterol sponge model, in which AmB primarily exists in the form of large 
extramembranous aggregates that extract Erg from lipid bilayers. 
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2.2 AMPHOTERICIN B FORMS AN EXTRAMEMBRANOUS AND FUNGICIDAL 
STEROL SPONGE 
Recent studies from our group have demonstrated that the channel-forming capacity of AmB 
is not required for fungicidal activity, whereas binding ergosterol (Erg) (Fig. 2.1A) is essential 
(25-27). However, the structural and biophysical underpinnings of this rare type of small 
molecule-small molecule interaction and its connection to cell killing all remained unclear. 
Sterols such as Erg in yeast play many essential roles in eukaryotic cell physiology, including 
functional regulation of membrane proteins, microdomain formation, endocytosis, vacuole 
fusion, cell division, and cell signaling (28-31). We thus hypothesized that sequestering Erg and 
thereby precluding its participation in multiple cellular functions may underlie the fungicidal 
action of AmB. 
Guided by this hypothesis, we considered three possible models for the primary structure and 
function of AmB in the presence of Erg-containing phospholipid membranes (Fig. 2.1B-D): (i) 
In the classic channel model, AmB primarily exists in the form of small (~1 nm) ion channel 
aggregates inserted into the membrane, perpendicular to the membrane surface, with Erg 
molecules interdigitated between AmB molecules (Fig. 2.1B) (7-9, 11, 12, 15-19, 22, 23). (ii) In 
an alternative surface adsorption model, AmB is primarily positioned in the 
intermediate/headgroup region, oriented parallel to the plane of the membrane, sequestering Erg 
to the membrane surface (Fig. 2.1C) (9, 22). (iii) In a new sterol sponge model, AmB primarily 
exists in large extramembranous aggregates that extract Erg from lipid bilayers (Fig. 2.1D). In 
the latter two models, we envisioned that membrane-permeabilizing ion channels represent 
relatively minor contributors to both the structure and cytocidal activity of AmB. Here we report 
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an extensive series of SSNMR, transmission electron microscopy (TEM), and cell-based 
experiments that all support the new sterol sponge model (Fig. 1D). 
Distinguishing amongst the aforementioned structural and functional models (Fig. 2.1B-D) 
required determining the location of AmB relative to lipid bilayers and the corresponding 
location of Erg in the absence and presence of AmB. Making these determinations turned out to 
be exceptionally challenging due to the lack of high-resolution methods for probing small 
molecule/membrane interactions (9-13, 15, 17-21). We developed an experiment based on the 
NMR paramagnetic relaxation enhancement (PRE) of 13C nuclei caused by lipid-appended spin 
labels (32-34). The 13C nuclei that lay proximal to a stable radical, such as 4,4-
dimethyloxazolidine-N-oxyl (DOXYL), experience large enhancements of their longitudinal 
relaxation rates (R1 = 1/T1). Due to the high gyromagnetic ratio of the electron spin, the PRE is 
detectable for distances up to ~20 Å. Harnessing this phenomenon, we designed a magic-angle 
spinning (MAS) SSNMR PRE experiment based on 16-DOXYL-PC and 5-DOXYL-PC to 
interrogate proximity to the hydrophobic core and intermediate/headgroup region, respectively 
(Fig. 2.1A). Importantly, the three models under consideration (Fig. 2.1B-D) each predict distinct 
PRE effects for AmB. The ion channel model predicts large PREs with both spin labels, the 
surface adsorption model predicts large PREs only with the 5-DOXYL-PC, and the sterol sponge 
model predicts little or no PRE effects with either spin label. 
To execute this experiment with maximized signal-to-noise ratio, we prepared highly 
enriched uniformly 13C-labeled AmB ([U-13C]AmB) via development of an improved 
biosynthetic protocol (18). By using uniformly 13C-labeled glucose ([U-13C]glucose) as the 
primary carbon source, we developed a robust procedure for attaining >80% 13C incorporation, 
the highest 13C enrichment yet reported for this natural product. This highly enriched [U-
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13C]AmB enabled confident assignment of 13C resonances and high sensitivity PRE 
measurements even at high lipid to AmB ratios. 
We next identified a physiologically relevant lipid bilayer system in which we could execute 
the targeted experiments. Our recent structure-function studies with AmB reveal that, in contrast 
to liposomes comprised of fully saturated lipids, liposomes derived from monounsaturated 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and Erg yield results that mirror those 
obtained with live yeast cells (26, 27). Additionally, unlike membranes derived from fully 
saturated lipids, the plasma membranes of yeast and bilayers derived from POPC:Erg are both in 
the liquid crystalline state at 23 °C (35, 36). In yeast, POPC is highly abundant, and Erg is the 
most common sterol (37). Moreover, at the minimum inhibitory concentration for AmB against 
both Saccharomyces cerevisiae and Candida albicans, there is at least as much AmB as there is 
Erg (27). Based on this finding, we prepared lipid bilayer samples throughout this study with 
molar ratios of at least 10:1 POPC:Erg; for the samples containing AmB, we used at least 1 
equivalent of AmB relative to Erg. These bilayers showed proper phase behavior and retained 
this behavior upon addition of DOXYL spin labels (Fig 2.2). 
 
Figure 2.2 1H T2 values of the bulk fatty acyl CH2 peaks of molar ratios of (A) 10:1 POPC:Ergosterol (B) 10:1 
POPC:Ergosterol + 5% 5-DOXYL-PC and (C) 10:1 POPC:Ergosterol + 5% 16- DOXYL-PC liposomes as a 
function of temperature. The data were acquired on a 600 MHz spectrometer over a calibrated temperature range 
of -8 to 28 °C. 
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To first confirm the position of each spin label in the bilayer, we determined the respective 
PREs on 13C resonances in natural abundance POPC lipids with 5 mol% of each DOXYL spin 
label (Fig. 2.3A). Consistent with the structure of POPC membranes (35), bilayers doped with 
5% 16-DOXYL-PC demonstrated a maximal PRE at the termini of the POPC fatty acid chains, 
and the PRE decreased as the distance from the center of the membrane increased (Fig. 2.3A). 
Similarly, the incorporation of 5-DOXYL-PC yielded maximal PREs in the intermediate and 
Figure 2.3 (A) PRE values have magnitude proportional to 1/r6, where r is the distance from spin label to NMR-
detected nucleus. POPC controls demonstrated this proportionality in the presence of 5 mol% 5-DOXYL-PC 
(black) or 16-DOXYL-PC (gray). (B) [U-13C]AmB demonstrated no PRE effects >0.03 s−1 in the presence of 
either 5-DOXYL-PC (black) or 16-DOXYL-PC (gray) paramagnetic probes. (C,D) Substantial differences were 
observed between longitudinal (T1) 13C relaxation times for sites in POPC (C) and AmB (D). (E) Selected 1H-13C 
two-dimensional spectra were collected with a 1 ms T2 filter and 1H-1H spin diffusion times of 1 ms, 100 ms and 
400 ms; cross-peaks were from lipid acyl chains (red) and water (blue) to the [U-13C]AmB polyene region. (F) 
The polarization transfer was quantified as a function of spin diffusion time from water and lipid to [U-13C]AmB 
polyene. PRE values were derived from the difference between 13C R1 relaxation rates measured via inversion 
recovery for diamagnetic samples and samples containing 5-DOXYL-PC and 16-DOXYL-PC. Error bars were 
determined by χ2 analysis. 1H-13C spin diffusion data were normalized relative to maximum intensity observed 
for both lipid and watercross-peaks for a given 13C site after correcting for 1H T1 relaxation. Error bars were 
derived from the signal-to-noise ratio of the observed cross peak. Spectra were acquired at 14.1 T (600 MHz, 1H 
frequency) at 20 °C, 10 kHz MAS. 
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headgroup regions of the lipid bilayer and much smaller yet still readily observable effects at the 
membrane interior. Together, these two spin label probes enabled confident and complementary 













We next prepared samples with [U-13C]AmB in POPC/Erg bilayers and used a series of 13C 
chemical shift correlation experiments (including constant-time uniform-sign cross-peak 
correlation spectroscopy (CTUC-COSY) (38), dipolar-assisted rotational resonance (DARR) 
(39), and supercycled POST-C5 (SPC5) recoupling (40) to assign de novo the 13C resonances of 
AmB (Fig. 2.4). We then performed PRE measurements in the presence of 16-DOXYL-PC or 5-
Figure 2.4 13C-13C 2D spectra of (1.44 ms SPC5 mixing) of 10:1:1 POPC:[U-13C]AmB:Erg (red) and 10:1:1 
POPC:[U-13C]AmB:Erg with 5 mol% 5-DOXYL-PC used to make site-specific assignments of the AmB and 
confirm that the addition of the DOXYL spin labels has no significant effect on AmB. Spectrum was acquired on 
a 600 MHz spectrometer, at 20 °C with and MAS rate of 10 kHz, and 75 kHz SPINAL 1H decoupling. 
	 38	
DOXYL-PC spin probes. The results were striking and unambiguous. As predicted by the 
extramembranous sterol sponge model, and inconsistent with both the membrane-inserted ion 
channel and surface adsorption models, we observed no significant PREs to any 13C resonances 
of AmB with either probe (Fig. 2.3B). Therefore, we concluded that the majority of AmB in 
these samples was >20 Å away from both membrane-embedded spin labels. 
A series of additional SSNMR experiments further revealed that AmB exists in the form of 
large aggregates that are more closely associated with water than lipids. The longitudinal 
relaxation times (T1 values) for AmB were substantially longer than those of the lipids, 
consistent with large and relatively immobile aggregates of AmB (Fig. 2.3C,D). SSNMR spin-
diffusion experiments, designed for the purpose of probing membrane protein topology (41), 
revealed that lipid-AmB correlations reached maximum intensity only at very long mixing times 
(~400 ms) for all resolvable carbons on AmB (Fig. 2.3E,F), indicating that the majority of the 
lipids were >15 Å away from the AmB. In contrast, we observed strong correlations between 
water and AmB within just 25 ms, consistent with intimate proximity of the AmB aggregates to 
water. 
Figure 2.5 (A) POPC/Erg 10:1 liposomes. (B) POPC/Erg 10:1 liposomes with 1 equiv. (relative to Erg) of 
added AmB. (C) AmB only. Scale bars, 200 nm. (D) AmB promotes robust K+ efflux from 200 mm LUV’s 
composed of 10:1 POPC:Erg. This activity mirrors both the in vitro and in vivo efflux activity of AmB 
previously reported by our laboratories. 10 mol% AmB was added as a DMSO solution (final AmB 
concentration of 1 µM) at t = 1.5 min, and efflux is reported as a percentage of total efflux observed upon 
addition of Triton X-100. The observed plateau at 60% efflux is likely reflective of equilibrium between the bulk 























To further probe these aggregates and distinguish between an intramembranous vs. 
extramembranous location, we also performed transmission electron microscopy analysis of 
Figure 2.6 (A) Samples prepared using 40:1 POPC/ [13C]Erg ± 5 mol% 16-DOXYL-PC showed a 
progressive decrease in PRE effects of resolved Erg resonances as the ratio of AmB/[13C]Erg increased. 
(B) The two-dimensional 13C-13C DARR spectrum of [13C]Erg (250-ms mixing, 
10:1:1 POPC/AmB/[13C]Erg) changed in the presence of AmB, exhibiting new cross-peaks. (C) The 1H-
13C polarization transfers from water (blue) and lipid (red) to Erg-7 were substantially different in the 
absence (closed circles and squares, dashed line) and presence (open circles and squares, solid line) 
of AmB. (D-F) Expansions of the olefin-to-methyl spectral region for two-dimensional [1H]-13C-[1H-1H]-
13C spectra42, 43 of only [13C]Erg (328 h signal averaging time) (D), only [U-13C]AmB (187 h) (E) and 
both [13C]Erg and [U-13C]AmB (187 h) (F). Error bars in A were derived from χ2 analysis of inversion 
recovery trajectories. The 1H-13C spin diffusion data in C were normalized relative to the maximum 
intensity observed for both lipid and water cross-peaks for a given 13C site after correcting 
for 1H T1 relaxation, and error bars were derived from the signal-to-noise of the observed cross-peak. 
Spectra were acquired at 14.1 T (600 MHz 1H frequency). Data in A-C were acquired at 10 kHz MAS, at 
20 °C and 10 °C, respectively. The [1H]-13C-[1H-1H]-13C spectra (D–F) were acquired at 10 °C, 11.628 
kHz MAS; processed with 40-Hz and 75-Hz line broadening in the direct and indirect dimensions, 
respectively; and were drawn with contour threshold set to four times the r.m.s. noise. 
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large unilamellar vesicles (LUVs) comprised of the same ratio of POPC:Erg ± AmB. In the 
absence of added AmB, we observed well-formed LUVs (Fig. 2.5A). When AmB was added, we 
observed large extramembranous aggregates (Fig. 2.5B). These aggregates were associated with 
one or more LUVs, suggesting an interaction between the surfaces of the aggregate and the lipid 
bilayer. When we added the same amount of AmB to the same volume of LUV-free buffer, 
similar aggregates of AmB were observed (Fig. 2.5C). These observations are consistent with the 
spontaneous formation in aqueous buffer of large AmB aggregates that externally associate with 
the surface of lipid bilayers. 
Importantly, parallel potassium efflux experiments revealed readily observable membrane 
permeabilization upon adding the same concentration of AmB to suspensions of the same 
POPC:Erg LUVs (Fig. 2.5D). This observation was consistent with a minor fraction of AmB 
existing in the form of membrane-permeabilizing ion channels that are too small to be visualized 
by TEM. This analysis was also consistent with all of our SSNMR data, in which the limits of 
detection permit up to 5% of the AmB existing in the membrane. 
With the structural aspects of the sterol sponge model confirmed, we aimed to test the 
functional prediction that these large extramembranous aggregates of AmB extract Erg from 
lipid bilayers. We first performed a modified SSNMR PRE experiment in which we analyzed 13C 
skip-labeled Erg ([13C]Erg, Fig. 2.6A) (19) in spin label-containing bilayers as a function of 
AmB:[13C]Erg ratio (Fig. 2.6A). This labeling pattern provided sufficient sensitivity that the ratio 
of POPC to Erg was increased to 40:1, readily enabling titrations of the AmB:Erg molar ratio 
while retaining the biophysical properties of the lipid bilayer. We then prepared bilayers 
comprised of POPC:[13C]Erg 40:1 ± 5 mol% 16-DOXYL without or with increasing amounts of 
natural abundance AmB. AmB had minimal effect on the POPC PRE (Fig. 2.7). In contrast, we 
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observed a progressive decrease in the [13C]Erg PRE as the amount of AmB increased, indicating 
that Erg increasingly occupied a position outside the lipid bilayer (Fig. 2.6A, Fig. 2.7A). In the 
absence of AmB (AmB:[13C]Erg 0:1), we observed substantial PREs for the resolved 13C signals 
of [13C]Erg; for several sites, such as Erg-18, Erg-21, Erg-22, Erg-24, Erg-26 and Erg-27, the 
PRE was ~1.5 s−1 or greater, and the 13C T1 values were relatively short (<1.5 s) (Fig. 2.7B). 
These findings are consistent with the structure of Erg-containing membranes in which the Erg is 
inserted into the hydrophobic core of the bilayer (35), with the isopropyl tail most deeply 
inserted and therefore most proximal to the 16-DOXYL label. These conformation-specific PREs 
Figure 2.7 The addition of AmB to POPC:Erg liposomes has a large effect on Erg, but a relatively small effect 
on POPC. The combination of the decrease in (A) PRE and substantial increase in the (B) longitudinal relaxation 
times (T1) of Erg are consistent with the formation of an AmB:Erg complex that is separated from the lipid 
bilayer. Note the small relative change in the POPC (C) PRE (~20% on average) and (D) 13C T1 values (~ 10% 
on average). (40:1 POPC:[13C]Erg (black), 40:1:1 POPC:AmB:[13C]Erg (orange), 40:4:1 POPC:AmB:[13C]Erg 
(blue), and 40:8:1 POPC:AmB:[13C]Erg (red) liposomes ± 5 mol% 16-DOXYL-PC.) Only methine (CH) and 
methylene (CH2) sites that do not shift significantly (< 0.5 ppm) upon addition of AmB are shown. SSNMR 
experiments were performed on a 600 MHz spectrometer, at 20 °C with an MAS rate of 10 kHz and 75 kHz 1H 
decoupling. (E) AmB extracts Erg from lipid bilayers. 1D 13C spectra of [13C]Erg titrated with natural abundance 
AmB. As a function of AmB:Erg ratio, the [13C]Erg resonances broaden from an average linewidth of 0.3 ppm to 
>1.0 ppm, consistent with formation of an AmB-Erg complex Spectra were acquired at 14.1 T (600 MHz 1H 
frequency), at 20 °C and 10 kHz MAS rate. 
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for [13C]Erg decreased markedly upon the addition of AmB (Fig. 2.6A, Fig. 2.7A). Specifically, 
with increasing amounts of natural abundance AmB (AmB:[13C]Erg ratios of 1:1, 4:1, 8:1), we 
observed a progressive decrease, with at least a three-fold reduction in observed PRE in the 
AmB:[13C]Erg 8:1 sample. These results support the interpretation that Erg increasingly occupies 











Additional SSNMR experiments also supported this conclusion and further demonstrated that 
the extracted Erg is physically bound to the extramembranous aggregates of AmB. As the ratio 
of AmB:[13C]Erg increased, Erg resonances, but not those of POPC, demonstrated 
inhomogeneous broadening (19), consistent with a transition from a mobile state to an immobile 
Figure 2.8 As a control experiment we also examined the effect of AmdeB, a derivative of AmB lacking the 
mycosamine appendage that does not bind Erg. There were no chemical shift perturbations observed upon the 
addition of AmdeB, as shown in (A) the over lay of 13C-13C 2D DARR (500ms mixing) spectra of 40:1 
POPC:[13C]Erg (black), 40:8:1 POPC:AmdeB:[13C]Erg (red). This is in stark contrast to the dramatic changes 
observed with the addition of AmB to POPC:[13C]Erg membranes. Furthermore there were only slight 
perturbations of the (B) 13C linewidth, and (C) 13C longitudinal (T1) relaxation times in comparison to those 
changes induced by the addition of an equivalent amount of AmB (40:8:1 POPC:AmB:[13C]Erg (blue)). Spectra 
were acquired on a 14.1 T (600 MHz 1H frequency) spectrometer, at 20 °C with an MAS rate of 10 kHz and 75 
kHz 1H decoupling. 
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state (Fig. 2.7E). The average 13C T1 relaxation values for [13C]Erg also followed the expected 
trend, increasing with the AmB:[13C]Erg ratio (Fig. 2.7B). Two-dimensional 13C-13C correlation 
spectra further revealed several 13C-Erg resonances that shifted significantly upon the addition of 
AmB (Fig. 2.6B), and resolved bound state resonances exhibited significantly higher linewidth 
and T1 values than those of the corresponding unbound state. In the absence of AmB, we 
observed very strong lipid-Erg correlations and no water-Erg correlations (Fig. 2.6C) (41), 
whereas in the presence of AmB we observed strong water correlations to all resolved Erg sites, 
with polarization transfer rates similar to those observed for AmB (Fig. 2.6C). We also repeated 
one- and two-dimensional chemical shift, linewidth, and T1 analyses of [13C]Erg in the presence 
of amphoteronolide B (AmdeB), a synthesized derivative of AmB that lacks the mycosamine 
appendage and does not bind Erg (26, 27), and observed no 13C-Erg chemical shift perturbations 
and only very small changes in linewidths and T1 values (Fig. 2.8). 
To definitively probe whether the extracted Erg is bound to the AmB aggregate, we prepared 
an additional series of samples in which 13C labels were placed on (i) only Erg (Fig. 4D), (ii) 
only AmB (Fig. 4E), and (iii) both AmB and Erg (Fig. 4F). [1H]-13C-[1H-1H]- 13C spectra (42, 
43) for the first two samples showed only the anticipated intramolecular correlations (Fig. 4D, 
4E), while the sample containing labels on both AmB and Erg revealed many new intermolecular 
AmB-Erg cross peaks (Fig. 4F), consistent with Erg aligned parallel to the polyene region of 
AmB and directly confirming the formation of a small molecule-small molecule complex. We 
also measured the 1H-13C dipolar couplings for resolved sites in both AmB and Erg using the T-
MREV recoupling sequence (44) (Fig 2.9A-F) and Erg (Fig 2.9G-L) to determine the relative 
mobility of these sites. In the absence of AmB, Erg was mobile as evidenced by the low order 
parameters, but in the presence of AmB, the order parameters shifted to the same rigid lattice 
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limit observed for AmB. Furthermore, we observed line widths of >110 Hz for both AmB and 
Erg in the sterol sponge. Therefore, we concluded that AmB extracts Erg from lipid bilayers into 
large, extramembranous aggregates. 
Figure	2.9	(A-F)	The	T-MREV	dipolar	lines	shapes	and	order	parameter	measured	select	AmB	resonances	
in	10:1:1	POPC:U-13C-AmB:Erg	MLVs	(black,	experimental	solid	line,	simulation	open	circle)	confirm	that	
sterol	sponge	 is	rigid.	Spectra	was	acquired	on	a	600	MHz	spectrometer,	 at	20	°C	with	and	MAS	 rate	of	
8.333	kHz,	and	85	kHz	TPPM	1H	decoupling59,	using	N=4	T-MREV.	(G-L)	The	substantial	broadening	of	
the	 T-MREV	 dipolar	 lines	 shapes	 and	 order	 parameter	 measured	 for	 select	 Erg	 resonances	 in	 40:0:1	
(black,	experimental	solid	line,	simulation	open	circle)	and	40:4:1	POPC:AmB:13C-Erg	(red,	experimental	




Finally, we tested the validity of the sterol sponge model in cells. First, we probed whether 
AmB extracts Erg from the cell membrane of yeast by adapting an ultracentrifugation-based 
membrane isolation assay (45) to quantify the amount of Erg in the membranes of live 
Saccharomyces cerevisiae cells in the absence and presence of AmB. As shown in Fig. 2.10A, 
AmB very effectively extracted Erg in a time-dependent fashion. In contrast, we observed no Erg 
Figure 2.10 (A) AmB extracted Erg from the membranes of S. cerevisiae cells in a time-dependent manner, 
whereas the non-Erg-binding derivative AmdeB showed no Erg-extracting activity. The percentage 
of Erg remaining in the cell membranes was normalized to that measured in DMSO-only treated controls. (B) 
Cell killing paralleled Erg extraction in AmB-treated cells. The non-Erg-extracting derivative AmdeB showed no 
cell-killing effects. (C) Erg extraction after 120 min of incubation. 500 mM MBCD extracted Erg from the 
membranes of S. cerevisiae cells, whereas a pre-formed 5 µM AmB:25 µM Erg complex did not. The percentage 
of Erg remaining in the cell membranes was normalized to that in DMSO-only and 25 µM Erg in DMSO-only 
treated controls, respectively. (D) Cell killing after 120 min incubation was observed for yeast treated with 500 
mM MBCD but not for yeast treated with 5 µM AmB:25 µM Erg complex. Data represent mean ± SEM for at 
least three independent experiments. *P < 0.02; **P < 0.002; NS, not significant. 
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extracting effects with the non-Erg-binding derivative AmdeB. It is interesting to note that AmB 
treatment also extracts lipids as measured by the progressive loss of palmitoyl (Fig. 2.11A) and 







Further experiments demonstrated that the Erg-extracting activity of AmB was responsible 
for its cell killing effects. As shown in Fig. 2.10B, we observed no cell killing with DMSO or 
AmdeB, whereas AmB promoted robust cell killing with a time course that paralleled Erg 
extraction. In addition, methyl-β-cyclodextrin (MBCD), a cyclic oligosaccharide known to 
extract sterols from membranes (46), similarly demonstrated both Erg extracting and cell killing 
activities (Fig. 2.10C and 2.10D). Finally, the sterol sponge model predicts that AmB aggregates 
pre-saturated with Erg will lose the ability to extract Erg from membranes and kill yeast. We 
found conditions that promoted the formation of stable and soluble aggregates of AmB and Erg, 
Figure 2.11 AmB extracted lipids 
(A) palmitoyl tails and (B) oleoyl 
tails from the membranes of S. 
cerevisiae cells in a time-dependent 
manner, whereas the non-Erg-
binding derivative AmdeB showed 
no lipid-extracting activity. The 
percentage of lipids remaining in the 
cell membranes was normalized to 
that measured in DMSO-only 
treated controls. Data represent 




thereby enabling this hypothesis to be tested. As predicted, treating cells with this pre-formed 
AmB:Erg complex resulted in no Erg extraction (Fig. 2.10C), and no cell killing (Fig. 2.10D).  
When we characterized this stable aggregate using UV/Vis, we saw distinct shift in UV 
spectra between the different forms of AmB and AmB bound to Erg in a complex (Fig. 2.12A). 
We also confirmed that the AmB aggregates we observed in our SSNMR, TEM, and cell- based 
experiments are similar (Fig. 2.12B-D). We also performed a series of assays where we heated 
the aggregates of AmB with different sterols, Erg and the endogenous human sterol cholesterol 
(Chol) and established melting curves. We found that both AmB:sterol aggregates dissociated at 
higher temperatures than the AmB only aggregate, which indicates increased thermal stability of 
the AmB:sterol complex (Fig. 2.12E). Notably, AmB:Erg requires a higher temperature than 
AmB:Chol to dissociate, which may preliminarily indicate a greater binding affinity for Erg than 
Chol (Fig. 2.12E). However, the nature of the interaction between AmB and sterol within the 
aggregate will require further study to fully elaborate. 
The sterol sponge model provides a new foundation for better understanding and more 
effectively harnessing the unique biophysical, biological, and medicinal properties of this small 
molecule natural product. Based on the classic ion channel model, many efforts over the past 
several decades to improve the therapeutic index of AmB focused on selectively permeabilizing 
yeast versus human cells (11, 13). This approach has not yielded a clinically viable derivative of 
the natural product. The sterol sponge model suggests that an alternative approach will be more 
effective. Specifically, analogous to the now clarified mechanism of antifungal activity, the 
extraction of cholesterol by large extramembranous aggregates of AmB may be primarily 
responsible for toxicity to human cells. This, in turn, suggests that the goal should be to 
maximize the relative binding affinity of AmB aggregates for Erg versus cholesterol. This insight 
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is already guiding development of the first derivatives of AmB that are toxic to yeast cells but 










The sterol sponge model also offers a new rationale for the paucity of clinically relevant 
microbial resistance that is a hallmark of AmB as a therapeutic. Because the extraction of Erg 
renders yeast membranes Erg-deficient, AmB may simultaneously perturb all cellular processes 
that depend on membrane Erg (28-31, 48). This likely includes many different membrane 
Figure 2.12 (A) Monomeric AmB in 
PBS:methanol and AmB aggregate in 
PBS buffer demonstrate spectral 
signatures by UV spectroscopy. 13C 
NMR and UV-Vis spectra of (B) AmB 
precipitated in YPD buffer used for in 
vivo studies, (C) AmB precipitated in 
HEPES buffer used for TEM studies, 
and (D) 10:1 mole ratio of 
POPC:AmB MLVs lyophilized and 




proteins that directly bind Erg (28-31), and simultaneous mutation of all such proteins in a 
manner that alleviates this Erg dependence is highly improbable. It has also remained unclear 
why, in contrast to the rarity with which AmB resistant mutants are found in patients, it is 
relatively easy to generate AmB-resistant yeast mutants in cell culture experiments (49). The 
sterol sponge model provides a rationale for this dichotomy. AmB-resistant mutants generated in 
cell culture generally possess modified sterols in their membranes, e.g., lanosterol (50) (and/or 
other biosynthetic precursors to Erg) to which AmB does not bind (described above) (26). It was 
previously assumed that such changes in sterol content minimize antifungal potency by 
minimizing membrane-permeabilizing activity (9, 10, 13, 49). The sterol sponge model 
alternatively suggests that, because AmB does not bind or extract lanosterol, this modified sterol 
remains in the membrane to serve as a surrogate binding partner for sterol-dependent proteins. 
Due to the structural differences between lanosterol and Erg described above, however, the 
former is likely only a minimally effective substitute, resulting in reduced activity of many 
proteins that require specific interactions with Erg to function properly. This, in turn, may 
translate into substantially reduced pathogenicity of the resulting yeast mutants. Consistent with 
this notion, strains of yeast with modified sterol content have markedly reduced pathogenicity in 
animal models (49). Such strains may routinely emerge in patients treated with AmB, but, due to 
their reduced pathogenicity, they cannot thrive and/or are rapidly cleared by the immune system 
of the host. A recently reported alternative series of studies provide complementary support for 
these conclusions (49). 
But most importantly, the clarified picture of the structural and functional underpinnings of 
AmB activity provided by the sterol sponge model now illuminates a rational roadmap for 
separating the ion channel forming and cytotoxic activities of AmB. Small, membrane-spanning 
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ion channel aggregates likely exist as minor components in equilibrium with the large 
extramembranous assemblies of AmB characterized herein. This proposal is consistent with the 
weak AmB-lipid correlations observed in the SSNMR spin diffusion experiments, and the limits 
of detection of the SSNMR PRE and TEM studies. As we have previously demonstrated, binding 
ergosterol in the absence of channel activity is sufficient for cell killing (27). Specifically, the 
capacity for channel formation can be selectively eliminated while preserving the capacity for 
both Erg binding and cell killing via deleting the C35 hydroxyl group appended to AmB (27). In 
the sterol sponge model, this result can be rationalized by invoking a selectively destabilizing 
influence of this functional group deletion on the smaller membrane-inserted channel aggregates. 
Future studies will aim to determine whether this putative equilibrium between large 
extramembranous and small membrane-spanning aggregates can be alternatively shifted to favor 
ion channel formation, thereby maximizing potentially useful membrane-permeabilizing 
functions (27) while minimizing cytotoxic sterol extracting activity. 
2.3 THE PROSPECT OF MOLECULAR PROSTHETICS 
There are many currently incurable human diseases that are caused by missing protein ion 
channels, including cystic fibrosis, Bartter syndrome, Dravet syndrome, and Dent’s disease (51, 
52). Like many other human diseases caused by missing proteins, these diseases are difficult to 
treat, and new approaches are needed. Some small molecules can perform ion channel-like 
functions (4, 53-61), suggesting the possibility of replacing missing protein ion channels with 
small molecule mimics. Closely replicating the functions of ion selective and tightly regulated 
protein channels with small molecules is challenging. However, robust protein networks 
comprising pumps and channels drive specific ions in targeted directions throughout the 
spectrum of living systems (62). We then questioned if relatively unselective and unregulated 
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small molecule mimics of missing protein channels might be capable of collaborating with the 
endogenous protein ion pumps and channels to restore physiology. 
Yeast represents an excellent model system for studying eukaryotic physiology (63, 
64). Moreover, deficiencies of specific protein ion transporters in yeast are known to lead to 
dramatic no-growth phenotypes, therefore providing a unique opportunity for using cell growth 
as a marker for physiology restoration. In yeast, ATP-driven V-ATPase and Pma1 proton pumps 
in the vacuolar and plasma membranes, respectively, collaborate with passive Trk potassium 
transporters in the plasma membrane to achieve intracellular movement of potassium required 
for cell growth (Fig. 2.13A, left) (65). Loss of Trk transporters impairs uptake of environmental 
potassium and results in a no-growth phenotype (Fig. 2.13A, middle) (66-68).  Because the ATP-
driven pumps, the primary drivers of ion movement, are still active in this yeast, we 
hypothesized that a small molecule ion channel permeable to potassium could collaborate with 
V-ATPase and Pma1 to restore cell growth (Fig. 2.13A, right). 
Following our previous work on AmB, we identified this ion channel-forming natural 
product (Fig. 2.13B) as a viable candidate to test this hypothesis (4). AmB is known to 
permeabilize yeast cells to potassium and other ions (10, 69). As discussed previously, AmB is 
also highly toxic to yeast, and this toxicity was considered inextricably linked to its membrane 
permeabilization. However, we found a synthesized derivative of AmB lacking a single oxygen 
atom at C35 (C35deOAmB) (Fig. 2.13B) does not form ion channels and yet still maintains 
potent fungicidal activity (27). AmB and C35deOAmB, which differ via a single atom, represent 
a unique pair of probes for determining the impact of small molecule-mediated ion channel 
activity on organismal physiology. This finding combined with the studies discussed in section 
2.2 suggested that the channel activity of AmB might be separated from its cytocidal activity by 
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2.4 RESTORED PHYSIOLOGY IN PROTEIN-DEFICIENT YEAST BY THE SMALL 
MOLECULE AMB CHANNEL 
We first tested the hypothesis that AmB could restore cell growth in potassium transporter-
deficient yeast with a modified functional complementation experiment (70). Consistent with 
prior reports (66, 67), growth was observed when wild type Saccharomyces cerevisiae were 
streaked onto agar plates containing normal concentrations of potassium (10 mM) (Fig. 2.14A, 
left), and no growth was observed for the potassium transporter-deficient strain (trk1Δtrk2Δ) 
Fig 2.13 (A) Prospect of replacing missing protein ion transporters with small molecule mimics. 
(B) Chemical structures of the archetypical ion channel-forming small molecule amphotericin B 




under the same conditions (Fig. 2.14A, middle). Strikingly, the addition of a low concentration 
of AmB (125 nM) to an otherwise identical agar plate vigorously restored growth of the 
















Figure 2.14. (A) Restoration of yeast cell growth under normal potassium conditions (10 mM) with a small 
molecule mimic of missing protein potassium transporters. (B) Disc diffusion with AmB on a plate of 
trk1Δtrk2Δ cells. (C) AmB restores cell growth at concentrations below its minimum inhibitory concentration, 
while C35deOAmB does not restore growth. (D) Tetraethylammonium diminishes AmB-mediated growth 
restoration in trk1Δtrk2Δ cells but has no effect on trk1Δtrk2Δ cells grown under permissive conditions (100 
mM KCl). (E) AmB restores uptake of extracellular 86Rb+, a tracer for K+, in trk1Δtrk2Δ cells, but C35deOAmB 
does not. (F) Vigorous restoration of cell growth is observed upon treating trk1Δtrk2Δ cells with AmB. (G) 
Similar to wild type cells, AmB-rescued trk1Δtrk2Δ cells show sustained growth over a period of >40 days. (H) 
A preformed AmB-ergosterol complex dramatically increases the range of concentrations over which physiology 















A series of additional experiments confirmed that the observed restoration of cell growth is 
caused by the small molecule-based ion channel activity. A disc diffusion assay visually revealed 
the predicted dependence of this growth rescue on the concentration of AmB (Fig. 2.14B). To 
quantify this concentration dependence and eliminate the potentially complicating issue of 
plating efficiency (71), we also measured trk1Δtrk2Δ yeast cell growth in a broth dilution assay 
using media containing a normal concentration of potassium (10 mM) (Fig. 2.14C).  Consistent 
Figure 2.15 AmB does not cause growth stimulatory effects to wild type yeast or trk1Δtrk2Δ yeast when both 
are grown under permissive high potassium (100 mM KCl) conditions. (A) AmB does not cause growth 
stimulatory effects in wild type cells grown in the presence of 100 mM KCl. Curves represent AmB 
concentrations of 0 nM, 62.5 nM, and 125 nM. No growth is observed at or above the minimum inhibitory 
concentration of 500 nM AmB. (B) AmB does not cause growth stimulatory effects on trk1Δtrk2Δ cells grown 
under permissive conditions (100 mM KCl). Curves represent AmB concentrations of 0 nM, 62.5 nM, and 125 
nM. No growth is observed at or above the minimum inhibitory concentration of 500 nM AmB. (C) Wild type 
and AmB-rescued (125 nM) trk1Δtrk2Δ yeast growth curve for 24 hours. The same potassium concentration (10 
mM) was used in both experiments. The doubling time for wild type and AmB-rescued trk1Δtrk2Δ yeast was 86 
± 2.4 minutes and 144 ± 2.8 minutes, respectively. (D) AmB-treated wild type and AmB-rescued trk1Δtrk2Δ 
cells show no decrease in cell viability compared to wild type as judged by propidium iodide staining. NS, not 
significant. Graph depicts means ± SEM.  
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with the disc diffusion results, no cell growth was observed in the absence of AmB, a dose-
dependent increase of growth was observed at intermediate concentrations, and no growth was 
observed at or above the minimum inhibitory concentration of this antifungal agent. Further 
ruling out any type of generic hormetic effects (72), no growth stimulatory effects were observed 
when wild type cells or trk1Δtrk2Δ cells grown under permissive conditions were treated with 








To directly probe the importance of the ion channel activity of AmB, we also tested the 
single atom-deficient variant C35deOAmB, which does not form ion channels (Fig. 2.13B) 
(27). This derivative failed to restore growth in trk1Δtrk2Δ cells at any tested concentration (Fig. 
2.14C). In a complementary experiment, we utilized the sterically bulky tetraethylammonium 
cation to block the AmB-based ion channel (73). This cation inhibited the functional 
complementation observed with AmB in a dose-dependent manner without causing general 
toxicity (Fig. 2.14D). We also monitored uptake of radioactive 86Rb+ as a reporter of 
transmembrane potassium movement (Fig. 2.14E) (74). 86Rb+ uptake was observed in wild 
Figure 2.16 Potassium efflux in wild type S. cerevisiae. AmB readily permeabilizes wild type S. cerevisiae 
compared to DMSO vehicle. A pre-formed AmB-ergosterol complex still permeabilizes yeast cells. Experiment 
was performed in triplicate. Plot is representative of each replicate.  
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typeyeast but not in the trk1Δtrk2Δ mutant, and no uptake was observed when the trk1Δtrk2Δ 
mutant was treated with the channel-inactivated derivative C35deOAmB. In 



















We further quantified the vigor and sustainability of this AmB ion channel-mediated 
restoration of yeast cell growth. AmB-treated trk1Δtrk2Δ cells reached a maximum cell density 
Figure 2.17 Series of potassium-transporting polyene macrolide natural products restore 
vigorous cell growth in trk1Δtrk2Δ yeast, whereas (A) no growth is observed upon treating with 
other small molecules that selectively transport other ions. (C-D) Nystatin, candicidin, and 
mepartricin were similarly able to restore physiology in a liquid broth dilution assay over a 
variety of concentrations. Graphs depict means ± SEM. 
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that matched that of the wild type (Fig. 2.14F) and the doubling time for AmB-rescued 
trk1Δtrk2Δ cells was only 1.7 times longer (Fig. 2.15C). We also observed equivalent levels of 
cell viability in wild type yeast, wild type yeast treated with 125 nM AmB, and trk1Δtrk2Δ cells 
rescued with 125 nM AmB (Fig. 2.15D). To probe the sustainability of this rescue effect, we 
reiterated the max cell density and doubling time experiments for over a month. Like wild type 
cells, the AmB-rescued trk1Δtrk2Δ cells showed sustained vigorous cell growth throughout this 
entire period of time (Fig. 2.14G). Removing AmB from the media at any point resulted in rapid 
loss of growth for the trk1Δtrk2Δ cells. We further confirmed the mechanism-based hypothesis 
that the preformed AmB:Erg complex discussed in section 2.2 should retain the capacity to 
permeabilize yeast cells (Fig. 2.16) but show substantially decreased cell killing (75). This 
Figure 2.18 (A) The potassium ion carrier valinomycin does not restore trk1Δtrk2Δ cell growth. Disc diffusion 
assay with valinomycin (4 mg/mL) on an agar plate containing 10 mM potassium and streaked with trk1Δtrk2Δ 
cells. (B) Broth microdilution assay with valinomycin. (C) Polyene macrolide natamycin does not restore 
trk1Δtrk2Δ cell growth. Disc diffusion assay with natamycin (4 mg/mL) on an agar plate containing 10 mM 
potassium and streaked with trk1Δtrk2Δ cells. (D) Broth microdilution assay with natamycin. Graph depicts 
means ± SEM. 
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preformed complex dramatically extended the range of concentrations over which rescue is 
observed (Fig. 2.14H). 
To probe the scope and limitations of this tolerance for imperfect mimicry of missing 
proteins with small molecules, a series of additional ion transporting natural products were 
evaluated. Vigorous restoration of trk1Δtrk2Δ cell growth was observed with other small 
molecules that form potassium ion channels, including nystatin, candicidin, and mepartricin, 
(Fig. 2.17B-D) but not with those that selectively transport NH4+ (nonactin), Cl– (prodigiosin), 
Figure 2.19 (A) AmB-treated wild type S. cerevisiae and trk1Δtrk2Δ cells are equally sensitive to the off-
pathway microtubule inhibitor nocodazole. (B) AmB-rescued trk1Δtrk2Δ cells are substantially more sensitive to 
the V-ATPase inhibitor bafilomycin compared to wild type cells. (C) AmB-rescued trk1Δtrk2Δ cells are 
substantially more sensitive to the Pma1 inhibitor ebselen than wild type cells. (D-F) EC50 values for various 
inhibitors of cell growth against wild type (black bars) and trk1Δtrk2Δ cells (white bars) treated with optimum 
rescue concentrations of potassium-transporting polyene macrolide natural products AmB, nystatin, candicidin, 
and mepartricin. NS, not significant. *P ≤ 0.05. **P ≤ 0.001. ***P ≤ 0.0001. Graphs depict means ± SEM. 
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and Ca2+ (calcimycin) (Fig. 2.17A). Interestingly, the potassium ion carrier valinomycin (76) is 
unable to restore cell growth (Fig. 2.18A,B). 
Finally, we tested the mechanistic hypothesis that these potassium channel-forming small 
molecules restore physiology by collaborating with the V-ATPase and Pma1 proton pumps. Such 
a model predicts selective sensitivity of the small molecule-rescued mutants to chemical 
inhibition of these pumps. As a negative control, AmB-treated wild type and AmB-rescued 
trk1Δtrk2Δ cells were equally sensitive to nocodazole, an off-pathway inhibitor of microtubule 
dynamics (Fig. 2.19A). In contrast, AmB-rescued trk1Δtrk2Δ cells were exceptionally sensitive 
to inhibition of V-ATPase with bafilomycin (Fig. 2.19B) and Pma1 with ebselen (Fig. 2.19C). 
Similar results were observed with nystatin-, candicidin-, and mepartricin-rescued trk1Δtrk2Δ 
cells (Figure 2.19D-F). 
2.5 SUMMARY 
 The ability of AmB to form membrane-spanning ion channels has long been thought to 
primarily contribute to its structure and antifungal activity, seemingly precluding it as a viable 
candidate for a small molecule prosthetic (4-23). In contrast, we found that AmB predominantly 
forms large extramembranous aggregates that extract Erg from lipid bilayers and thereby kill 
yeast. Membrane-inserted ion channels are relatively minor contributors, both structurally and 
functionally, to the antifungal action of this natural product. While previous studies have 
reported large aggregates of AmB or its derivatives (17, 21), the interpretation of these findings 
has been in terms of the ion channel model. Here we described PRE, 1H spin diffusion trajectory, 
and TEM studies that collectively demonstrated that AmB primarily exists in the form of large 
extramembranous aggregates. Moreover, changes in PREs, 1H spin diffusion trajectories, T1 
relaxation, order parameters, line widths, and chemical shift perturbations, as well as the 
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observation of direct intermolecular cross peaks and the results of cell-based ergosterol 
extraction experiments demonstrated that extramembranous aggregates of AmB directly bind 
Erg. We further confirmed that the AmB aggregates we observed in our SSNMR, TEM, and cell-
based experiments were similar. Collectively, these results strongly support the proposed sterol 
sponge model in which extramembranous aggregates of AmB extract ergosterol from 
phospholipid bilayers and thereby kill yeast, independent of channel formation. 
These findings revealed two unique strategies with which to approach testing AmB as a small 
molecule ion channel mimic. Our first approach to separating the channel activity of AmB from 
its cell killing activity was simply using low concentrations, staying below the toxic ratio of 
AmB to sterol. The second approach was to use a preformed AmB:Erg complex, which 
maintains its channel-forming capacity while mitigating toxicity. Using these two strategies 
guided by our previous work, we concluded that imperfect small molecule mimics of missing 
protein ion transporters can restore physiology in yeast, and evidence supports that this 
phenomenon is attributable to functional collaboration between small molecule channels and 
protein ion pumps. A common channels and pumps architecture is responsible for directional ion 
movement in organisms from yeast to humans (62), suggesting that the same type of functional 
collaboration observed herein might enable small molecule surrogates for missing protein ion 
channels to have an impact on human health. Therefore, our two strategies for AmB as a 
molecular prosthetic are well positioned for further testing in a human disease model system.  
2.6 METHODS 
Materials. Commercially available materials were purchased from Sigma-Aldrich, Alfa Aesar, 
Avanti Polar Lipids, Cambridge Isotope Laboratories, or Fisher Scientific and were used without 
further purification unless stated otherwise. Natural abundance amphotericin B (AmB) was 
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purchased from Sigma-Aldrich or a gift from Bristol-Myers Squibb Company. Unless stated 
otherwise, all solvents were dispensed from a solvent purification system that passes solvents 
through packed columns according to the method of Pangborn and coworkers (77) (THF, Et2O, 
CH2Cl2, toluene, dioxane, hexanes: dry neutral alumina; DMSO, DMF, CH3OH: activated 
molecular sieves). Water was dispensed from a MilliQ water purification system (Millipore 
Corporation, Billerica, MA). 
Purification and analysis. Preparative scale HPLC purification was performed using an Agilent 
1260 series instrument equipped with a multiple-wavelength detector and a Waters SunFire Prep 
C18 OBD 5 µm 30×150 mm column at a flow rate of 25 mL/min. All HPLC solvents were 
filtered through 0.2 µm Millipore filters prior to use. UV/Vis analyses were performed on a 
Shimadzu PharmaSpec UV-1700 spectrophotometer. Electrospray ionization mass spectra (ESI-
MS) were obtained at the University of Illinois mass spectrometry facility. 
Amphotericin and amphoteronolide B. Due to light and air sensitivity of polyenes, all 
manipulations of AmB and amphoteronolide B (AmdeB) were carried out under low-light 
conditions and compounds were stored under a dry argon atmosphere at −20 °C. AmdeB was 
prepared synthetically from natural abundance AmB as previously described (25-27). All AmB 
and AmdeB used for current experiments were purified by preparative scale HPLC. All 
manipulations of HPLC-purified AmB and AmdeB were performed using either Optima MeOH, 
0.2 µm-filtered HPLC grade solvents, or solvents dispensed from a solvent purification system 
(77). 
For purification, solid AmB was dissolved in DMSO (10 mg/mL), filtered through Celite 545 
and purified (100 µL injections) with gradient of 5% to 65% MeCN / 5 mM ammonium acetate 
(NH4OAc) over 12 minutes with detection at 406 nm. The column was subsequently flushed 
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with isocratic 95% MeCN / 5 mM NH4OAc for 2 min and re-equilibrated to 5% MeCN / 5 mM 
NH4OAc prior to the next injection. The combined AmB solution was concentrated in vacuo, 
with filtered (0.2 µm) MeCN added back to the flask as needed for azeotropic removal of water. 
The resulting yellow solid was suspended via bath sonication in 1:1 MeCN:toluene and again 
concentrated in vacuo for azeotropic removal of residual NH4OAc. Residual solvent was 
removed under high vacuum for ≥ 8 h to furnish a pale yellow solid, which was stored under 
argon at −20 °C. 
AmdeB was dissolved in DMF, filtered (Celite 545), injected, and eluted with a mobile phase 
gradient of 5% to 95% MeCN / 5 mM NH4OAc over 25 min. 
Biosynthesis of [U-13C]AmB. [U-13C]AmB was prepared using a modified version of the 
method previously reported (18), with [U-13C]glucose replacing natural abundance fructose in 
the culture medium. All simple carbon sources were thus uniformly 13C-labeled, resulting in 
unprecedented isotopic enrichment of >80%, as measured by mass spectrometry. After work up 
and precipitation, [U-13C]AmB was purified by gradient C18 chromatography followed by 
HPLC. 
Erg preparation. Natural abundance Erg was purchased from Sigma-Aldrich and recrystallized 
from EtOH before use. Stock solutions of 4 mg/mL Erg in CHCl3 were stored under argon at −20 
°C for up to 1 month. [13C]Erg was prepared biosynthetically using the method previously 
described (19, 78). 
Solid-state NMR spectroscopy. SSNMR experiments were performed using a 600 MHz 
InfinityPlus spectrometer (Varian, now a subsidiary of Agilent Technologies, Inc.) equipped with 
a 3.2 mm T3 HXY MAS probe tuned to 1H-31P-13C mode. Pulse widths (π/2) for 1H, 13C, and 31P 
were 2–2.5 µs, 3.2 µs, and 3.2 µs, respectively. Spinning was controlled with a Varian MAS 
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controller to 10,000 ± 2 Hz. SPINAL-64 decoupling (~75 to 80 kHz) was used during evolution 
and acquisition periods.53 The flow rate of sample cooling gas was maintained at 100 scfh at 20 
°C, resulting in a calibrated sample temperature of 19.2±1 °C. Chemical shifts were referenced 
externally with adamantane, with the downfield 13C resonance referenced to 40.48 ppm (79). 
13C T1 and PRE experiments. T1 values were measured using standard T1 inversion recovery 
pulse sequence with a 5 second pulse delay. Data were processed and fit with Varian Spinsight 
software version 4.3.2. For each of the resolved methine and methylene in [U-13C]AmB and 
[13C]Erg, the longitudinal 13C PRE was obtained by calculating the difference between the 13C R1 
values for sample with and without 5 mol% of the DOXYL lipids, determined by modeling the 
individual relaxation trajectories as single exponential decays. T1 trajectories were fit using the 
integrated volume of a given peak as a function of delay time (tau_1); integration boundaries 
were set to the linewidth at half height. The average line widths were ~40–60 Hz for POPC, ~50 
Hz for Erg with no AmB present, 127 Hz with AmB present, and ~187 Hz for AmB alone. 
1H-13C spin-diffusion experiments. We performed 1H-13C spin-diffusion correlation 
experiments as previously described (41) using a 1 ms T2 filter, to detect interactions between the 
mobile 1H signals of lipid acyl chains (1.35 ppm) and/or water (4.7 ppm) with the [U-13C]AmB, 
and [13C]Erg in the presence and absence of AmB. 1H-13C polarization transfer trajectories were 
extracted from 1H-13C two-dimensional spectra collected with 1H-13C mixing times ranging from 
1 ms to 625 ms, by fitting peaks with a minimum signal to noise of 5, using a box integration 
method in Sparky. Trajectories were then normalized based on maximum observed intensity for 
a single resolved water or lipid 1H-13C cross peak after correction for 1H T1 relaxation, which 
was measured in a separate T1 inversion recovery experiment. Error bars are derived from the 
signal-to-noise ratios observed for each crosspeak. 
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Order parameters from 1H-13C dipolar couplings. Dipolar order parameters (S) were 
measured using the T-MREV pulse sequence (44) at an MAS rate of 8.333 kHz (N=4 condition, 
100 kHz 1H decoupling nutation frequency, 2.5 µs 1H π/2 pulse length). The T-MREV 13C-1H 
dephasing was incremented by 30 µs and a total of 25 increments were recorded in t1. Fortran 
fitting routines (80) were used to determine the 13C-1H dipolar coupling, taking into account the 
effects of relaxation and contributions from weaker couplings from neighboring protons. We 
calibrated the scaling factor of the T-MREV sequence by measuring the 13C-1H dipolar coupling 
for crystalline N-acetyl-L-valine under the identical experimental conditions. 
 [1H]-13C-[1H-1H]- 13C correlation spectra. [1H]-13C-[1H-1H]- 13C SSNMR experiments to yield 
performed at 10 °C, at an MAS rate 11.628 kHz, with the heteronuclear contact time (tHC) set to 
400 µs, and 1H-1H mixing time of 400 µs. These conditions reveal cross peaks for internuclear 
13C-13C distances of ~4–6 Å. In order to properly identify new intermolecular AmB-Erg cross 
peaks the [1H]-13C-[1H-1H]- 13C spectra were acquired back-to-back under identical conditions, 
including and signal averaging, adjusting the total measurement time based on the amount of 
material. The rotors of POPC/[U-13C]AmB/Erg (10:1:1 molar ratio) and POPC/[U-
13C]AmB/[13C]Erg (10:1:1 molar ratio) were packed with ~25 mg and the spectra signal 
averaged for 7.8 days each. The 10:1:1 POPC/AmB/[13C]Erg sample was ~16 mg and therefore 
signal averaged for 13.6 days. The three spectra were all processed identically, with 40 and 75 
Hz 13C line broadening applied in the direct and indirect dimensions, respectively. 
Preparation of stock solutions for SSNMR. A fresh stock solution of HPLC-purified AmB 
(natural abundance or [U-13C]AmB) was prepared for each experiment by dissolving AmB in a 
large volume of Optima methanol, typically 75–100 mL for 10 mg of AmB. Stock solution 
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concentration was measured in triplicate by dilution in MeOH and measuring absorbance at 406 
nm (ε406 = 146000 M−1 cm−1) (25). 
Stock solutions of Erg were prepared by dissolving recrystallized (commercial) or HPLC-
purified (biosynthetic) Erg in a minimum volume of CHCl3 and the concentration determined by 
UV/Vis spectroscopy (ε282 = 10,400 M−1 cm−1) (26). Erg stock solutions were stored in I-Chem 
vials under a dry argon atmosphere at −20 °C for up to 1 month. 
Phospholipids were purchased as stock solutions in CHCl3 and these solutions were used 
directly for liposome preparation. Unused phospholipid solutions were stored in vials/bottles 
under a dry argon atmosphere at −20 °C, and discarded after 1 month. 
Preparation of liposome vesicles for SSNMR. Liposomes were prepared using a modified 
version of the protocol previously reported (18). A suspension of POPC/Erg/AmB in 1:1 
CHCl3/MeOH was prepared as follows: The desired amount of AmB stock solution (typically 
30–40 mL) was concentrated in vacuo to 2–3 mL and transferred to a 7 mL Wheaton vial, with 
three Optima MeOH washes to ensure complete transfer. This resulting AmB suspension was 
concentrated in vacuo. The desired amounts of stock solutions of phospholipid and Erg were 
then added via Hamilton gastight syringe, and an equivalent volume of Optima MeOH was 
added to resuspend the AmB. The vial was capped and this suspension was briefly vortexed and 
bath-sonicated until no AmB remained adherent to the sides of the vial (2–3 cycles). Solvent was 
removed under a gentle stream of nitrogen gas. Residual solvent was removed under high 
vacuum for ≥8 h. 
To the dried solid was added filter-sterilized 0.3 mM HEPES buffer, pH 7.0 to yield a final 
phospholipid concentration of 40 mM. This aqueous suspension was vortexed and sonicated 3 
times or until a homogeneous suspension was observed. Samples were then submitted to 5 
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freeze/thaw cycles (liquid nitrogen, lukewarm tap water). Samples were again frozen in liquid 
nitrogen and lyophilized for ≥8 h. The lyophilization chamber was then back-filled with dry 
argon to prevent samples from absorbing ambient water. Samples were immediately capped and 
packed into rotors for SSNMR as soon as possible. 
Dry samples were packed in 3.2-mm-diameter-limited-speed SSNMR rotors (Agilent 
Technologies, Inc.) and hydrated with 8–10 µL of MilliQ H2O. Rubber discs were used in the 
rotors to maintain hydration levels by creating a seal. Samples were placed at 4 °C for at least 24 
hours to allow water to equilibrate. 
General information for electron microscopy. LUVs were prepared by the method reported 
previously (26, 27), and AmB was added to the LUV suspension as a freshly-prepared DMSO 
stock solution. Microscopy was performed using a 120-keV FEI Spirit Transmission Electron 
Microscope. Images were recorded using a bottom mount TVIPS CMOS based camera system at 
nominal magnifications of 23,000–49,000x at the specimen level. Measurements were taken in 
ImageJ32 (v 1.47). 
Sample preparation for electron microscopy. AmB was prepared as a stock DMSO solution 
(8.82 mM). 5 µL of the stock AmB solution was added to 95 µL of the 50x-diluted LUV 
solutions. For AmB-free samples, 5 µL of DMSO was added to 95 µL of the 50x-diluted LUV 
solutions. Samples were vortexed gently for 5 seconds then incubated at 37 °C for 1 hour. EM 
samples were prepared as previously described (81) with the following modifications. A 4 µL 
drop of the sample was applied to a negatively charged carbon-coated copper grid (Gilder 200 
mesh, Ted Pella, Inc., Redding CA) for 30 seconds. Subsequently, two drops of freshly prepared 
2% uranyl acetate were added to the sample and incubated for 1 minute before drying via 
aspiration. Samples were then screened on the electron microscope. 
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Growth conditions for S. cerevisiae for in vivo sterol extraction and membrane isolation. S. 
cerevisiae was grown in autoclave-sterilized yeast peptone dextrose (YPD) media consisting of 
10 g/L yeast extract, 20 g/L peptone and 20 g/L of filter-sterilized dextrose added as a sterile 
40% w/v solution in water. Solid media was prepared by pouring sterile media containing agar 
(20 g/L) onto Corning (Corning, NY) 100×20 mm polystyrene plates. Liquid cultures were 
incubated at 30 °C on a rotary shaker and solid cultures were maintained at 30 °C in an 
incubator. 
Sample preparation for in vivo sterol extraction and membrane isolation. 750 mL overnight 
cultures of S. cerevisiae were grown to stationary phase (OD600 of ~1.7 as measured with a 
Shimadzu PharmaSpec UV-1700 UV/Vis spectrophotometer). This culture was divided equally 
into 50 mL Falcon centrifuge tubes. 
Stock solutions of AmdeB, AmB, and Erg were prepared in DMSO. Methyl-β-cyclodextrin 
(MBCD) was added directly to the liquid culture. Cells were treated with either a DMSO only 
control, 5 µM AmdeB, or 5 µM AmB for 1, 30, 60, or 120 minutes. Cells were treated with 
DMSO control, 500 mM MBCD, 25 µM Erg control, and the 5 µM AmB:25 µM Erg complex 
for 120 minutes. Treated tubes were incubated on the rotary shaker (200 rpm) at 30°C for the 
time of exposure. 
For the quantification of colony forming units (CFUs), at the end of exposure, aliquots were 
taken from the samples, diluted, and plated on YPD agar plates. The plates were then incubated 
for 48 hours at 30°C and colony-forming units were counted. 
For the quantification of percent ergosterol remaining, yeast membranes were isolated using 
a modified version of Haas’ spheroplasting and isosmotic cell lysis protocol and simple 
differential ultracentrifugation (45). At the end of the exposure time, tubes were removed from 
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the shaker and centrifuged for 5 minutes at 3000 µg at room temperature. The supernatant was 
decanted and 5 mL of wash buffer (dH2O, 1M DTT, 1M Tris-HCl, pH 9.4) was added. The tubes 
were vortexed to resuspend and incubated in a 30°C water bath for 10 minutes. Tubes were then 
centrifuged again for 5 minutes at 3000 µg and the supernatant decanted. 
1 mL of spheroplasting buffer (1M KPi, YPD media, 4M sorbitol) and 100 µL of a 5 mg/mL 
solution of lyticase from Arthrobacter luteus (L2524 Sigma-Aldrich) was added to each tube, 
and each tube was then vortexed to resuspend. Tubes were incubated in a 30°C water bath for 30 
minutes, with occasional swirling. After incubation, tubes were centrifuged for 10 minutes at 
1080 µg at 4 °C and the supernatant decanted. 
1 mL of PBS buffer and 20 µL of a 0.4 mg/ml dextran in 8% Ficoll solution was added to 
each tube, mixed very gently to resuspend. This suspension was placed on ice for 4 minutes and 
then heat-shocked in a 30°C water bath for 3 minutes. 
The suspensions were then transferred to Eppendorf tubes, vortexed to ensure complete lysis, 
and centrifuged at 15000 µg at 4 °C for 15 minutes to remove un-lysed cells and cell debris. The 
resulting supernatants were transferred to thick-wall polycarbonate ultracentrifuge tubes (3.5 mL, 
13×51 mm, 349622 Beckman Coulter) and spun for 1 hour at 100,000 µg at 4°C in a Beckman 
Coulter TLA-100.3 fixed-angle rotor in a Beckman TL-100 Ultracentrifuge. The supernatant was 
poured off. The remaining membrane pellet was resuspended in 1 mL PBS buffer and stored at 
−80 °C until further analysis. 
Gas chromatography quantification of sterols. 750 µL of each membrane pellet sample and 
20 µL of internal standard (4 mg/mL cholesterol in chloroform) were dissolved in 3 mL 2.5% 
ethanolic KOH in a 7 mL vial, which was then vortexed gently, capped, and heated in a heat 
block on a hot plate at 90°C for 1 hour. The vials were then removed from the heat source and 
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allowed to cool to room temperature. 1 mL of brine was added to the contents of each vial. 
Extraction was performed twice, each with 3 mL of hexane. Organic layers were removed in 
both extractions, dried over magnesium sulfate, filtered through Celite® 545 (Sigma-Aldrich), 
and transferred to another 7 mL vial. The contents of the vial were then concentrated in vacuo in 
a 30°C water bath. 
The resulting sterol films were resuspended in 100 µL pyridine and 100 µL N,O-bis-
(trimethylsilyl)-trifluoroacetamide with 1% trimethylchlorosilane (T6381-10AMP Sigma-
Aldrich) by vortexing gently (82). This solution was heated at 60 °C for 1 hour. The vials were 
placed on ice and the solvent was evaporated off by nitrogen stream. Vials must be kept at a low 
temperature to prevent evaporation of the sterol TMS ethers along with the solvent. The resulting 
films were resuspended in 100 µL of decane, filtered and transferred to a GC vial insert for 
analysis. 
Gas chromatography analysis was carried out on an Agilent 7890A gas chromatograph 
equipped with a FID, an Agilent GC 7693 Autosampler, and a Dell computer running Microsoft 
XP that utilizes ChemStation v.B.04.02 SP1. Samples were separated on a 30 m, 0.320 mm ID, 
0.25 um film HP-5 capillary column (19091J-413 Agilent) using hydrogen as a carrier gas with 
an average velocity of 84.8 cm/s. Nitrogen make-up gas, hydrogen and compressed air were used 
for the FID. A split/splitless injector was used in a 20:1 split. The injector volume was 2 µL. The 
column temperature was initially held at 250 °C for 0.5 min, then ramped to 265 °C at a rate of 
10 °C /min with a final hold time of 12.5 min. The injector and detector temperature were 
maintained at 270 °C and 290 °C, respectively. The value reported for each time point was 
calculated by dividing the value for the treatment group by the value for the DMSO control at the 
same time point, and then normalizing the DMSO control to 100%. 
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Preparation of an AmB:Erg complex. Erg was prepared as a stock solution, 4 mg/mL in 
CHCl3, and the solvent removed under a gentle stream of nitrogen gas. Residual solvent was 
removed under high vacuum for at least 8 h. A DMSO solution of 5 µM AmB was then added to 
this solid Erg (25 µM final Erg concentration, 5:1 mole ratio Erg:AmB). The resulting 
suspension was gently vortexed and then heated to 80 °C for one hour in an aluminum heating 
block to allow Erg to fully dissolve. The resulting AmB/Erg solution was then allowed to cool to 
room temperature. This solution was left to complex at room temperature for another hour before 
use. 
The absorbance spectra of the two types of aggregate, (1) 5 µM AmB only in PBS buffer, (2) 
5 µM AmB:25 µM Erg complex in PBS buffer, and the monomeric form of AmB (AmB in 25% 
PBS buffer, 75% methanol) were investigated using a Shimadzu PharmaSpec UV-1700 UV/Vis 
spectrophotometer (83).  
UV/Vis melting curve assays. 200 µM stock solutions of the compounds to be tested were 
prepared. The AmB:sterol complex was prepared as described in the previous section. A UV/Vis 
spectrophotometer with a Peltier temperature module was used for these assays. The UV/Vis was 
first blanked with a solution of 2 mL methanol and 50 µL DMSO at room temperature (~25oC). 
50 µL of the compound solution was added to 2 mL methanol, pipetted into the cuvette, and read 
from 300 to 500 nm. The monomer peak was at around 409 nm (rightmost peak). To examine 
aggregate melting, 50 µL of the compound solution was added to 2 mL PBS buffer, pipetted into 
the cuvette, and read from 300 to 500 nm. The aggregate appears as a large peak on the left. The 
Peltier temperature control was set to take a new scan every 5oC. The leftmost aggregate peak 
disappeared and the monomer peak at 409nm increased with temperature, indicating movement 
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towards the monomeric species. The absorbance value was plotted at the 409nm peak versus 
temperature.  
Growth conditions for S. cerevisiae for rescue experiments. All growth rescue experiments 
were performed using the same normal concentration of potassium (10 mM) for both wild type S. 
cerevisiae (ATCC 9763) and trk1∆trk2∆ S. cerevisiae (SGY 1528). This yeast peptone adenine 
dextrose (YPAD) growth media consisted of 10 g/L yeast extract, 20 g/L peptone, 20 g/L 
dextrose, 0.015 g/L adenine hemisulfate salt (final potassium concentration = 10 mM), and the 
media was adjusted to pH 5.0 using citric acid. For culturing on solid media, 20 g/L agar was 
added to this same mixture. After autoclave sterilization, dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter-sterilized using a 0.22 µm filter). 
As previously described (84), to culture trk1∆trk2∆ prior to performing these experiments, 
additional potassium was added in the form of potassium chloride (100 mM KCl) to the same 
(YPAD) growth media (“permissive conditions”). To ensure the same conditions for both strains, 
wild type yeast were also cultured prior to performing these experiments under the same 
permissive conditions. Overnight liquid cultures were incubated at 30 °C on a rotary shaker (200 
rpm). Wild type stock cultures were maintained on solid YPAD media at 4 °C, and trk1∆trk2∆ 
stock cultures were maintained on solid YPAD media under permissive conditions (100 mM 
KCl) at 4 °C.  
Growth rescue assay on solid media. These growth rescue experiments were performed using 
solid media prepared as described above containing normal concentrations of potassium (10 
mM). For solid media containing AmB (AK Scientific), the same media was allowed to cool for 
15 minutes before addition of AmB as a solution in DMSO to provide a final concentration of 
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125 nM AmB. Cultured yeast diluted to an OD600 of 0.1 was streaked onto these plates, and 
plates were examined for growth after 24-48 hours of incubation. 
Disc diffusion assay. The assay was performed using a previously described protocol (85). Discs 
containing either DMSO vehicle or the indicated small molecule were added. For AmB, nystatin, 
candicidin, and mepartricin, 10 µL of either a 4 mg/mL or 1 mg/mL solution were added to the 
disc and growth was observed in all cases. The data pictured in Figs. 2.12 and 2.15 represent the 
results observed with 1 mg/mL. For nonactin, prodigiosin, calcimycin, natamycin, and 
valinomycin, 10 µL of a 4 mg/mL solution were added to the discs, and in all cases no growth 
was observed. A normal media concentration of potassium (10 mM) was used for all 
experiments.  
Broth microdilution assay. The protocol was adapted from the minimum inhibitory 
concentration assay described in the Clinical and Laboratory Standards Institute document M27-
A23 with the following modifications: After culturing as described above, wild type or 
trk1∆trk2∆ yeast were transferred to normal potassium (10 mM) YPAD liquid media adjusted to 
pH 5.0 using citric acid containing DMSO vehicle or the indicated concentration of the indicated 
small molecule and growth was monitored at 24 h via UV/Vis spectroscopy (OD600). The 
experiments in Fig. 2.13 were performed the same way but using media to which was added 100 
mM KCl.  
Tetraethylammonium block assay. The broth microdilution assay described above was 
performed with the addition of the indicated concentration of tetraethylammonium to trk1∆trk2∆ 
yeast in YPAD media containing the normal concentration of potassium (10 mM) and 125 nM 
AmB. The control experiment was performed by adding the indicated concentration of 
tetraethylammonium to trk1∆trk2∆ yeast in YPAD media to which was added KCl (100 mM).  
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86Rb+ uptake assay. The procedure for 86Rb+ uptake was adapted from Mulet and coworkers 
(86). Yeast were cultured overnight as described above. After centrifugation, the supernatant was 
poured off, and the cells were resuspended in sterile water. This wash was repeated two more 
times. The cells were then resuspended in 40 mL of the potassium starvation/uptake buffer (50 
mM succinic acid, 2% glucose, adjusted to pH 5.5 with Tris). The same buffer was used for all 
experiments for both trk1∆trk2∆ and wild type yeast. After 3-hour incubation in the potassium 
starvation buffer, cells were centrifuged and washed twice with sterile water. Cells were 
resuspended in 1 mL of the potassium starvation/uptake buffer. Cell concentration was 
determined using an INCYTO Neubauer disposable hemocytometer, and wild type S. cerevisiae 
and trk1Δtrk2Δ cells were diluted to the same cell density (3x107 cells/mL). 700 µL of the yeast 
suspension was added to a 1.5 mL Eppendorf tube. After a 5-minute preincubation in the 
potassium starvation/uptake medium, trk1∆trk2∆ yeast were then treated with DMSO solutions 
of AmB or C35deOAmB (final concentration 3 µM). 86RbCl (1.1 µCi) was then added to the 
reaction mixtures. Reaction mixtures were vortexed to ensure a homogeneous solution. At the 
indicated times, the uptake reaction was stopped by taking a 100 µL aliquot from the reaction 
mixture and diluting with 10 mL of ice-cold 20 mM MgCl2. Cells were then collected via 
vacuum filtration through a 0.45-µm-pore-size nitrocellulose filter (Millipore HAWP). Cells 
were washed with two 15 mL aliquots of 20 mM ice-cold MgCl2. Moist filters were transferred 
to plastic vials for measuring radioactivity. Radioactivity was monitored using a Perkin Elmer 
Wizard2 automatic gamma counter. Results are reported in counts per minute as an average of 
three biological replicates.  
Cell viability assay. Assay was adapted from Corliss and coworkers (87). Wild type and 
trk1Δtrk2Δ cells were inoculated in high potassium (100 mM KCl) YPAD media. Starter 
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cultures were grown at 30 °C for 14-15 hours. Cells were then cultured in high potassium YPAD 
at 30 °C for 2-2.5 hours. 100 µL of a 0.25 mg/mL propidium iodide (PI, Sigma-Aldrich P4864) 
solution was prepared. After 2-2.5 hours, cells were centrifuged at 23 °C at 800g for 5 minutes. 
The supernatant was decanted, cells were resuspended in 40 mL of high potassium YPAD, 
vortexed, and centrifuged. The wash step was repeated. After pouring off the supernatant, cells 
were resuspended in 15 mL of high potassium YPAD, vortexed, and diluted to an OD600 of 0.5. 
To set one (WT, WT + PI, trk1Δtrk2Δ, and trk1Δtrk2Δ + PI) and set two (WT + PI + AmB, 
trk1Δtrk2Δ + PI + AmB), 26.4 µL of DMSO were added to 1 mL aliquots of WT and 
trk1Δtrk2Δ, and incubated at 30 °C for 30 minutes. A 1% w/v low gelling temperature agarose 
(Sigma-Aldrich A9414) was prepared in normal potassium (10 mM) YPAD. When set one 
incubation completed, cells were pulse centrifuged, supernatant was removed, and cells were 
resuspended in normal potassium YPAD to wash. Cells were centrifuged and resuspended in 250 
µL of normal potassium YPAD. Afterwards, 1 µL of 0.25 mg/mL PI dye was added to 
appropriate samples and 250 µL of 1% agarose was added. Samples were plated onto microscope 
slides with cover slips and were incubated in humidity chambers for 24 hours at 30°C. For set 
two, cells were resuspended in normal potassium YPAD containing 125 nM AmB. Cells were 
resuspended in 250 µL of normal potassium YPAD containing 250 nM AmB before adding to 
1% agarose (to obtain 125 nM AmB final). Confocal microscope (Zeiss LSM700) images were 
taken at 40x where ~15 random images were taken per slide, per treatment group, per 
experiment. The total number of PI stained cells was subtracted from the total cells recorded, and 
divided by total cells to give % viability. At least 200 cells were recorded per treatment group 
and 4 independent sets of data were obtained.  
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Doubling time and sustainable restoration of cell growth assay. Wild type and trk1∆trk2∆ 
yeast were treated as described in the broth microdilution assay described above, with the 
trk1∆trk2∆ yeast treated with 125 nM AmB. The OD600 was measured at time zero and then 
every hour for 24 hours. Wild type yeast were then streaked onto normal potassium (10 mM) 
YPAD agar plates and AmB-rescued trk1∆trk2∆ yeast were streaked onto AmB-containing (125 
nM) normal potassium (10 mM) YPAD agar plates. These agar plates were then incubated at 30 
°C for about 48 hours. The same procedure was then repeated for over 42 days, measuring the 
max OD600 and doubling time every three days. Doubling time was determined using the 
following equation: Td = (t2-t1) x [log(2)/log (q2/q1)], where t2 and t1 represent the time at the two 
points and q2 and q1 represent the OD600 values in the exponential phase of growth (OD600 from 
0.2 to 0.6).  
Potassium efflux assay. Performed as previously described (27). 
Sensitivities to chemical inhibitors assay. Broth microdilution assays were performed as 
described above with the following changes: prior to harvesting cells, small molecules AmB, 
nystatin A1 (Riedel-de-Haen), candicidin (TOKU-E), or mepartricin B (Santa Cruz 
Biotechnology) and chemical inhibitors nocodazole (Sigma-Aldrich), ebselen (Cayman 
Chemical) (88), or bafilomycin B1 (Santa Cruz Biotechnology) (89) were prepared as stock 
solutions in DMSO. Saturated cell cultures were centrifuged for 5 minutes at 1000g. The 
supernatant was poured off, and cells were resuspended in sterile MilliQ water. Cells were 
centrifuged again, and supernatant was poured off. The wash step was repeated. The supernatant 
was poured off, and cells were resuspended in normal potassium (10 mM) YPAD. Cells were 
diluted with normal potassium (10 mM) YPAD to an OD600 of 0.01. Next, an appropriate volume 
of AmB, nystatin A1, candicidin, or mepartricin B solution was added to give a final rescuing 
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concentration of 125 nM, 1000 nM, 8 nM, and 8 nM, respectively. A control was prepared by 
adding the corresponding volume of DMSO to trk1∆trk2∆ cells. 195 uL of WT + small 
molecule, 195 uL of trk1∆trk2∆ + small molecule, and 195 uL of trk1∆trk2∆ + DMSO were 
added to a 96 well plate. Next, 5 µL of DMSO or chemical inhibitor was added to each well, 
with each concentration tested in triplicate for both WT and trk1∆trk2∆. The plate was covered 
and incubated at 30 °C for 24 hours. A BioTek Synergy H1 Hybrid Reader was used to measure 
the OD600. Utilizing GraphPad PRISM, data were fitted by nonlinear regression, inhibition dose 
response, variable slope (four parameters) to yield EC50 values with SEM. For statistical 
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AMPHOTERICIN B RESTORES AIRWAY SURFACE PHYSIOLOGY IN CYSTIC 
FIBROSIS HUMAN LUNG EPITHELIA AND ANIMALS 
Small molecule ion transporters have been shown to restore physiology in protein-deficient 
cells and animals, and could potentially address diseases such as cystic fibrosis (CF) caused by a 
deficiency of protein function even in cases of severely reduced or absent protein production. 
Loss-of-function mutations in the CFTR anion channel result in reduced apical bicarbonate 
transport and decreased airway surface liquid (ASL) pH, which impairs respiratory host defenses 
and leads to chronic lung infections. Because basolateral pumps and channels remain active in 
the absence of functional CFTR, we hypothesized that an outward-facing bicarbonate gradient 
would develop across the apical membrane, which could be harnessed by a bicarbonate-
permeable small molecule channel. Here we report the small molecule amphotericin B (AmB) 
facilitates apical bicarbonate transport thereby increasing ASL pH. This effect is sustained for at 
least 48 hours and restores ASL viscosity and antimicrobial activity in CF patient-derived human 
lung epithelia across a range of genotypes, including those with little to no production of CFTR. 
AmB similarly increases ASL pH in CFTR-/- piglets. Dependence of the AmB-mediated rescue 
on Na+/K+ ATPase indicates that this unselective CFTR surrogate is functionally interfaced with 
the endogenous ion transport network driving transepithelial bicarbonate movement. These 
results suggest a potential CFTR-independent mechanism for addressing CF. 
Contributions to the work presented in this chapter are as follows: Rajeev Chorghade 
performed 13C-NMR bicarbonate efflux assays, proton, potassium, and chloride efflux assays, 
14C bicarbonate transport assays, and 36Cl transport assays. Dr. Bo Ram Kim, Rajeev Chorghade, 
and I performed CFTR-/- pig experiments. Dr. Viral Shah and I performed ASL antibacterial 
	 83	
activity assays. Dr. Xiao Xiao Tang performed ASL viscosity assays. Philip Karp cultured and 
maintained primary human lung epithelia. Page N. Daniels performed Ussing chamber 
experiments specifically for assessing CFTR surface expression. Dr. Anthony S. Grillo 
synthesized compounds 2-4. Rajeev Chorghade, Page N. Daniels and I cultured and maintained 
all cell lines and epithelial monolayers. Portions of this chapter were adapted from Muraglia, 
K.A.; Chorghade, R.S.; Kim, B.K.; Tang, X.X.; Shah, V.S.; Grillo, A.S.; Daniels, P.N.; Cioffi, 
A.G.; Karp, P.H.; Zhu, L.; Welsh, M.J.; Burke, M.D. “CFTR-independent rescue of cystic 
fibrosis with a small molecule bicarbonate channel” Manuscript in preparation. 
3.1 CYSTIC FIBROSIS:  A DISEASE CAUSED BY PROTEIN DEFICIENCY 
As discussed in previous chapters, many human diseases are caused by a deficiency of 
protein function, and therefore are refractory to conventional pharmacological strategies. One 
such disease is cystic fibrosis (CF), a genetic disorder caused by loss-of-function mutations in 
the CF transmembrane conductance regulator (CFTR) protein ion channel and characterized by 
abnormal epithelial anion transport, elevated sweat chloride concentrations, pancreatic 
insufficiency, and chronic lung infection and bronchiectasis (1, 2). There are almost 2000 known 
CFTR mutations, hundreds of which cause disease in CF patients through at least five different 
mechanisms of functional loss (1). About 10% of all CF-causing mutations in the CFTR anion 
channel are Class I nonsense and splice defects that result in little to no functional CFTR at the 
apical membrane (2). Major clinical advances have been made with genotype-specific small 
molecule-based therapies, which were detailed in the introduction chapter. However, because 
these therapeutics require a CFTR protein substrate, this subset of mutations remains inherently 
unaddressable (3). Therefore, this creates an unmet medical need for an alternative small 
molecule approach that is fundamentally CFTR-independent, and thus could be applied across all 
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classes of CFTR mutations. We have recently reported that small molecules with the capacity to 
autonomously transport ions across lipid membranes can restore physiology in protein-deficient 
cells and animal models by functionally interfacing with the endogenous ion transport system (4, 
5). We saw CFTR deficiency, particularly in cases where protein production is significantly 
reduced or absent, as another opportunity to test the mechanistic hypothesis that an 
independently functioning small molecule mimic of a protein could interface with the existing 
network of protein ion transporters and thereby restore physiology. 
CFTR is an anion channel and is able to transport both chloride and bicarbonate ions. In 
contrast to dysfunctional chloride transport, recent studies have revealed that maintenance of 
airway surface liquid (ASL) pH is critical in the prevention of chronic lung infections seen in CF 
patients (6, 7). It has been hypothesized that this requires a balance between proton export 
through the nongastric H+/K+ adenosine triphosphatase proton pump ATP12A and bicarbonate 
ion secretion through CFTR (6). Loss of CFTR therefore leads to a decrease in ASL pH, which 
in turn increases ASL viscosity and decreases activity of pH-sensitive antimicrobial proteins (6, 
8). The decrease in ASL pH and its downstream effects largely contribute in the chronic airway 
infections that cause morbidity and mortality in CF patients (6, 8). Consistent with this 
mechanism, potentiation of the CFTR channel by the clinically approved drug ivacaftor 
increased ASL pH by 0.20 units and decreased viscosity by about 1.5 units relative to untreated 
controls in primary sinonasal epithelia from a patient with a G551D mutation, and this seemingly 
small correction of ASL physiology translates to substantial clinical impact (9, 10). Respiratory 
pathogens such as Pseudomonas aeruginosa can also contribute to the observed decrease in ASL 
pH by secreting protons through monocarboxylate lactate-H+ co-transporters, a process 
countered by bicarbonate secretion in normal airways but not in CF (11). Notably, administration 
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of aerosolized bicarbonate or buffers to CF epithelia also increased ASL pH and normalized 
antimicrobial activity. However, these effects are transient and clinically impractical, with pH 
returning to baseline values within an hour (7).  
3.2 THE PROSPECT OF MOLECULAR PROSTHETICS IN CYSTIC FIBROSIS 
Importantly, partial restoration of CFTR function has significant clinical impact (3). Ivacaftor 
restores only about 30% of open time probability in G551D CFTR, yet in large-scale clinical 
trials yielded a substantial increase in forced expiratory volume, increased body weight and 
quality of life, and decreased incidence of pulmonary exacerbation (10, 12). The combination of 
ivacaftor and correctors such as lumacaftor and tezacaftor targets patients with the most common 
∆F508 mutation, and while only about 23% and 47% of wild type short-circuit current are 
restored by each respective combination, clinical trials have been reported to show promise (3, 
13). Therefore, if we were able to even partially restore ion channel function with an imperfect 
small molecule mimic of CFTR, it may have the potential for clinical impact. To test this 
hypothesis, we looked within the specific framework of the ASL pH-based pathophysiology and 
built upon concepts established in previous studies of small molecule mimics (4, 5). In the lung, 
a network of pumps and channels on the basolateral membrane of epithelial cells, driven by the 
sodium gradient created by the Na+/K+ ATPase, normally facilitates transepithelial bicarbonate 
transport (Fig. 3.1A). In the absence of CFTR, bicarbonate ions continue to be brought into cells 
through the basolateral membrane but apical release is abated, yielding increased intracellular pH 
(14). We reasoned that this would results in a large outward-facing pH gradient across the apical 
membrane that could move ions through a passive small molecule ion channel (Fig. 3.1B). We 
thus hypothesized that even an unregulated and non-selective small molecule ion channel 
capable of permeabilizing the apical membrane to bicarbonate ions could functionally interface 
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with the endogenous protein network that drives and regulates transepithelial bicarbonate 












The pair of molecular probes we used to test our hypothesis consists of the clinically 
approved antifungal natural product amphotericin B (AmB), which is known to form ion 
channels in lipid membranes, and C35deOAmB, a single-atom-deficient synthetic derivative that 
we previously showed to lack ion channel activity (15) (Fig. 3.1D), thus making this derivative 
an important negative control. Previous studies on these molecules showed that AmB treatment 
Fig. 3.1. Proposed model and small molecule probe for genotype-agnostic rescue of CF. (A) 
Schematic showing transepithelial bicarbonate transport in a normal airway epithelial cell. Red spheres 
represent bicarbonate (HCO3-) ions. Green and purple spheres represent sodium (Na+) and potassium 
(K+) ions, respectively. (B) A large transapical gradient of bicarbonate is hypothesized in CF epithelia 
lacking the CFTR bicarbonate channel. (C) A small molecule-based channel is predicted to leverage 
this transapical gradient to promote bicarbonate secretion into the ASL and thereby restore physiology 
in CF lung epithelia. (D) Structures of amphotericin B (AmB) and channel-inactivated derivative C35-
deoxyamphotericin B (C35deOAmB). (E) Efflux studies of H13CO3--loaded POPC/10% cholesterol 
liposomes show that AmB is able to facilitate transmembrane bicarbonate efflux while C35deOAmB or 




restored growth to a strain of Saccharomyces cerevisiae missing the Trk 1 and 2 potassium 
transporters (trk1∆trk2∆) and therefore unable to grow under normal potassium conditions (4). 
The channel-inactivated derivative C35deOAmB failed to restore growth in trk1Δtrk2Δ cells at 
any tested concentration (4). With this promising validation of our small molecule ion channel 
approach in yeast, we prepared to test them in CF human lung epithelia. We first determined if 
AmB and C35deOAmB had the capacity to transport bicarbonate, the relevant ion in this system, 
across cholesterol-containing POPC liposomes using an adapted 13C NMR-based assay (16). We 
observed robust and rapid release of 13C-labeled bicarbonate from liposomes treated with AmB, 
Figure 3.2. Amphotericin B can permeabilize human cultured lung epithelia.  Ussing traces of (A) 0.5 µM 
amphotericin B vs. 0.5 µM C35deOAmB, (B) 5 µL DMSO vehicle, (C) TPPMn(III) 35 µM (left) and 350 µM 
(right), (D) Yang Channel 1 µM (left) and 10 µM (right), (E) Cholapod 2e 80 µM (left) and 800 µM (right), (F) 
GL-172 50 µM (left) and 500 µM (right). No permeabilization was observed with small molecules previously 
described to permeabilize liposomes, non-human tissues, or other human lung tissues, or with the channel-
inactivated AmB derivative, C35deOAmB. (G) Structures of compounds used in Ussing studies. 
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but not from those treated with C35deOAmB (Fig. 3.1E, Fig. 3.3). We confirmed that AmB also 
transports potassium (4, 15, 17), sodium and chloride ions (Fig. 3.4) and hypothesized that in the 
absence of CFTR, there would be a gradient-driven selective transport of bicarbonate ions that is 
independent of the inherent selectivity of the molecule. 
 
 
3.3 AMB INCREASES ASL PH IN CYSTIC FIBROSIS LUNG EPITHELIA 
We then grew human airway epithelial cultures derived from a CF patient with the most 
common ∆F508/∆F508 mutation (CuFi-1). In an Ussing chamber, we tested if AmB, along with 
a series of natural products and synthetic compounds previously reported to permeabilize 
liposomes, cells, and/or nasal epithelia of mice to anions (Fig. 3.2G) (18-21), could permeabilize 
the apical membrane of these epithelia, which have fully differentiated apical and basolateral 
sides. AmB (Fig. 3.1D) (22) was exceptionally effective in causing an increase in short circuit 
current (Fig. 3.2A), but little or no permeabilization was observed with any of the other 
compounds tested, including the channel-inactivated derivative C35deOAmB. We then tested the 
hypothesis that there will be an actionable increase in pH gradient across the apical membrane in 
Figure 3.3. Amphotericin B can transport bicarbonate ions across a lipid membrane. (A) 13C-NMR spectra 
of H13CO3--loaded POPC/10% cholesterol liposomes showing the appearance of a bicarbonate 13C resonance in 
the external solution after addition of 1:1000 AmB but not C35deOAmB or DMSO control, demonstrating that 
AmB is able to facilitate bicarbonate efflux. (B) MnCl2 quenching of the external bicarbonate 13C resonance. (C) 
Triton X lysing of liposomes at the conclusion of the experiment. For (A) to (C), representative spectra from at 
least three independent experiments are shown. 
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CF vs. normal lung epithelia (Fig. 3.1A,B). Fluorescent pH dyes (6, 23) confirmed that relative 
to differentiated epithelial monolayers derived from a normal individual (NuLi) (24), CuFi-1 
epithelia have both an increased intracellular pH (Fig. 3.5A) and a decreased ASL pH (Fig. 






Addition of AmB (2 µM) to the apical membrane of CuFi-1 epithelia caused a progressive 
increase in pH over 2 hours (Fig. 3.5C). Remarkably, this increase in pH was then sustained for 
at least 48 hours, contrasting sharply with the transient effect on ASL pH caused by aerosolized 
bicarbonate buffer (7). No increase in pH was observed with apical addition of the non-channel-
forming variant C35deOAmB, basolateral addition of AmB, or addition of the genotype-specific 
potentiator ivacaftor, which is specific for a different mutation than that of CuFi-1 epithelia (Fig. 
Figure 3.4. Amphotericin B can transport potassium, sodium, and chloride, protons, and bicarbonate 
across a lipid membrane. (A) 1:1000 AmB:lipid can promote potassium efflux from POPC/10% cholesterol 
liposomes in the presence of a potassium gradient but DMSO control does not, as measured by a potassium-
selective electrode. (B) 1:1000 AmB:lipid can promote sodium efflux from POPC/10% cholesterol liposomes in 
the presence of a sodium gradient but DMSO control does not, as measured by a sodium-selective electrode. (C) 
1:1000 AmB:lipid can promote chloride efflux from POPC/10% cholesterol liposomes in the presence of a 
chloride gradient but DMSO control does not, as measured by a chloride-selective electrode. (D) 1:1000 
AmB:lipid can promote proton efflux demonstrated from POPC/10% cholesterol liposomes in the presence of a 
pH gradient but DMSO control does not, as measured by a pH electrode. (E) 1:1000 AmB:lipid can promote 
bicarbonate efflux demonstrated from POPC/10% cholesterol liposomes in the presence of a bicarbonate 
gradient but DMSO control does not, as measured by 13C NMR. In (A) to (E), a representative graph from at 
least three independent experiments is shown. 
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3.5D). Importantly, AmB-treated CuFi-1 epithelia did not respond to chemical activation of 
CFTR with forskolin/IBMX, providing evidence that the AmB-mediated increase in ASL pH is 
not due to increasing CFTR activity/trafficking to the surface (Fig. 3.6). AmB addition also did 
not disrupt membrane integrity (Fig. 3.6). Notably, no increase in ASL pH was observed with 
apical AmB addition to NuLi epithelia (Fig. 3.7), which provides important evidence for the 
gradient-driven selective transport of bicarbonate ions independent of inherent AmB selectivity.  
 
 
3.4 MECHANISM OF AMB-MEDIATED ASL PH INCREASE 
We next interrogated the mechanism by which AmB mediates this increase in ASL pH. We 
hypothesized that AmB increases ASL pH by promoting the efflux of bicarbonate ions across the 
apical membrane. However, AmB is also permeable to protons (Fig. 3.4) and thus proton 
absorption represents an alternative or complementary mechanistic possibility that would 
increase ASL pH even in the absence of basolateral bicarbonate ions. To probe this, we 
performed pH-stat titration experiments in large NuLi and CuFi-1 epithelia (25). These epithelia 
were mounted in an Ussing-type chamber and either bicarbonate (25 mM) or bicarbonate-free 
Fig. 3.5. AmB increased ASL pH in cystic fibrosis cultured airway epithelia. 
(A) The intracellular pH was elevated in CF (CuFi-1) relative to normal (NuLi) 
cultured airway epithelia (n = 12). (B) The ASL pH was decreased in CF (CuFi-1) 
relative to normal (NuLi) cultured airway epithelia (n = 8 to 31). (C) AmB (2 µM) 
increased ASL pH relative to a untreated CuFi-1 control over 2 hours and persisted 
for at least 48 hours (n = 6 to 28). (D) An increase in ASL pH was not observed 
over 48 hours in CuFi-1 monolayers with C35deOAmB (2 µM), basolateral 
addition of AmB (2 mM), or ivacaftor/forskolin (10 µM) (n = 6 to 14). In (A) to 




buffer was placed in the basolateral chamber. Subsequent pH changes in the apical chamber 
solution simulate changes in ASL pH due to transepithelial ion movement. As expected, we 
observed that NuLi epithelia have a higher rate of ASL pH increase over 20 minutes than CuFi-1 
epithelia when bicarbonate buffer is present on the basolateral side. With bicarbonate-free buffer 
on the basolateral side, we did not observe a difference in rate of pH change between NuLi and 
CuFi-1 epithelia, consistent with the known bicarbonate-dependence of CFTR (26) (Fig. 3.8A). 
AmB addition caused a dose-dependent rise in the rate of ASL pH increase with basolateral 
bicarbonate buffer but not with bicarbonate-free buffer (Fig. 3.8A). These findings are consistent 












Figure 3.6. Increase in AmB-mediated transepithelial permeabilization is not due to increased CFTR 
activity.  Ussing traces of (A) NuLi cultured epithelia, (B) CuFi-1 cultured epithelia, and (C) CuFi-1 
epithelia treated with AmB for 48 hours. NuLi cultured epithelia have increased short-circuit current and 
therefore permeabilization in response to activation of CFTR with 10 µM forskolin/IBMX (FI), and 
conversely have decreased current in response to inhibition of CFTR with administration of 1 µM CFTR 
inh-172. Consistent with the lack of functional CFTR, no response is observed with CuFi-1 epithelia 
cultures to either activator of inhibitor treatment. A similar lack of response is observed in CuFi-1 epithelia 
treated with AmB for 48 hours, indicative that CFTR activity is not increased in the presence of AmB. In 











To directly probe whether AmB promotes bicarbonate efflux into the ASL, we spiked the 
basolateral buffer with 14C bicarbonate and quantified the amount of radiolabel that reaches the 
ASL over 10 minutes. As expected, relative to NuLi, there is a substantial reduction in the rate of 
14C bicarbonate efflux in CuFi-1 epithelia (Fig. 3.8B). Apical addition of AmB increased the rate 
of 14C bicarbonate to a level similar to that observed in NuLi epithelia (Fig. 3.8B). The channel-
inactivated derivative C35deOAmB, basolateral addition of AmB, and addition of ivacaftor 
caused no increase in the rate of ASL 14C bicarbonate efflux (Fig. 3.8B).  
We then used the clinically approved potentiator ivacaftor as a genotype-specific (G551D 
and similar gating mutations) comparator to AmB and clinically relevant positive control. Due to 
this genotype specificity, we had observed in CuFi-1 epithelia (∆F508/∆F508) that ivacaftor 
treatment showed no increase in ASL pH or bicarbonate efflux (Fig. 3.5D, 3.8B). Consistent 
with previous reports (9, 10), treating CuFi-4 epithelia (G551D/∆F508) with ivacaftor increased 
ASL pH by about 0.2 units (Fig. 3.8C). We found that AmB was also able to similarly increase 
ASL pH in this second cell line, implying that AmB is able to act in a genotype-agnostic manner 
and potentially be effective across different classes of mutations (Fig. 3.8C). ). Importantly, we 
Fig. 3.7. AmB does 
not increase ASL 
pH in WT 
epithelia. AmB (2 
uM) does not 
increase ASL pH in 
NuLi cultured 
epithelia (n = 6 to 
14). Graph depicts 
means ± SEM; NS, 
not significant. 
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also for the first time directly linked apical bicarbonate efflux to ASL pH increase, as CFTR 
potentiation by ivacaftor in fact leads to increased rate of apical bicarbonate efflux (Fig. 3.8D). 
This validates our bicarbonate hypothesis with a clinically impactful positive control. The rate of 
bicarbonate efflux is also increased with AmB treatment, consistent with the observed increase in 




Fig. 3.8. The AmB-mediated 
increase of ASL pH is bicarbonate-
dependent and Na+/K+ ATPase-
dependent. (A) pH-stat titration in 
NuLi and CuFi-1 monolayers showed 
a dose-dependent increase in ASL pH 
with AmB treatment in the presence of 
basolateral bicarbonate (n = 4 to 23). 
(B) Quantification of basolateral to 
apical transport of H14CO3- in CuFi-1 
monolayers indicated that AmB (2 
µM) restored normal bicarbonate 
transport after 48 hours of incubation, 
but C35deOAmB (2 µM), basolateral 
addition of AmB (2 µM), or 
ivacaftor/forskolin (10 mM) did not (n 
= 4 to 38). (C) Both AmB (2 µM) and 
ivacaftor/forskolin (10 µM) increased 
ASL pH in CuFi-4 (G551D/∆F508) 
epithelia over 48 hours. (D) Both AmB 
(2 µM) and ivacaftor/forskolin (10 
µM) increased H14CO3- transepithelial 
transport in CuFi-4. epithelia over 48 
hours (n = 10 to 16). (E and F) 48-
hour AmB-mediated increases in 
transepithelial bicarbonate transport  
 and ASL pH were abrogated by chemical blocking of Na+/K+ ATPase with ouabain (10 mM) (n = 6). In (A) to 
(F), graphs depict means ± SEM; NS, not significant; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.	
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As AmB is still permeable to other ions, we sought to determine if salt/fluid homeostasis of 
the epithelia is maintained. ASL height serves as a phenomenological readout for 
hyperabsorption of other ions through the AmB channel, particularly sodium. It has been 
previously reported that in normal lungs, the ASL is approximately the same height as the length 
of the cilia when it is fully outstretched (7 µm) and allows for normal beating movement 
unimpeded by the mucus layer above. In CF tissues, this is depleted to 3 µm, as the airway 
surface may be dehydrated from sodium hyperabsorption and the lack of anion transport through 
CFTR and subsequently water movement across the epithelia (27, 28). Confocal images showed 
that CuFi-1 epithelia treated with FC-72 vehicle were markedly dehydrated relative to NuLi (Fig. 
3.9A,B). Apical AmB treatment (0.5 µM) increases the ASL height in CuFi-1 epithelia to match 
NuLi (Fig. 3.9A,B). It is interesting to note that very low (0.005 µM) and very high (50 µM) 
Fig. 3.9. AmB increases ASL height. (A) Confocal 
microscope images of ASL height restoration by AmB. (B) 
0.5 µM AmB increases ASL height in CuFi epithelia to NuLi 
(WT) levels but very low (0.005 µM) and very high doses 
(50 µM) of AmB, 0.5 µM of C35deOAmB, and 0.5 µM  
basolateral addition of AmB do not. (C) Basolateral 
bumetanide addition decreases the ASL height of both NuLi 
and AmB-treated CuFi-1 epithelia. In (B) and (C), graphs 
depict means ± SEM; NS, not significant; ****P ≤ 0.0001. 
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AmB doses do not have this effect (Fig. 3.9B). Basolateral addition of AmB and treatment with 
the channel-inactivated derivative C35deOAmB also had no effect (Fig. 3.9B). AmB-mediated 
restoration of ASL height was blocked via inhibition of NKCC with bumetanide (Fig. 3.9C) 
supporting collaboration with basolateral chloride transporters. Interestingly, NuLi ASL height is 
also reduced with chemical inhibition of NKCC with bumetanide (Fig. 3.9C). It is yet unclear if 
this is due to an importance of transepithelial chloride transport or if basolateral sodium, 
potassium or chloride entry through NKCC has some downstream impact on apical bicarbonate 
release, and will require further study. 
The rate of bicarbonate import through the basolateral membrane is primarily driven by a 
sodium gradient created by Na+/K+ ATPase. The tissue-specific activity of Na+/K+ ATPase is 
largely regulated by the FXYD family of proteins, and is modulated based on physiological 
stimuli (29). Previous studies showed that FXYD5 is increased three-fold and Na+/K+ ATPase 
activity is increased twofold in CF vs. non-CF epithelial cells (29, 30). As discussed in Chapter 
2, potassium influx into yeast through Trk transporters is similarly driven by a proton gradient 
generated by V-ATPase and Pma1, and AmB-mediated growth rescue in Trk-deficient yeast is 
highly sensitive to V-ATPase or Pma1 chemical inhibition (4). We thus hypothesized that the 
AmB-mediated rescue of ASL pH in CF epithelia would be mitigated by chemically blocking 
Na+/K+ ATPase. Adding ouabain, a specific inhibitor of Na+/K+ ATPase, to basolateral buffer of 
CuFi-1 epithelia in fact abolished the AmB-mediated increase in rate of 14C bicarbonate efflux 
and increase in ASL pH (Fig. 3.8D,E). This is preliminary evidence for a functional interface of 
AmB to the endogenous protein network. 
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3.5 AMB RESTORES ASL PHYSIOLOGY IN PRIMARY HUMAN LUNG EPITHELIA 
AND A CFTR-/- PIG MODEL 
To determine if the capacity for AmB to restore ASL pH in a genotype-agnostic manner 
translates to primary human airway epithelia, we obtained samples from 9 CF patient donors 
representing a range of different CFTR mutations (Fig. 3.10A, Table 3.1). These include multiple 
patients with the most common ∆F508/∆F508 genotype, a double null genotype (R553X/E60X) 
and a rare splice site allele (1717-1G->A) that both result in little to no CFTR protein produced. 
Another patient had a V520F allele, which is in the same functional category as G551D but is 
refractory to treatment with ivacaftor (31). Patients were also included with uncategorized alleles 
(D259G, ∆F508/c.2052dupA) (32). As these mutation phenotypes are unknown, rational 
development of specific treatment is challenging. 
On average, AmB increased ASL pH by 0.2 pH units in the genotypes tested (Fig. 3.10A), 
consistent with our results in CuFi-1 and CuFi-4 epithelia (Fig. 3.5C, 3.8C). This AmB-mediated 
increase in the ASL pH is also sustained for at least 48 hours (Fig. 3.8B). One mutation with an 
Table 3.1. Genotypes and Δ pH measurements of patient donors in ASL pH assay. 
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unknown allele (∆F508/c.2052dupA) gave two opposing results during assay replication that 
resulted in net no change in ASL pH. C35deOAmB and basolateral addition of AmB did not 
increase ASL pH (Fig. 3.11A). As seen in the cell lines, AmB treatment had no effect on the pH 
of non-CF primary cultured epithelia, further providing evidence for dependence upon the pH 













Fig. 3.10. AmB restored ASL physiology in primary cultured human lung epithelia derived from CF 
patients with a wide range of CFTR genotypes and in CFTR-/- piglets. (A) Genotypes and mutation classes of 
patient donors. An increase in ASL pH was observed upon AmB (2 µM) treatment across a wide range of CFTR 
genotypes. On average, AmB (2 µM) increased ASL pH by about 0.2 pH units over 48 hours (n = 9). (B) On 
average, AmB (2 µM) increased ASL pH relative to an untreated CF control over 2 hours and this effect persists 
for at least 48 hours (n = 3 to 9). (C) AmB (2 µM) decreased ASL viscosity of genetically diverse CF epithelia 
over 48 hours (n = 6). (D) AmB (2 µM) increased ASL antibacterial activity of genetically diverse CF epithelia 
over 48 hours (n = 8). (E) AmB increased ASL pH in CuFi-1 monolayers at low but not at high concentrations. 
Complexation of AmB with cholesterol extends the window of efficacy to at least 100 uM (n = 9 to 31). (F) 
AmBisome® (1 mg/mL) increased bicarbonate transport in CuFi-1 cultured epithelia over 2 hours. (G) 
AmBisome® (100 ug/mL) increased ASL pH in CuFi-1 cultured epithelia over 2 hours. (H) A high dose of 
AmBisome ® (1 mg/mL) increased ASL pH in CFTR-/- piglets sustained for at least 1 hour (n = 2). In (A) to 
(G), graphs depict means ± SEM; NS, not significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.  
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We further tested in genetically diverse primary cultured human CF epithelia (Table 3.2) 
whether a single treatment with AmB leads to decreased viscosity in the ASL at the 48 h time 
point. AmB decreased ASL viscosity across a wide range of patient genotypes (Fig. 3.10C). The 
average amplitude of viscosity reduction (~1.5 units) matched that previously observed with 
ivacaftor-treated primary sinonasal epithelia from a CF patient with a G551D allele (9). We also 
determined the capacity for the ASL of AmB-treated primary CF epithelia to kill bacteria at the 
same 48-hour timepoint. We did this by briefly touching the ASL with a gold grid coated with 
Staphylococcus aureus and then determining the percentage of bacteria killed (6). As controls, 
bacteria-coated grids were also placed in saline or AmB in FC-72 laid over saline to simulate the 
administration method. Treatment with AmB increased antibacterial activity for a range of 
patient genotypes (Table 3.3). On average, AmB treatment nearly doubled ASL bacterial killing 
(Fig. 3.10D), whereas C35deOAmB had no effect (Fig. 3.12A). Importantly, AmB alone does 











Fig. 3.11. AmB restores ASL pH in primary human lung epithelia isolated from CF patients. (A) 
On average, AmB (2 µM) increased ASL pH while C35deOAmB (2 µM) and basolateral addition of 
AmB (2 µM) did not (n = 3 to 9). (B) AmB (2 µM) does not increase ASL pH in non-CF cultured 











The porcine model of CF (7) has been invaluable to translational research of the disease due 
to its similarity to human respiratory anatomy, physiology, and CF pathophysiology. However, 
based on our understanding of AmB, we foresaw a number of challenges to in vivo testing and 
later clinical application, which include a narrow dosage range, drug delivery to the lung, and 
variable dosing due to distribution limitations. The AmB-mediated increase in ASL pH in CuFi-1 
epithelia reaches a maximum at 2 µM and then decreases at higher concentrations (Fig. 4E). 
Table 3.2. Genotypes of patient donors in ASL 
viscosity assay. 
 
Table 3.3. Genotypes of patient donors in ASL 
antibacterial activity assay. 
 
Fig. 3.12. AmB restores ASL antibacterial activity in primary human lung epithelia isolated from CF 
patients. (A) AmB (2 µM) increased ASL antibacterial activity while C35deOAmB (2 µM) did not (n = 5 to 
8). (B) AmB (2 µM) alone does not have antibacterial activity against S. aureus as compared to saline (n = 
36). In (A) and (B), graphs depict means ± SEM; NS, not significant; **P ≤ 0.01; ****P ≤ 0.0001. 
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Suspecting that this loss of activity at higher concentrations may be due to toxic cholesterol 
binding activity (15, 33) and to potentially address the issue of a narrow dosage range, we looked 
to previous work on the sterol sponge model of AmB (33). Saturating the AmB sterol sponge 
with endogenous sterol has been shown to prevent sterol extraction and therefore toxicity, while 
still maintaining channel-forming activity (4, 33). As shown in Chapter 2, by pre-complexing 
AmB to the native sterol in yeast, ergosterol, the range of doses for which trk1∆trk2∆ growth 
rescue is observed can be extended by more than an order of magnitude (4, 33). A similar pre-
complexation of AmB to the endogenous human sterol, cholesterol, could potentially allow us to 
test our hypothesis in CF epithelia at a greater dosage range. 
When we pre-formed an AmB:cholesterol complex and repeated this concentration 
dependence experiment, a similar increase in ASL pH was observed and then sustained even up 
to very high concentrations of AmB (100 µΜ) (Fig. 3.10G). The same pattern was previously 
Figure 3.13. AmBisome® increases bicarbonate transport 
and ASL pH in a time and dose-dependent manner. (A) 
AmBisome®  administered at a 1:1000 AmB:lipid ratio, like 
AmB (1:1000 AmB:lipid) and AmB:Chol (1:1000 
AmB:lipid) complex facilitates bicarbonate efflux but 
DMSO control does not. (B) Quantification of basolateral to 
apical transport of H14CO3- in CuFi-1 monolayers indicated 
that AmBisome® (1 mg/mL) increased bicarbonate transport 
compared to the FC-72 vehicle control after 48 hours of 
treatment (n = 16). (C) AmBisome® increases ASL pH in 
CuFi-1 monolayers at all tested concentrations over 48 hours 
(n = 6 to 9). In (A), A representative graph from at least three 
independent experiments is shown. In (B) to (C), graphs 
depict means ± SEM; NS, not significant; *P ≤ 0.05; ****P 
≤ 0.0001 relative to vehicle control. 
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observed upon progressively increasing CFTR protein expression, suggesting some kind of 
homeostatic control over an optimum ASL pH value inherent in the cellular system (26). With 
these sterol complexation results in hand, we decided to test AmBisome®, an FDA-approved 
formulation of AmB that contains a 2.5:1 cholesterol to AmB ratio. We hypothesized that such a 
formulation of AmB may recapitulate our finding of an extended dosage window with the 
AmB:Chol complex (Fig. 3.10G). It is notable that AmBisome® has been safely delivered to the 
lungs in aerosolized form (34), and variable dosing may not be an issue with the extended range 
of efficacy observed in the presence of cholesterol. 
Like AmB alone, AmBisome® is able to transport bicarbonate ions in a liposomal system 
(Fig. 3.13A) and increased the rate of 14C bicarbonate efflux across the apical membrane of 
CuFi-1 cultured epithelia over 2 hour and 48 hour time periods (Fig. 3.10F, 3.13B). Consistent 
with the bicarbonate efflux data, apical AmBisome® treatment increases ASL pH over 2 hours 
and is sustained for at least 48 hours (Fig. 3.10G). Increase of ASL pH is observed up to at least 
2450 mg/mL AmBisome®, equivalent to 100 µM AmB (Fig. 3.13C). This provided a means for 
testing AmB channel function in the porcine model that may extend the small dosage window of 
AmB alone.  
We then tested AmBisome® in CFTR-/- piglets. We observed in two CFTR-/- piglets from 
different litters that, compared to baseline values, 1 mg/mL AmBisome® administered to the 
surface of a 1 cm2 tracheal window significantly increased ASL pH (Fig. 3.10H). This effect was 
sustained for at least 60 minutes (Fig. 3.10H). 
3.6 CONCLUSIONS AND PROSPECTUS 
Thus, imperfect CFTR mimicry with a bicarbonate-permeable small molecule ion channel is 
sufficient for restoring important aspects of ASL physiology even in cultured epithelia that 
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produce little to no CFTR as well as CFTR-/- piglets. This approach is CFTR-independent and 
therefore genotype-agnostic. Small molecule ion channels can functionally interface with the 
protein-based bicarbonate transport pathway inherent in lung epithelia. The specific intersection 
of AmB channels with Na+/K+ ATPase adds to a growing list of examples where a small 
molecule surrogate for a missing protein can interact with other ion transport mechanisms in 
eukaryotic cells (5). Our results further reveal that alternative activities of CFTR that are not 
replicated by AmB, including regulation of other ion transporters (35), are not required for 
maintaining ASL pH, viscosity, and antibacterial properties. Collectively, these findings 
demonstrate a mechanism for CFTR-independent rescue of CF using small molecules that 
promote apical membrane bicarbonate permeabilization and substantially brighten the prospect 
of using small molecules as surrogates for missing protein ion channels in the clinic. Strategic 
derivatization of AmB has been shown to modify conductance and selectivity of the 
corresponding ion channels, suggesting a pathway for optimization of this phenomenon should 
further evaluation of the natural product reveal challenging limitations (17). If shown in future 
studies to be sustainable as an ongoing treatment in human patients, AmB and its derivatives 
could be powerful tools in the treatment of yet-incurable channelopathies like cystic fibrosis. 
3.7 METHODS 
Cell lines and growth conditions. NuLi and CuFi-1 cells (24) (a gift from the Welsh 
Laboratory, University of Iowa) were first grown from cryostock on Thermo Scientific BioLite 
Cell Culture Treated 75 cm2 flasks, seeded at 1.5 x 104 cells/cm2 and 1 x 103 cells/cm2 
respectively. These flasks were previously coated with 3 mL of 60 µg/ml human placental 
collagen type VI (Sigma-Aldrich) for a minimum of 18 hours at room temperature, rinsed twice 
with 1X PBS, and then dried prior to seeding. The cells were cultured with 12 mL of the 
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Bronchial Epithelial Cell Growth Medium (BEGM) BulletKit (Lonza CC-3170), which includes 
the basal media and eight SingleQuots of supplements. The gentamycin-amphotericin B aliquot 
was discarded and the media was instead supplemented with 50 µg/ml penicillin-streptomycin 
(Corning Cellgro), 50 µg/ml gentamycin (Sigma-Aldrich G1397), and 2 µg/ml fluconazole 
(Sigma-Aldrich).  
Cells were grown to a 90% confluence at 37oC and 5% CO2  with media changed every 2 
days, and then trypsinized with 4 mL of standard 0.25% trypsin with 1 mM EDTA (Gibco 
25200-056). Trypsin was inactivated with 10 mL of HEPES Buffered Saline Solution (Lonza 
CC-5024) with added 1% bovine calf serum. Cells were spun down in an Eppendorf Centrifuge 
5430 R at 1500 rpm for 5 minutes and resuspended in BEGM media for passaging. 
For culturing onto membrane supports for differentiation, cells were resuspended after 
centrifugation in Ultroser G media. This is composed of a 1:1 ratio of DMEM:Ham’s F-12 
supplemented with 2% V/V Ultroser G (Crescent Chemical). The membrane supports used were 
Millicell 0.4 µm PCF inserts (0.6 cm2) (Millipore PIHP01250) for Ussing chamber studies of 
candidate ionophores, Falcon® Permeable Support for 6 Well Plate with 0.4 µm Transparent 
PET Membranes (4.67 cm2) (Fisher 08-771) in 6-well companion plates (Fisher 08-771-24) for 
pH-stat studies, and the Corning Costar 0.4 µm 24-well plate Transwell Clear Polyester 
Membrane inserts (0.33 cm2) (Corning 3470) for all other studies. These membranes were coated 
with collagen in the same manner as the flasks detailed above. The Millicell inserts were seeded 
with 200,000 cells each, the Falcon inserts were seeded with 500,000 cells each, and the 
Transwell inserts were seeded with 115,000 cells each. These membranes were allowed to 
mature at an air-liquid interface for a minimum of 14 days to reach full differentiation, with the 
Ultroser G media changed every other day. At full maturation, media was changed every 7 days. 
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Primary cultures of airway epithelia. Airway epithelial cells were obtained from human 
trachea and bronchi of CF and non-CF specimens obtained from the Iowa Donor Network, either 
as post-mortem specimens or from tissue deemed not fit for transplant. Studies were approved by 
the University of Iowa Institutional Review Board. Airway epithelial cells were obtained from 
the trachea and bronchi of pigs and from trachea of mice after euthanasia. After pronase 
enzymatic digestion, cells were seeded onto collagen-coated semi-permeable membranes (0.33 – 
1.12 cm2, Corning 3470 polyester, 3460 polyester, 3413 polycarbonate) and grown at an air-
liquid interface using previously described methods (36). Airway epithelial cell cultures were 
analyzed after they had differentiated and at least 14 days post-seeding. 
Statistics. All data depicts the means ± SEM with a minimum of 3 biological replicates. 
Statistical analysis represents P values obtained from student t-test. NS, not significant. * P < 
0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 unless otherwise noted. 
Ussing Chamber studies of NuLi and CuFi monolayers. For evaluation of candidate 
ionophores, differentiated cultures of CuFi-1 epithelia grown on Millicell® 0.4 µm PCF inserts 
were mounted in a dual-channel Ussing chamber (Warner U2500) using the culture cup insert for 
Millicell adapter, 12 mm (Warner U9924M-12). Stock solutions of 100 mM amiloride and 4,4’-
diisothiocyano-2,2’-stilbenedisulfonic acid (DIDS) were prepared in DMSO. Stocks of the 
experimental solutions of HPLC-purified AmB, C35deOAmB, 2, 3, and 4 were prepared in 
DMSO 1000 times more concentrated than the desired final concentration in buffer. 1 was 
purchased from Sigma-Aldrich (15, 16, 18-20). All recordings were acquired using Acquire & 
Analyze revision II (Physiologic Instruments). 
Electrodes were prepared with 3.5% agar and 3 M KCl. 5 mL of 37oC high chloride buffer 
(135 mM NaCl, 5 mM HEPES, 2.4 mM K2HPO4, 0.6 mM KH2PO4, 1.2 mM CaCl2, 1.2 mM 
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MgCl2, 5 mM dextrose, pH 7.4 with 10 N NaOH) was placed on both sides of the chamber, kept 
warm by circulating heater (Lauda E 100) and gassed with compressed air. Epithelial sodium 
channel (ENaC) and calcium-activated chloride channel (CaCC) were inhibited by apical 
addition of 1 µM amiloride and 1 µM DIDS (4,4’-disothiocyanostilbene-2,2’-disulfonic acid), 
respectively, to achieve a baseline for small molecule-mediated permeabilization. To establish a 
basolateral (135 mM) to apical (4.9 mM) chloride gradient, the buffer on the apical side of the 
membrane was replaced by 5 mL of low chloride buffer (135 mM sodium gluconate, 5 mM 
HEPES, 2.4 mM K2HPO4, 0.6 mM KH2PO4, 1.2 mM CaCl2, 1.2 mM MgCl2, 5 mM dextrose, pH 
7.4 with 10 N NaOH). When baseline was stabilized, 5 µL of the small molecule for testing was 
added to the apical buffer and was given a minimum of 10 minutes to observe permeabilization 
(24).  
To assess the presence of membrane-expressed CFTR, differentiated cultures of NuLi and 
CuFi-1 epithelia grown on Corning Costar 0.4 µm 24-well plate Transwell Clear Polyester 
Membrane inserts were used. NuLi and CuFi-1 epithelia were treated with 20 µL of 
perfluorocarbon (FC-72, Sigma) vehicle or 2 µM amphotericin B (AmB) sonicated into a 
suspension in FC-72. After 48 hours of incubation, the epithelia were mounted in a dual-channel 
Ussing chamber (Warner U2500) using the culture cup insert for Transwell adapter, 6.5 mm 
(Warner U9924T-06) and bathed on both the apical and basolateral sides with a bicarbonate 
solution (120 mM NaCl, 25 mM NaHCO3, 5 mM KCl, 2 mM CaCl2, 1.2 mM MgCl2, 13.75 mM 
NaH2PO4, pH 7.0) at 37°C and gassed with compressed air. Dextrose was added to this solution 
immediately prior to experiments to a final concentration of 5.6 mM. ENaC and CaCC were 
inhibited as previously described herein. 0.1 µM forskolin/IBMX (3-isobutyl-1-methylxanthine) 
added apically was used to activate CFTR, and 1 µM CFTR-inh172 was used to inhibit CFTR. 
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Each successive addition of reagent was allowed approximately 10 minutes to equilibrate before 
the addition of the next reagent.  
13C NMR studies of H13CO3- efflux from POPC liposomes. Palmitoyl oleoyl 
phosphatidylcholine (POPC) was obtained as a 25 mg/mL solution in CHCl3 from Avanti Polar 
Lipids (Alabaster, AL) and was stored at -20 ºC under an atmosphere of dry argon and used 
within 3 months. Prior to preparing a lipid film, this solution was warmed to ambient 
temperature to prevent condensation from contaminating the solution and degrading the lipid 
film. Cholesterol (Sigma Aldrich) was purified by recrystallization from ethanol. NaH13CO3 was 
obtained as a white solid from Sigma Aldrich. To a 20 mL scintillation vial (Fisher Scientific) 
was added 42 mg of solid cholesterol, followed by 14 mL of POPC solution. The solvent was 
removed with a gentle stream of nitrogen, and the resulting lipid film was stored under high 
vacuum for a minimum of twelve hours prior to use. The film was then hydrated with 2 mL of 
260 mM NaH13CO3 in 40 mM HEPES buffer pH 7.5 (D2O), and vortexed vigorously for 
approximately 3 minutes to form a suspension of multilamellar vesicles (MLVs). The lipid 
suspension was then subjected to 15 freeze-thaw cycles, where the suspension was alternatingly 
allowed to freeze in a liquid nitrogen bath, followed by thawing in a 50 °C water bath. The 
resulting lipid suspension was pulled into a Hamilton (Reno, NV) 1 mL gastight syringe and the 
syringe was placed in an Avanti Polar Lipids Mini-Extruder. The lipid solution was then passed 
through a 5.00 µm Millipore (Billerica, MA) polycarbonate filter 35 times, the newly formed 
large unilamellar vesicle (LUV) suspension being collected in the syringe that did not contain the 
original suspension of MLVs to prevent the carryover of MLVs into the LUV solution. To obtain 
a sufficient quantity of LUVs, two independent 1 mL preparations were pooled together for the 
dialysis and subsequent efflux experiments. The newly formed LUVs were dialyzed using Pierce 
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(Rockford, IL) Slide-A-Lyzer MWCO 3,500 dialysis cassettes, 3 mL capacity. The LUV 
suspension was dialyzed 10 times against 300 mL of 87 mM Na2SO4 in 40 mM HEPES buffer 
pH 7.3 (H2O) with stirring. The first dialysis was four hours long, while the subsequent nine 
dialyses were performed for 1 hour. 
Determination of total phosphorus was adapted from a previous report (37). The LUV 
solution was diluted fortyfold with 87 mM Na2SO4 in 40 mM HEPES buffer pH 7.3 (D2O). 
Three 10 µL samples of the diluted LUV suspension were added to three separate 7 mL vials. 
Subsequently, the solvent was removed with a stream of N2. To each dried LUV film, including 
a fourth vial containing no lipids that was used as a blank, was added 450 µL of 8.9 M H2SO4. 
The four samples were incubated open to ambient atmosphere in a 225 °C aluminum heating 
block for 25 min and then moved to 23 °C and allowed to cool for 5 minutes at room 
temperature. After cooling, 150 µL of 30% w/v aqueous hydrogen peroxide was added to each 
sample, and the vials were returned to the 225 °C heating block for 30 minutes. The samples 
were then moved to 23 °C and allowed to cool for 5 minutes at room temperature before the 
addition of 3.9 mL water. Then 500 µL of 2.5% w/v ammonium molybdate was added to each 
vial, and the resulting mixtures were then vortexed briefly and vigorously five times. 
Subsequently, 500 µL of 10% w/v ascorbic acid was added to each vial, and the resulting 
mixtures were then vortexed briefly and vigorously five times. The vials were enclosed with a 
PTFE lined cap and then placed in a 100 °C aluminum heating block for 7 minutes. The samples 
were moved to 23 °C and allowed to cool for approximately 15 minutes at room temperature to 
23 °C prior to analysis by UV/Vis spectroscopy. Total phosphorus was determined by observing 
the absorbance at 820 nm and comparing this value to a standard curve obtained through this 
method and a standard phosphorus solution of known concentration. 
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The pooled LUV solution was diluted to 70 mM with 87 mM Na2SO4, 40 mM HEPES buffer, 
pH 7.3 (D2O), and 0.025% (w/v) 13C D-glucose (1-13C) (Sigma Aldrich) was added as an internal 
standard. 13C NMR spectra were acquired on a Bruker Avance III HD 500 MHz NMR 
spectrometer equipped with a 5 mm BBFO CryoProbe. The 13C frequency was set to 125.83 
MHz, and spectral width was 31,512 Hz. The instrument was locked on D2O. Experimental 
conditions were: acquisition time, 0.93 s; 90° pulse width, 10.0 µs; relaxation delay, 0.2 s; 
number of scans, 256; temperature 25 °C.  
For each experiment, 1.4 µL of vehicle, AmB, or C35deOAmB (17.5 µM final concentration, 
stock solution was 100 times more concentrated in DMSO) was added to 140 µL of the liposome 
suspension. The liposome suspension was immediately transferred to a New Era (Vineland, NJ) 
micro NMR sample tube (3 mm lower/5 mm upper), and 12 consecutive FIDs were obtained as 
described above. For experimental runs with MnCl2, 5 µL of a 50 mM MnCl2 solution was added 
after the addition of AmB. To effect complete ion release, 10 µL of a 30% (v/v) solution of triton 
X-100 (Sigma Aldrich) was added to the liposome suspension before data acquisition (16, 38-
40).  
Studies of proton efflux from POPC liposomes. Proton efflux from POPC/10% cholesterol 
liposomes was determined as previously described (17). 
Studies of Na+, K+, Cl-, and H13CO3- efflux from POPC liposomes. Sodium, potassium, and 
chloride measurements were obtained using a Denver Instruments (Denver, CO) Model 225 pH 
meter equipped with the appropriate ion selective probe inside a Faraday cage. Sodium selective 
measurements were obtained using an Orion micro sodium electrode (Thermo 9811BN). 
Potassium selective measurements were obtained with a World Precision Instruments potassium 
selective electrode (World Precision Instruments KWIKPOT-2, TIPK) and a reference electrode 
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(World Precision Instruments DRIREF-2). The electrode was filled with 1000 ppm KCl standard 
solution and conditioned in a 1000 ppm KCl standard solution for 15 minutes prior to potassium 
selective measurements. Chloride selective measurements were obtained using an Orion 
combination chloride electrode (Thermo 9617BNWP). For sodium and potassium efflux 
experiments, measurements were made on 1.5 mL solutions that were magnetically stirred in 7 
mL vials incubated at 23 °C. For chloride efflux experiments, measurements were made on 4 mL 
solutions that were magnetically stirred in 20 mL vials incubated at 23 °C. For sodium, 
potassium, and chloride efflux experiments, the concentration of each ion was sampled every 10 
seconds throughout the course of the efflux experiments.13C NMR spectra for bicarbonate efflux 
experiments were acquired on a Varian Inova 600MHz NMR spectrometer with a Varian 5 mm 
broadband autox probe. The 13C frequency was set to 150.8 MHz, and spectral width was 38 
kHz. The instrument was locked on D2O. Experimental conditions were: acquisition time, 0.93 s; 
90° pulse width, 6.70 µs; relaxation delay, 0.2 s; number of scans, 256; temperature 27 °C. The 
inverse-gated 13C spectra were collected. 
Liposome preparation. Cholesterol-containing POPC lipid films were prepared as described 
above and stored under high vacuum for a minimum of twelve hours prior to use. For sodium 
efflux experiments, the film was rehydrated with 2 mL of 250 mM NaHCO3, 40 mM HEPES 
buffer, pH 7.5 and vortexed vigorously for approximately 3 minutes to form a suspension of 
multilamellar vesicles (MLVs). For potassium efflux experiments, the film was rehydrated with 
2 mL of 250 mM KHCO3, 40 mM HEPES buffer, pH 7.5. For chloride efflux experiments, the 
film was rehydrated with 2 mL of 250 mM NaCl, 40 mM HEPES buffer, pH 7.5. For bicarbonate 
efflux experiments, the film was rehydrated with 2 mL of 250 mM NaH13CO3, 40 mM HEPES 
buffer, pH 7.5 (D2O). To obtain a sufficient quantity of LUVs, at least two independent lipid film 
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preparations were pooled together for the subsequent formation of LUVs. The freeze-thaw and 
extrusion protocol was as previously described for 13C liposomes. Multiple 1 mL preparations 
were pooled together for the dialysis and subsequent efflux experiments. The newly formed 
LUVs were dialyzed using Pierce (Rockford, IL) Slide-A-Lyzer MWCO 3,500 dialysis cassettes, 
15 mL capacity. The LUV suspension was dialyzed 3 times against 600 mL of 62.5 mM MgSO4, 
40 mM HEPES buffer, pH 7.3. The first two dialyses were two hours long, while the final 
dialysis was performed overnight. Determination of phosphorous content was performed as 
described above.  
Efflux from LUVs. The pooled LUV suspension was diluted to 70 mM with 62.5 mM MgSO4, 
40 mM HEPES buffer, pH 7.3. The LUV suspension (1.5 mL for sodium, and 4 mL for chloride 
and potassium) was added to either a 7 mL or 20 mL vial and gently stirred. The appropriate 
probe was inserted, and data were collected for one minute prior to addition of AmB. For sodium 
efflux experiments, 15 µL of either vehicle or AmB (70 µM final concentration, stock solution 
was 100 times more concentrated in DMSO) was added to 1.5 mL of LUV suspension, and data 
were collected for 10 minutes. To effect complete ion release, 15 µL of a 30% v/v solution of 
triton X-100 was added, and data were collected for an additional five minutes. For chloride and 
potassium efflux experiments, 40 µL of either vehicle or AmB (70 µM final concentration, stock 
solution was 100 times more concentrated in DMSO) was added to 4 mL of LUV suspension, 
and data were collected for 10 minutes. To effect complete ion release, 40 µL of a 30% v/v 
solution of triton X-100 was added, and data were collected for an additional five minutes. For 
bicarbonate efflux experiments, 5 µL of either vehicle or AmB (70 µM, 100X stock in DMSO) 
was added to 500 µL of the pooled LUV suspension, and consecutive FIDs were acquired for 60 
minutes. 5 µL of a 30% v/v solution of triton X-100 to effect complete ion release. 
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The efflux data from each run was normalized to the percent of total ion release from 0 to 
100%. For bicarbonate efflux experiments, after lysis of the liposome suspension, the integration 
of the signal corresponding to extravesicular bicarbonate relative to the integration of the 13C 
glucose standard was scaled to correspond to 100% efflux. For each experimental run with AmB 
addition, the signal corresponding to extravesicular bicarbonate was integrated relative to the 13C 




− 1 ∙ ! = 100 
Each data point was then multiplied by S before plotting as a function of time. 
Intracellular pH of NuLi and CuFi monolayers. Intracellular pH was measured using 
pHrodo® Green AM Intracellular pH Indicator (Invitrogen, P35373). NuLi and CuFi-1 epithelia 
cultured on 0.33 cm2 24-well plate Transwell Clear Polyester Membrane inserts were used for 
this experiment and basolateral media was changed the day prior to experimentation. 10 µL of 
the pHrodo™ Green AM in DMSO was added to 100 µL of PowerLoad™ concentrate. The dye 
solution was then diluted into 10 mL of USG media to make the staining solution. The existing 
basolateral media was removed from cells, and the basolateral side of each culture was rinsed 
once with USG media. The basolateral media was then replaced with the pHrodo™ AM staining 
solution and incubated at 37°C for 30 minutes. The basolateral staining solution was then 
removed and replaced with USG media prior to measurement. The cultures were analyzed using 
a Synergy H1 MONO Plate Reader on fluorescent endpoint setting with excitation 506 nm and 
emission 540 nm to establish the baseline fluorescence of the untreated cultured epithelia. To 
quantify absolute pH value, a cell loading solution was prepared utilizing an Intracellular pH 
Calibration Buffer Kit (Invitrogen, P35379). 10 µL of the provided valinomycin/nigericin stock 
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solution was diluted in 10 mL of the desired Cellular pH Calibration Buffer (Component C/pH 
6.5, Component D/pH 7.5, Component D/adjusted to pH 8.5) for a final concentration of 10 µM. 
After the baseline measurement, the basolateral media was removed, washed one time, and 
replaced with the prepared cell loading solution. This was incubated at 37°C for 5 minutes. The 
cultures were again analyzed using a plate-reader on fluorescent endpoint setting with excitation 
506 nm and emission 540 nm to measure the calibrated fluorescence values. These three values 
per culture were pooled and averaged to get a linear standard curve, from which the intracellular 
pH was extrapolated.  
Measurement of ASL pH in cell line and primary cultures of airway epithelia. 0.33 cm2 
NuLi, CuFi, and primary cultured epithelia were used for this experiment. The ratiometric pH 
indicator SNARF-conjugated dextran (Molecular Probes) was used to measure ASL pH. SNARF 
powder was suspended via sonication in perfluorocarbon (FC-72, Sigma) and distributed onto 
the apical surface. ASL pH was measured 2 hr later (6, 9, 41). SNARF was excited at 488 nm 
and emission was recorded at 580 nm and 640 nm using a Zeiss LSM 800 microscope at 40X 
water immersion for cell line cultures and a Zeiss LSM 510 microscope for primary cultures. To 
generate a standard curve for pH determination, SNARF was dissolved in colorless pH standards 
and fluorescence ratios were converted to pH. 
Agents tested in this assay were first lyophilized into powder and then suspended in the 
appropriate volume of perfluorocarbon (FC-72, Sigma) and sonicated for 1 minute to suspend. 
AmBisome should not be sonicated; instead, the fine powder was suspended by vortexing. 20 µL 
of this suspension was administered onto the surface of cultured airway epithelia (0.33 cm2) at 
the following approximate concentrations in suspension: 
amphotericin B 0.25-100 µM 
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amphotoricin B-cholesterol complex 0.5-100 µM 
C35deOamphotericin B 2 µM (15) 
10 mM ouabain (inhibition of Na+/K+ ATPase) (42) 
10 µM ivacaftor/10 µM forskolin (9) 
AmBisome 0.25-2450 µg/mL 
In all experiments, ASL pH of compound-treated epithelia was measured compared the 
results to vehicle-treated epithelia.  
For apical AmB administration, cultured airway epithelia were incubated for 30 min – 48 hrs 
at 37°C before measurement of ASL pH. For AmB-cholesterol complex and C35deOAmB 
administration, cultured airway epithelia were incubated for 48 hrs at 37°C before measurement 
of ASL pH. To test the effect of Na+/K+ ATPase inhibition, AmB was administered 47 hours 
prior to 10 mM ouabain addition, and cultured airway epithelia were incubated for an additional 
1 hr at 37°C before measurement of ASL pH. For 10 µM ivacaftor/10 µM forskolin 
administration, cultured airway epithelia were incubated for 2 hrs at 37°C before measurement of 
ASL pH (9). For basolateral AmB administration, a 2 mM stock of AmB in DMSO was diluted 
1000-fold to a final concentration of 2 µM in USG media. The basolateral media of cultured 
airway epithelia was replaced with the AmB-containing USG media and incubated for 48 hrs at 
37°C before measurement of ASL pH. 
pH-stat titration of NuLi and CuFi monolayers. Large diameter NuLi and CuFi-1 cultured 
epithelia were used for this experiment (4.67 cm2). These cultures were mounted in a dual-
channel Ussing chamber (Warner U2500) using the culture cup insert for Transwell adapter, 
24mm (U9924T-24). The membranes were bathed at 37°C on the apical side with a buffer-free 
solution (140 mM NaCl, 2 mM KCl, 2 mM CaCl2, and 1 mM MgCl2, 15 mM dextrose, gassed 
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with air) and on the basolateral side with either a bicarbonate buffer (120 mM NaCl, 25 mM 
NaHCO3, 5 mM KCl, 2 mM CaCl2, 1.2 mM MgCl2, 13.75 NaH2PO4, 5.6 mM dextrose, pH 
adjusted to 7.0) or a bicarbonate-free buffer (140 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM HEPES, 5 mM dextrose, pH adjusted to 7.0). A microdiameter pH electrode 
(89231-590) and temperature probe (Radiometer Analytical T201 Temperature Sensor, 
E51M001) and titration burette attached to a Hach TIM856 NB pH/EP/Stat pH-STAT Titrator 
(R41T028) were inserted into the apical chamber. The basolateral chamber was covered with the 
chamber lid to prevent gas exchange. The pH electrode was then calibrated using known pH 
solutions (Hach, S11M002, S11M004, S11M007).  
The apical pH was titrated to a target pH of 6.0 using 1 mM HCl as titrant (min speed 0.25 
mL/min, max speed 0.35 mL/min) (25, 43-45). Acid titration was measured over 20 minutes to 
establish a baseline value for the cultured epithelia (max speed 2 mL/min). Both apical and 
basolateral bathing solutions were then removed. A stock solution of AmB in DMSO was added 
to a final concentration of 0.5, 1, or 2 µM in an aliquot of buffer-free solution and added to the 
apical chamber, and the basolateral chamber was replaced with fresh bicarbonate or bicarbonate-
free buffer. The apical pH was once again titrated to a target pH of 6.0 using 1 mM HCl as 
titrant. Acid titration was then measured over another 20 minutes to evaluate AmB-mediated pH 
change in the apical solution. 
Data was plotted as nmoles of H+ titrated in per minute, and the slope of this curve was 
divided by the area of the culture (4.67 cm2) to obtain the rate of acid titration (nmoles 
H+/min/cm2). 
H14CO3- transport across NuLi and CuFi monolayers. 14C-labeled sodium bicarbonate was 
obtained as a sterile 35.7 mM aqueous solution pH 9.5 (MP Biomedicals). 0.33 cm2 NuLi and 
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CuFi cultured epithelia were used in this experiment. All experiments were run less than 2 
months post seeding. Fresh USG media was added to the basolateral side prior to 
experimentation. The apical membrane was treated with 20 µL of vehicle, AmB, or 
ivacaftor/forskolin as a suspension in perfluorocarbon-72 (Sigma Aldrich), and the cultured 
epithelia were incubated for 48 hours at 37 °C in a 5% CO2 atmosphere. After 48 hours, 5 µL of 
a 1.4 mM H14CO3- solution in USG media was added to the basolateral media. The cultured 
epithelia were then incubated at 37 °C for 10 minutes. After 10 minutes, the apical membrane of 
the cultured epithelia was washed with 200 µL of PBS. The ASL wash and a 200 µL aliquot of 
the basolateral media were diluted in scintillation cocktail and analyzed via liquid scintillation 
counting (5). 
Airway surface liquid (ASL) height assay. ASL height was studied using an established 
fluorescent dye assay (27, 46). 0.33 cm2 NuLi and CuFi-1 cultured epithelia were used in this 
experiment. 24 hours prior to the start of experiment, the apical side of all cultured epithelia was 
rinsed three times with warm PBS to remove excess mucus. NuLi epithelia were treated with 
perfluorocarbon (FC-72) vehicle, and CuFi epithelia were treated with 20 µL vehicle, 0.005, 0.5, 
or 50 µM AmB, or 0.5 µM C35deOAmB suspended in perfluorocarbon (FC-72, Sigma) and 
incubated for 24 hours at 37 oC. Basolateral treatments of 0.5 µM AmB or 500 µM bumetanide 
were administered in DMSO. After 24 hours, 2.5 µL of a 2 mg/mL 70kDa Texas Red-dextran 
conjugate (Molecular Probes) solution in PBS was added to the apical side of the epithelia, 
followed by 100 µL of FC-770 to prevent evaporation. Then the culture support was placed on 
top of 100 µL of PBS on a 10 mm glass bottom Fluorodish for imaging (World Precision 
Instruments). Epithelia were imaged immediately after dye addition and again at 24 hours to 
examine dye absorption. Three Z-stack images per membrane in biological n = 3 were taken on 
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an Zeiss LSM700 confocal microscope at 40x oil immersion. These images were analyzed using 
ImageJ29 to determine the average ASL height in the center 1300 pixels of each image. Images 
were smoothed, converted to 8-bit, and thresholded to most accurately represent the red area. 
The parameters for Analyze Particles were particles from 1-Infinity µm2 in size and from 0%-
100% circularity. Height was determined by dividing the area output in pixels by the known 
1300 pixel width and converted to microns using the known scaling factor of 0.49 µm/pixel. 
Viscosity of AmB-treated primary cultures of airway epithelia. ASL viscosity in airway 
epithelial cultures was determined as previously described (8, 9). The apical surface was not 
washed for at least 2 weeks before study. Cultured epithelia were treated with 2 µM AmB 
administered in perfluorocarbon (FC-72, Sigma) as previously described for 48 hours. FITC-
dextran (70 kD, Sigma) was then administered to the apical surface of epithelia as a dry powder 
2 hrs before measurement of viscosity. FRAP was assayed in a humidified chamber at 37°C 
using a Zeiss LSM 510 META microscope. Images were acquired until maximal recovery was 
reached. At least 6 recovery curves from different locations in each culture were acquired and 
averaged to obtain data for one epithelial culture. The time constant (τsaline) was calculated by 
regression analysis from fluorescence recovery curves. Viscosity is expressed relative to the time 
constant of saline (τASL/τsaline). 
Antibacterial activity of AmB-treated primary cultures of airway epithelia. Staphylococcus 
aureus-coated gold grids were used to measure antibacterial activity of airway epithelial cultures 
as previously described (6, 41). Bacteria-coated gold TEM grids were placed onto the apical 
surface of airway epithelia for 1 minute after 48 hours of perfluorocarbon (FC-72, Sigma), 2 µM 
AmB, or 2 µM C35deOAmB treatment. As controls, bacteria-coated grids were also placed in 
saline or AmB in FC-72 laid over saline to simulate the administration method for 1 minute. 
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After removal, bacteria on the grids were assessed for viability using Live/Dead BacLight 
Bacterial Viability assay (Invitrogen). Viability was determined in 4-6 fields to determine the 
percentages of dead bacteria.  
Animals for study. We studied female and male newborn pigs with targeted disruption of the 
CFTR gene CFTR–/–, generated from mating CFTR+/– pigs. We also studied WT siblings using 
the same protocol. Pigs were obtained from Exemplar Genetics. The University of Iowa Animal 
Care and Use Committee approved all animal studies.  
Measurement of ASL pH in CFTR-/- and WT piglets. ASL pH was measured in pigs in vivo as 
previously described (7, 41). To administer AmBisome in pig trachea, pigs were initially sedated 
with ketamine (Ketaject, Phoenix; 20 mg/kg, i.m. injection) and anesthetized using propofol 
(Diprivan, Fresenius Kabi; 2 mg/kg, i.v. injection). The trachea was surgically exposed and 
accessed anteriorly, and a small anterior window was cut through the tracheal rings. To mimic 
physiologic conditions, data was obtained in a 100% humidified chamber at 37°C and constant 
5% CO2.  
 For the first CFTR-/- and one WT piglet, a baseline ASL pH measurement was taken for 
about 8 minutes before 60 µL of 100 µg/mL AmBisome® was administered to the tracheal 
window. ASL pH was continually measured for 60 minutes. Then, 60 µL of 1 mg/mL of 
AmBisome was administered to the tracheal window and continually measured for another 60 
minutes. For the second CFTR-/- piglet, a baseline ASL pH measurement was taken for about 8 
minutes before 60 µL of FC-72 vehicle was administered to the tracheal window as an internal 
control. ASL pH was continually measured for another 30 minutes. Then, 60 µL of 1 mg/mL of 
AmBisome was administered to the tracheal window and continuous measurements were then 
taken for 106 minutes. 
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Synthesis and characterization of small molecules. Commercial reagents were purchased from 
Sigma-Aldrich, Fisher Scientific, or Steraloids, and were used without further purification unless 
otherwise noted. Solvents were purified via passage through packed columns as described by 
Pangborn and coworkers (THF, MeOH, CH2Cl2: dry neutral alumina; DMF: activated molecular 
sieves)1. All water was deionized prior to use. Triethylamine was freshly distilled under an 
atmosphere of nitrogen from CaH2 before use. 1 was commercially available through Sigma-
Aldrich. The following compounds were prepared according to known literature procedures: 22-4, 
35-7, and 48-9. Their full spectroscopic analysis can be found below. 	
Reactions were monitored by analytical thin layer chromatography (TLC) performed using 
the indicated solvent on E. Merck silica gel 60 F254 plates (0.25 mm). Compounds were 
visualized by exposure to a UV lamp (λ = 254 nm or 366 nm), and/or a solution of KMnO4 stain, 
followed by heating using a Varitemp heat gun. Flash column chromatography was performed 
using Merck silica gel grade 9385 60Å (230-240 mesh). 
1HNMR and 13CNMR were recorded at 20°C on Varian Unity 400, Unity Inova 400, Unity 
Inova 500NB, Varian XR500, or Unity 500 instruments. Chemical shifts (δ) are reported in parts 
per million (ppm) downfield from tetramethylsilane and referenced to residual protium in the 
NMR solvent (CHCl3, δ=7.26; MeOH, δ=3.31, center line; acetone, δ=2.05, center line) or to 
added tetramethylsilane (δ=0.00). Data are reported as follows: chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad, app=apparent), coupling 
constant (J) in Hertz (Hz), and integration. 13CNMR are referenced to carbon resonances in the 
NMR solvent (CDCl3, δ=77.16, center line; MeOH, δ=49.00, center line; acetone, δ=29.84, 
center line). High resolution mass spectra (HRMS) were performed at the University of Illinois, 
School of Chemical Sciences Mass Spectrometry Laboratory. HPLC characterization were 
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performed using an Agilent 1260 Infinity series analytical HPLC with a 3.5 µm C18 column 
(Agilent Technologies).  
	 120	
Synthesis of Hydroxybisnorcholenic-spermine-sulfonate, GL-172 (2)   
 
2 was prepared according to literature precedent in 19.6% overall yield starting from Fernholz 
Acid2-4. Characterization of this compound was consistent with previously reported data4. 
TLC (8:2:1 CHCl3:MeOH:NH4OH) 
Rf = 0.58, visualized by KMnO4 stain 
1HNMR (500 MHz, CD3OD) 
δ 5.44-5.29 (m, 1H), 4.18-4.10 (m, 1H), 3.29-3.19 (m, 1H), 3.17 (dt, J = 13.6, 6.7 Hz, 1H), 2.77 
(app t, J = 7.1 Hz, 2H), 2.71 (app t, J = 7.2 Hz, 2H), 2.69-2.62 (m, 6H), 2.58-2.46 (m, 1H), 2.38-
2.31 (m, 1H), 2.31-2.18 (m, 2H), 2.07 (d, J = 13.0 Hz, 1H), 1.99 (app t, J = 13.4 Hz, 1H), 1.91-
1.83 (m, 1H), 1.79-1.67 (m, 6H), 1.64-1.55 (m, 4H), 1.55-1.45 (m, 4H), 1.37-1.22 (m, 3H), 1.15 
(d, J = 6.8 Hz, 3H), 1.14-1.07 (m, 2H), 1.03 (s, 3H), 0.97 (td, J = 11.2, 4.9 Hz, 2H), 0.75 (s, 3H) 
13CNMR (125 MHz, CD3OD) 
δ 179.8, 142.2, 122.3, 72.4, 57.9, 54.0, 51.7, 50.1, 49.9, 48.0, 47.5, 45.1, 43.4, 43.0, 41.0, 40.4, 
38.6, 37.7, 37.6, 33.3, 33.0, 32.3, 31.6, 29.8, 28.5, 27.8, 27.8, 25.4, 22.2, 19.9, 18.0, 12.5 
HRMS (ESI+) 
 Calculated for C32H59N4O5S [M+H+]+ :  611.4206  
 Observed : 611.4205 
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Synthesis of Methyl 3α-acetoxy-7α,12α-di[(4-nitrophenylaminocarbonyl)amino]-5β-cholan-
24-oate, Cholapod 2e (3) 
 
3 was prepared according to literature precedent in 14.9% overall yield starting from cholic 
acid5-7. Characterization of this compound was consistent with previously reported data5-7. 
TLC (1:2 Hexanes:Ethyl Acetate) 
Rf = 0.40, visualized by UV (254 nm and/or 366 nm) and/or KMnO4 stain 
1HNMR (500 MHz, Acetone-d6) 
δ 8.85 (br s, 1H), 8.66 (br s, 1H), 8.15 (app d, J = 9.1 Hz, 4H), 7.73 (app d, J = 9.2 Hz, 4H), 
6.24-6.14 (app br s, 2H), 4.56-4.47 (m, 1H), 4.21-4.16 (m, 1H), 4.12-4.06 (m, 1H), 3.55 (s, 3H), 
2.29-2.23 (m, 4H), 2.20-2.09 (m, 2H), 2.02-1.94 (m, 4H), 1.91 (s, 3H), 1.89-1.77 (m, 4H), 1.75-
1.55 (m, 4H), 1.52-1.22 (m, 6H), 0.91 (s, 3H), 0.89 (s, 3H), 0.87 (s, 3H) 
13CNMR (125 MHz, Acetone-d6) 
δ 174.4, 170.2, 154.5, 148.0, 148.0, 147.9, 142.2, 142.1, 125.9, 117.7, 117.7, 74.6, 53.9, 51.5, 
49.1, 47.0, 45.6, 42.1, 38.0, 35.8, 35.8, 35.5, 33.4, 31.5, 31.2, 27.9, 27.6, 27.3, 24.0, 23.2, 21.3, 
17.5, 14.0 
HRMS (ESI+) 
 Calculated for C41H55N6O10 [M+H+]+ : 791.3980  
	 123	
 Observed : 791.3977 




Synthesis of N1,N3-bis(((R)-1-( isobutylamino)-4-methyl-1-oxopentan-2-  
yl)oxy)isophthalamide, Yang Channel (4) 
 
4 was prepared according to literature precedent in 37.3% overall yield starting from leucine8,9. 
Characterization of this compound was consistent with previously reported data8,9.  
TLC (1:1 Hexanes:Ethyl Acetate) 
Rf = 0.33, visualized by UV (254 nm) and/or KMnO4 stain 
1HNMR (500 MHz, CDCl3) 
δ 11.06 (br s, 2H), 8.16 (br s, 3H), 8.01 (dd, J = 7.7, 1.6 Hz, 2H), 7.51 (t, J = 7.8 Hz, 1H), 4.39 
(dd, J = 9.7, 3.6 Hz, 2H), 2.99 (dt, J = 13.0, 6.4 Hz, 2H), 2.87 (dt, J = 13.0, 6.4 Hz, 2H), 1.84-
1.77 (m, 2H), 1.75-1.60 (m, 4H), 1.56 (ddd, J = 13.7, 9.0, 3.6 Hz, 2H), 0.87 (d, J = 6.6 Hz, 12H), 
0.80 (d, J = 6.6 Hz, 6H), 0.74 (d, J = 6.6 Hz, 6H) 
13CNMR (125 MHz, CDCl3) 
δ 172.3, 166.1, 131.9, 131.4, 129.5, 125.3, 85.4, 46.8, 41.3, 28.4, 24.9, 23.3, 21.9, 20.1, 20.1 
HRMS (ESI+) 
 Calculated for C28H47N4O6 [M+H+]+ :  535.3496  
	 125	
 Observed :           535.3497 





















1. D. A. Stoltz , D. K. Meyerholz , M. J. Welsh Origins of Cystic Fibrosis Lung Disease. 
New England Journal of Medicine 372, 351-362 (2015). 
2. M. P. Rogan, D. A. Stoltz, D. B. Hornick, Cystic Fibrosis Transmembrane Conductance 
Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific 
Treatment. Chest 139, 1480-1490 (2011). 
3. L. Maiuri, V. Raia, G. Kroemer, Strategies for the etiological therapy of cystic fibrosis. 
Cell Death Differ 24, 1825-1844 (2017). 
4. A. G. Cioffi, J. Hou, A. S. Grillo, K. A. Diaz, M. D. Burke, Restored Physiology in 
Protein-Deficient Yeast by a Small Molecule Channel. J Am Chem Soc 137, 10096-10099 
(2015). 
5. A. S. Grillo et al., Restored iron transport by a small molecule promotes absorption and 
hemoglobinization in animals. Science 356, 608-616 (2017). 
6. V. S. Shah et al., Airway acidification initiates host defense abnormalities in cystic 
fibrosis mice. Science 351, 503-507 (2016). 
7. M. H. Abou Alaiwa et al., Repurposing tromethamine as inhaled therapy to treat CF 
airway disease. JCI Insight 1,  (2016). 
8. X. X. Tang et al., Acidic pH increases airway surface liquid viscosity in cystic fibrosis. J 
Clin Invest 126, 879-891 (2016). 
9. E. H. Chang et al., Medical reversal of chronic sinusitis in a cystic fibrosis patient with 
ivacaftor. Int Forum Allergy Rhinol 5, 178-181 (2015). 
10. B. W. Ramsey  et al., A CFTR Potentiator in Patients with Cystic Fibrosis and the 
G551D Mutation. New England Journal of Medicine 365, 1663-1672 (2011). 
11. J. P. Garnett et al., Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis 
airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent 
lactate-H+ secretion. Sci Rep 6, 37955 (2016). 
12. F. Van Goor et al., Rescue of CF airway epithelial cell function in vitro by a CFTR 
potentiator, VX-770. Proceedings of the National Academy of Sciences 106, 18825-
18830 (2009). 
13. J. L. Taylor-Cousar et al., Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis 
Homozygous for Phe508del. New England Journal of Medicine,  (2017). 
14. N. M. Walker et al., Cellular chloride and bicarbonate retention alters intracellular pH 
regulation in Cftr KO crypt epithelium. Am J Physiol Gastrointest Liver Physiol 310, 
G70-80 (2016). 
15. K. C. Gray et al., Amphotericin primarily kills yeast by simply binding ergosterol. Proc 
Natl Acad Sci U S A 109, 2234-2239 (2012). 
16. J. T. Davis et al., Using small molecules to facilitate exchange of bicarbonate and 
chloride anions across liposomal membranes. Nat Chem 1, 138-144 (2009). 
17. S. A. Davis et al., C3-OH of Amphotericin B Plays an Important Role in Ion 
Conductance. J Am Chem Soc 137, 15102-15104 (2015). 
18. B. Shen, X. Li, F. Wang, X. Yao, D. Yang, A synthetic chloride channel restores chloride 
conductance in human cystic fibrosis epithelial cells. PLoS One 7, e34694 (2012). 
19. A. V. Koulov et al., Chloride transport across vesicle and cell membranes by steroid-
based receptors. Angew Chem Int Ed Engl 42, 4931-4933 (2003). 
	 127	
20. C. Jiang et al., Partial correction of defective Cl(-) secretion in cystic fibrosis epithelial 
cells by an analog of squalamine. Am J Physiol Lung Cell Mol Physiol 281, L1164-1172 
(2001). 
21. M. El-Etri, J. Cuppoletti, Metalloporphyrin chloride ionophores: induction of increased 
anion permeability in lung epithelial cells. Am J Physiol 270, L386-392 (1996). 
22. L. N. Ermishkin, K. M. Kasumov, V. M. Potseluyev, Properties of amphotericin B 
channels in a lipid bilayer. Biochim Biophys Acta 470, 357-367 (1977). 
23. H. Kawase et al., A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac 
remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis. J Mol Cell Cardiol 
98, 37-47 (2016). 
24. J. Zabner et al., Development of cystic fibrosis and noncystic fibrosis airway cell lines. 
Am J Physiol Lung Cell Mol Physiol 284, L844-854 (2003). 
25. D. Y. Cho, P. H. Hwang, B. Illek, H. Fischer, Acid and base secretion in freshly excised 
nasal tissue from cystic fibrosis patients with DeltaF508 mutation. Int Forum Allergy 
Rhinol 1, 123-127 (2011). 
26. V. S. Shah et al., Relationships among CFTR expression, HCO(3)(−) secretion, and host 
defense may inform gene- and cell-based cystic fibrosis therapies. Proceedings of the 
National Academy of Sciences of the United States of America 113, 5382-5387 (2016). 
27. M. M. Myerburg et al., AMPK agonists ameliorate sodium and fluid transport and 
inflammation in cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 42, 676-
684 (2010). 
28. R. C. Boucher, Evidence for airway surface dehydration as the initiating event in CF 
airway disease. J Intern Med 261, 5-16 (2007). 
29. T. J. Miller, P. B. Davis, FXYD5 modulates Na+ absorption and is increased in cystic 
fibrosis airway epithelia. Am J Physiol Lung Cell Mol Physiol 294, L654-664 (2008). 
30. D. Peckham, E. Holland, S. Range, A. J. Knox, Na+/K+ ATPase in lower airway 
epithelium from cystic fibrosis and non-cystic-fibrosis lung. Biochem Biophys Res 
Commun 232, 464-468 (1997). 
31. F. Van Goor, H. Yu, B. Burton, B. J. Hoffman, Effect of ivacaftor on CFTR forms with 
missense mutations associated with defects in protein processing or function. Journal of 
Cystic Fibrosis 13, 29-36 (2014). 
32. J. Hull, S. Shackleton, A. Harris, Abnormal mRNA splicing resulting from three different 
mutations in the CFTR gene. Hum Mol Genet 2, 689-692 (1993). 
33. T. M. Anderson et al., Amphotericin forms an extramembranous and fungicidal sterol 
sponge. Nat Chem Biol 10, 400-406 (2014). 
34. V. Monforte et al., Nebulized liposomal amphotericin B prophylaxis for Aspergillus 
infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 
28, 170-175 (2009). 
35. W. B. Guggino, The Cystic Fibrosis Transmembrane Regulator Forms Macromolecular 
Complexes with PDZ Domain Scaffold Proteins. Proceedings of the American Thoracic 
Society 1, 28-32 (2004). 
36. P. H. Karp et al., An in vitro model of differentiated human airway epithelia. Methods for 
establishing primary cultures. Methods Mol Biol 188, 115-137 (2002). 
37. P. S. Chen, T. Y. Toribara, H. Warner, Microdetermination of Phosphorus. Analytical 
Chemistry 28, 1756-1758 (1956). 
	 128	
38. N. J. Andrews et al., Structurally simple lipid bilayer transport agents for chloride and 
bicarbonate. Chemical Science 2, 256-260 (2011). 
39. N. Busschaert et al., Tripodal transmembrane transporters for bicarbonate. Chem 
Commun (Camb) 46, 6252-6254 (2010). 
40. N. Busschaert et al., Synthetic transporters for sulfate: a new method for the direct 
detection of lipid bilayer sulfate transport. Chemical Science 5, 1118-1127 (2014). 
41. A. A. Pezzulo et al., Reduced airway surface pH impairs bacterial killing in the porcine 
cystic fibrosis lung. Nature 487, 109-113 (2012). 
42. D. C. Devor et al., Bicarbonate and chloride secretion in Calu-3 human airway epithelial 
cells. J Gen Physiol 113, 743-760 (1999). 
43. D. Y. Cho, M. Hajighasemi, P. H. Hwang, B. Illek, H. Fischer, Proton secretion in freshly 
excised sinonasal mucosa from asthma and sinusitis patients. Am J Rhinol Allergy 23, 
e10-13 (2009). 
44. H. Fischer, J. H. Widdicombe, Mechanisms of Acid and Base Secretion by the Airway 
Epithelium. The Journal of membrane biology 211, 139-150 (2006). 
45. H. Fischer, Function of Proton Channels in Lung Epithelia. Wiley Interdiscip Rev Membr 
Transp Signal 1, 247-258 (2012). 
46. E. N. Worthington, R. Tarran, Methods for ASL measurements and mucus transport rates 
in cell cultures. Methods Mol Biol 742, 77-92 (2011). 
 
